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ABSTRACT 
Melanoma is the most deadly form of skin cancer due to its great metastatic potential. 
Targeted therapy that inhibits the BRAF-V600E driver mutation has shown impressive initial 
responses in melanoma patients. However, drug resistance, as the universal phenomenon for 
any cancer therapy, always limits treatment efficacy and compromises outcomes. As the 
early-step of resistance development, non-genetic mechanisms enable cancer cells to 
transition into a drug-resistant state in as early as a few days after drug treatment without 
alteration of the genome. This early mechanism is, to a large extent, due to the heterogeneous 
and highly plastic nature of tumor cells. Therefore, it imperative to understand the plastic and 
heterogeneous nature of the melanoma cells in order to identify combination therapies that 
can overcome resistance.  
In this thesis, we investigate these two fundamental natures of non-genetic drug resistance 
using BRAF inhibition of BRAF-mutant melanomas as the model system. These melanoma 
cells undergo multi-step, reversible drug-induced cell-state transitions from the original 
sensitive phenotype to a drug-resistant one.  
We first conducted bulk analysis to characterize the detailed kinetics of the entire transition 
from drug-sensitive state towards drug-resistant state, revealing expression changes of 
thousands of genes and extensive chromatin remodeling. A 3-step computational biology 
approach greatly simplified the complexity and revealed that the whole cell-state transition 
was controlled by a gene module activated within just the first three days of drug treatment, 
with the RelA transcription factor driving chromatin remodeling to establish an epigenetic 
program encoding long-term phenotype changes towards resistance. From there, a detailed 
mechanism connecting tumor epigenetic plasticity with non-genetic drug resistance was 
resolved through in-depth molecular biology experiments. The mechanism was validated in 
clinical patient samples. 
We further investigated heterogeneity by moving from bulk cellular studies to single-cell 
analysis. The single-cell view further revealed that two driving forces from both cell-state 
interconversions and phenotype-specific drug selection control the cell-state transition 
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dynamics. The single-cell studies also pinpointed the signaling network hub, RelA, as the 
driver molecule of the initiation of the adaptive transition. These two competing driving 
forces were further quantitatively modeled via a thermodynamic-inspired surprisal analysis 
and a modified Fokker-Planck-type kinetic model. 
Finally, using integrated single-cell proteomic and metabolic technology I developed to 
characterize the early-stage signaling and metabolic changes upon initial drug responses, we 
further identified two distinct paths connecting drug-sensitive and drug-tolerant states. 
Melanoma cells exclusively traverse one of the two paths depending on the level of MITF in 
the drug-naïve cells. The two trajectories are associated with distinct signaling and metabolic 
susceptibilities and are independently druggable. 
In total, this thesis combines and synergizes various physical science and systems biology 
approaches together with several unique single-cell technologies and analysis to obtain a 
deep and comprehensive understanding of non-genetic drug resistance in cancer. The 
findings from this thesis provide several novel insights into the rational design of effective 
combination therapy for overcoming the development of resistance in response to cancer 
treatments. 
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C h a p t e r  1  
INTRODUCTION 
Melanoma, BRAFi Targeted Therapy and Drug Resistance 
Cancer is a leading cause of death worldwide, accounting for an estimated 9.6 million deaths 
in 2018. With all of the cancer deaths, 90% care caused by metastases [1]. Melanoma, as one 
of the most metastatic of all cancers, is the most deadly form of skin cancer. It is the fifth 
most common type of new cancer diagnosis in American men and the seventh most common 
type in American women [2,3]. During 40 years of employing chemotherapy, radiation, and 
combinations of the two,  limited progress has been made in the treatment of metastatic 
melanoma [4].  
A deeper and more detailed understanding of the molecular drivers of cancer development 
facilitated a trend from the old "one-size-fits-all" chemo/radiotherapy towards a more 
personalized and less cytotoxic "molecular targeted therapy" [5–8]. Molecular targeted 
therapy is a class of medication that interferes with specific molecules that are critical for 
tumor progression to block the growth and spread of cancer [5,7]. Targeted therapy focuses 
on a specific abnormal molecular property present in cancer but not in normal cells. This 
potentially makes targeted therapy more effective and less toxic to normal cells given that 
traditional chemotherapy targets all rapidly dividing cells (Fig1.1) [4,5,7].  
 
 
Traditional 
chemotherapy
• Target all dividing
cells
• Cytotoxic
Targeted
therapy
• Target specific
tumor cell
• Cytostatic
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Figure1.1. Comparison of traditional chemotherapy and targeted therapy. The targeted therapy 
is superior to traditional chemotherapy in both increased specificity and less cytotoxicity. 
Targeted therapy tailored to specific mutations that dominantly activate mitogenic signaling 
of the tumor has been shown to be effective in several recent examples: ALK, EGFR, KIT, 
HER2, and ABL kinases inhibitor have unprecedented clinical activity in those tumors that 
are caused by a certain genetic mutation [9–11]. However, in most cases, the patient relapsing 
and the cancer progress after the significant but temporary clinical response. Melanoma with 
BRAF V600E driver mutation is one of the most remarkable illustrations of this 
phenomenon[12–14]. 
The RAS/RAF/MEK/ERK signaling pathway plays a key role in melanoma development 
making it an important therapeutic target [15]. In normal cells, the tightly regulated pathway 
relays extracellular proliferative signals from cell surface receptor into the nucleus via a 
cascade of protein phosphorylation. In melanomas, oncogenic mutations dysregulate the 
pathway which leads to increased signaling activity promoting cell proliferation, invasion, 
metastasis, migration, survival, and angiogenesis (Fig. 1.2) [16–18]. Among all mutated 
genes in the MAPK signaling cascade in melanoma, BRAF is the highest, with more than 
60% of advanced tumors expressing constitutively active mutant protein. Almost all of the 
BRAF mutants are the single substitution V600E, whose discovery spurred investigations 
into the development of targeted therapies for melanoma [13–15,19].  
 
Figure 1.2. BRAF-V600E oncogenic driver mutation and its effects. In normal cells, if 
growth signal exists, will BRAF become active and promote cell growth. In BRAF-V600E 
melanoma, the mutated BRAF is always activated even if there is no growth signal. This 
effect will cayse the cell to hyperactively proliferate and lead to cancer formation. (Figure is 
taken from [20]) 
 
  
3 
Inhibition of the oncogenic BRAF-V600E protein with the small, orally available molecule 
inhibitor PLX4032 (vemurafenib, also known as VEM) showed impressive initial responses 
in patients with BRAF mutant melanoma [13,14]. Patients treated with  vemurafenib had a 
significant response: the great majority of treated patients experienced a reduction in tumor 
volume and nearly half had a confirmed partial or complete response [12–14]. These led to 
the FDA (Food and Drug Administration)-approval of vemurafenib in 2011 and a dramatic 
improvement in the standard of care for the patients with BRAF-V600E oncogenic mutation 
[14]. 
 
 
 
Figure 1.3. Targeted therapy resistance in melanoma. It is a very common phenomenon that BRAF 
mutated melanoma patients treated with BRAFi targeted therapy will have a good initial response, 
but will almost always suffer from tumor reoccurrence. Figure adapted from [21]. 
However, in most of these patients, despite their initial tumor shrinkage, tumor relapse is 
inevitable after a median duration of around 5 to 7 months indicating resistance development 
(Fig. 1.3) [9,21]. A diverse range of molecular mechanisms have been reported in drug 
resistance; these include increased rates of drug efflux, mutation of drug targets, adaptive 
activation of survival signaling pathway, epigenetic changes, etc. [22–27] Moreover, the high 
plasticity and heterogeneity of melanoma make the investigation of resistance mechanism 
more complicated [28–30]. Therefore, it is imperative first to understand the plastic and 
heterogeneous nature of the tumor and the connections to drug resistance, and second to 
identify potential combination therapies that will overcome resistance. 
Non-Genetic Drug Resistance And Cellular Plasticity 
Before 
therapy
Initial 
response Resistance
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Traditionally, drug resistance was believed to derive from the selection of clones with 
secondary mutations or other genomic alterations that are generated by chance during the 
time course of treatment [31]. Although this genetic mechanism of resistance is still the 
dogma for explaining resistance development, recently, the non-genetic type of mechanism 
has also been recently recognized as another important alternative route for acquiring 
resistance without even alternating the genome [32–35]. In fact, these two types of 
mechanisms are not mutually exclusive, since the non-genetic resistance is believed to occur 
early on and provide a reservoir of drug-tolerant cells from which the genetic-resistant cells 
can be selected (Fig. 1.4) [36,37] (Fig.1.4). 
 
 
Figure 1.4. The relationship between genetic and non-genetic mechanisms of resistance. Upon 
drug treatment, the cancer cells will first enter a drug-tolerant state, which shares the exact same 
genome as the untreated cells but can tolerant the drug and survive. Cells at this drug-tolerant cell 
state can reversibly return to the drug-sensitive state upon drug removal. With prolonged drug 
treatment, this reservoir of drug-tolerant cells will have some chance to gain secondary mutations or 
other genetic alterations to become genetic-resistant cells. These genetic resistant cells once generated 
from the reservoir of tolerant cells can then be further enriched due to drug selection pressure as they 
are stable and are irreversibly different from the original tumor cells due to changes in the genome. 
Figures adapted from [38]. 
The non-genetic resistance is, to a large extent, caused by the plasticity of cancer cells, 
formally defined as the cells’ ability to change phenotype without alternating the genome. In 
fact, such an ability to change phenotype is not unique to cancer cells, but rather a universal 
process utilized in all healthy cells. A simple example is to consider the human body: as a 
multi-cellular organism, all humans have many different cell types (e.g. blood cell, skin cell, 
muscle cell, etc.), displaying different gene expression programs and performing very 
different functions; but considering the origin of life, those different cell types are all 
originally derived from the same single cell (a fertilized egg cell) and therefore share the 
exact same genome. It is the cellular plasticity that grants the diverse cellular phenotypes in 
our bodies. Many healthy cells, once committed to their respective phenotypes, will lose their 
ability to change phenotype (e.g. a skin cell cannot spontaneously change to a blood cell and 
vice versa). In contrast, cancer cells maintain their cellular plasticity and can easily switch 
phenotypes upon exposure to environmental changes. In particular, during the time course 
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of treatment the cancer cell can utilize this plasticity to survive by changing its phenotype 
from the original drug-sensitive one to a new drug-tolerant one.  
Several labs including the Heath group recently discovered that melanoma cells can utilize 
their innate plasticity to develop resistance to BRAF inhibitor drugs [30,39–41]. Upon 
BRAFi treatment, melanoma cells can acquire a new stem-cell-like phenotype simply by 
accessing the cell states of their developmental precursors. Melanoma is skin cancer that is 
originally derived from a healthy skin cell type called melanocyte, which are the cells that 
produce the skin-color pigment melanin. Heathy melanocytes are originally differentiated 
from healthy neural-crest stem cells [42]. In melanoma, the drug-resistance development 
process resembles the reverse process of such developmental biology. Before drug treatment, 
melanoma cells are typically in the melanocytic cell state with many melanocytic genes 
highly upregulated. However, upon BRAF inhibitor treatment, cells gradually lose their 
melanocytic features and gain neural-crest stem cell features to dedifferentiate into a neural-
crest-like cell state, which is a drug-tolerant and slow cycling cell state [39–41]. After 
prolonged BRAFi treatment, the cell can undergo further transition from the neural-crest-
like state to a fully dedifferentiated mesenchymal phenotype (Fig. 1.5), which is also a well-
known fully resistant phenotype in BRAFi treatment melanoma cells [43,44]. All three 
phenotypes involved in this multi-step cell state transition share the same genome but the last 
two phenotypes are not sensitive to the drug anymore. Investigating the molecular 
mechanism of such cell-state transitions is an unmet need in order to understand and prevent 
resistance development. This is the central topic of the thesis and will be discussed in more 
detail in the subsequent chapters. 
 
Figure 1.5 Melanocyte to neural-crest transition in BRAFi induced drug resistance of 
melanoma cell. Upon BRAFi treatment, melanoma cells will de-differentiate from a melanocytic 
phenotype to the neural-crest like phenotype and eventually move towards the mesenchymal 
phenotype to gain drug resistance.  
Physical Science and Systems Biology Approaches to Understanding 
Cancer 
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Non-genetic drug resistance and the associated cell state transitions are usually systems-
level changes accompanied by expression changes of thousands of genes, with a dramatic 
restructuring of the epigenome, as well as rewiring of many signaling pathways and 
reprogramming of the metabolism. Luckily, recent technological advances have enabled 
investigation of the major changes and the reprogramming of the epigenome [45,46], 
transcriptome [47], proteome [48], and metabolome [49] of either bulk cell populations or 
even single cells [50,51]. This capability enables researchers to have a more complete, 
unbiased view of complex biological events. 
From the perspectives of physical scientists and engineers, this thesis views biological 
processes as highly coordinated systems with many interacting units (genes, proteins, 
metabolites) functioning under the constraint of a regulatory network. The unbiased systems-
level view from many of the recent or emergent technologies is just starting to provide 
physical scientists and engineers with the proper foundation to better understand the 
biological complexity through statistical mechanics, thermodynamics and reaction kinetics.  
Such physical science and systems biology approaches, when utilized to investigate drug 
resistance in cancer, can have many unique advantages. First, it is highly unbiased since a 
systems-level view enables people to see many regulators simultaneously [52]. On the 
contrary, traditional approaches are a bit biased since they usually focus on no more than a 
few molecules of interest. Second, systems-level approaches can be predictive and 
preventative [53]. Instead of waiting until drug resistance occurs and proceeding to treat the 
resistant cells, these approaches anticipate how the cancer cell will become resistant by 
looking for the molecular drivers that initiate resistant early on. By drugging such molecular 
drivers, one could potentially prevent resistance before it actually establishes. With such 
advantages, an interdisciplinary physical science and systems biology approach is perfectly 
suited for understanding both the nature of resistance and the underlying mechanism. In fact, 
thermodynamics-inspired information-theoretical analysis (surprisal analysis) [54], is well 
as reaction kinetics (ordinary differential equations and partial differential equations), are the 
key systems-biology approaches utilized in this thesis in resolving the puzzles of drug 
resistance, which will be discussed in many of the following chapters. 
Tumor Heterogeneity and Single-Cell Analysis  
Biological processes under single-cell levels are rarely deterministic [55]. Such stochastic 
information it is very hard to gain from the traditional bulk assay, which is often based on 
lysis of complex cell populations into mixtures to enable an analysis of their component 
parts. The differences among cells, which have been recently repeatedly shown to be 
important, are often lost in traditional bulk biochemical approaches due to averaging cell 
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signals across the entire cell mixture sample. When it comes to a tumor with an immense 
amount of genetic and epigenetic heterogeneity the phenotypic differences among 
subpopulations (including renewal capacity and drug resistance, etc.) are far from fully 
characterized [56–58]. An incomplete understanding of the tumor was previously largely due 
to the lack of effective tools for characterizing the difference among individual cells [56].  
Luckily, many powerful single-cell technologies have just been developed in the past few 
years, including many from the Heath lab [59–62]. Now is the perfect time to utilize these 
novel single-cell tools to study heterogeneous tumor systems. A deeper understanding of 
resistance from single-cell tools can guide the rationale design of a more effective 
combination therapy to overcome the clinical negative effects of classic therapeutic 
approaches (including non-response to therapy or drug resistance after the initial response). 
In recent years, major advances in single-cell technology have mostly focused on the 
genomic and transcriptomic levels, which are both studying nucleic acids that can be 
amplified through PCR reactions for sequencing. Reported technologies include whole-
genome sequencing (WGS), whole mRNA transcriptome sequencing; and targeted 
sequencing of DNA regions (that is, exome sequencing) or mRNA transcripts [51,59,63,64]. 
Protein abundance and protein-phosphorylation states are also of great importance to study 
tumor heterogeneity, but are difficult to characterize because proteins cannot be amplified, 
in a manner similar to PCR, to provide enough material for analysis.  Currently, single-cell 
functional proteomics technologies are not as mature, with just a few technologies presently 
available, ranging from flow cytometry to microfluidics-based platforms (many of which are 
listed and briefly characterized in Table 1.) Within all of these single-cell proteomic 
techniques, this thesis primarily utilizes the single-cell barcode chip (SCBC) technology that 
has been developed and well used in the Heath group. 
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Table1.1 Single-cell proteomics technologies (adapted from[63]) 
Techniqu
e 
Numbers 
and types 
of protein 
assayed 
Through
put 
Detection 
limit 
Statistical 
accuracy and 
signal 
quantification 
Notes and feature 
Fluoresc
ence flow 
cytometry 
Up to 15 
proteins 
but mostly 
membrane 
protein 
10^4 
cell per 
second 
500 copies 
per cell 
90% phenotyping 
accuracy; relative 
protein abundance 
Standard for sorting and 
enumeration of cellular 
phenotypes. Secretion blocked 
and cell fixed for cytoplasmic 
protein 
Cytof Up to 
around40 
10^3 cell 
per 
second 
more than 
1000 
copies per 
cell 
good counting 
statistics; relative 
protein abundance 
cell handled in bulk prior to 
analysis. Secretion blocked and 
cell fixed for cytoplasmic protein 
Micro-
engravin
g 
3 secreted 
plus 3 
membrane 
proteins 
10^5 cell 
per chip 
Not 
available 
Very good cell 
number statistics; 
relative protein 
abundance 
Cells isolated in microwells; 
surface immunoassay: protein 
colorimetrically detected; 
secretome kinetics from single 
cells; proteomic and functional 
assays from the same cell 
Single-
cell 
barcode 
chips 
Up to 46 
secreted 
membrane 
or 
cytoplasmi
c proteins 
10^3 to 
10^5 cell 
per chip 
100 copies Good cell 
counting statistics, 
absolute 
quantification 
Cells isolated in microchambers 
miniature antibody arrays yield 
spatial separation of specific 
protein assay; proteomic and 
functional assay from the same 
single cell; adaptable for small 
cell group study 
 
 
SCBCs can connect genomic information to biological function via quantitative assays of a 
panel of functional proteins (typically 14 to 46 proteins) across hundreds to thousands of 
single cells[61,62,65,66]. The SCBC concept is simple: a single or defined number of cells 
are isolated within a small volume microchamber that contains a miniature antibody array 
for the capture and detection of a panel of proteins via sandwich ELISA-like assays. 
Although the amount of proteins from a single cell is very low and cannot be amplified 
directly through PCR reaction, the microfluidic device shrinks the reaction volume of the 
chamber to several nanoliter; therefore, the concentration is maintained at a high enough 
level for detection and quantification.  
  
9 
 
Figure 1.6. The workflow of a single-cell barcode chip. The single-cell suspension has flowed into 
the microfluidic device and cells will be captured into nano-liter-sized champers. Once the cells are 
captured, perturbing, lysing and analyzing single cells within the chamber is also feasible through 
programming the nano-liter fluid. As shown in the zoom-in view of an individual chamber, cells were 
trapped at the left-hand side of the chamber and the lysis buffer is at the other side of the chamber, 
separated by the blue valve in between. When releasing the blue valve, the lysis buffer will be able to 
diffuse to the other side and lyse the cell. The intracellular proteins will then be released into the 
chamber for quantification. At the bottom of each chamber, there are barcoded arrays of antibodies 
installed orderly. These antibodies will capture proteins of our interest in order. So, simply by adding 
stripes in the chamber we can increase the multiplicity all the way to more than 40 different analytes. 
After the proteins are capture onto the antibody, we will be loading another set of detection antibodies 
with dye on it to convert the captured protein abundance into fluorescent intensity readout. Based on 
such multi-functional, programmable, nano-chamber, many important regulators from each 
individual cell are quantified simultaneously, and hundreds to thousands of single-cells can be 
analyzed simultaneously on one chip. Figure adapted from [67,68] 
SCBCs have been developed into a robust tool with benchtop to bedside applications already 
demonstrated, and are currently being commercialized through a company called “IsoPlexis”. 
Applications of SCBC include predicting drug resistance in GBM tumors [67], predicting 
tissue structures [69], and patient monitoring for cancer immunotherapy trials [61,70]. 
SCBCs have also been validated against flow cytometry and various bulk immunoassays on 
cell lines and primary cells. Compared to flow cytometry or mass cytometry (cytof), SCBC 
offers the following advantages: (i) as few as 1000 cells can be studied [71], (ii) protein levels 
and measurement errors are both absolutely quantitated, in copy numbers of molecules[72], 
(iii) the local environment of the cell can be controlled z (iv) discrete cell populations can be 
assayed to measure cell-cell interactions [73] and (v) SCBCs are cost-effective. Absolute 
quantitation of protein levels enables direct comparisons across cell types, proteins, time 
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points, and patient samples, etc. While such quantitation is standard in the physical 
sciences, it is novel (and challenging) in biology. Absolute quantitation of protein level 
uantitation also opens up the possibility of using theories derived from physico-chemical 
principles and/or statistic methods to investigate cellular steady states, perturbations, etc. In 
fact, the combination of SCBC based single-cell proteomic measurement with physico-
chemical principle enables identification of the central regulators of drug resistance as early 
as a few days after drug treatment. It is further illustrated in Chapter 3 and Chapter 5 of the 
thesis. 
Meanwhile, compared to single-cell proteomic technologies, there are even fewer single-cell 
metabolic assays currently available. SCBC technology addresses this shortcoming, with its 
ability to co-measure metabolites from the same single cell together with many proteins or 
phosphor-proteins. Considering the importance of metabolic rewiring in drug resistance and 
the heterogeneous nature of the tumor, it is also worthwhile to investigate the metabolic 
phenotypes of single tumor cells, ideally in conjunction with their signaling activities. Since 
SCBC can co-measure the metabolites together with proteomics from the same single cell 
[65,68,74], we applied the SCBC-based integrated single-cell proteomic and metabolic assay 
to drug resistance development of melanoma. This technology provides us with a very deep 
insight into the signaling rewiring and metabolic reprogramming during the heterogeneous 
drug-response trajectories of tumor cells. We now have the capability to augment the 
paradigm of adaptive resistance development in an isogenic cell population and can use this 
information to offer insight into the design of more effective combination therapies.  
Thesis Overview 
This thesis investigated the fundamental plastic and heterogeneous nature of cancer cells and 
their connection with non-genetic drug-resistance development, using BRAF inhibition of 
BRAF-mutant melanomas as the model system. These melanoma cells undergo multi-step, 
reversible drug-induced cell-state transitions, ultimately yielding a drug-resistant 
mesenchymal-like phenotype.  
In Chapter 2, bulk analysis was conducted to characterize the detailed kinetics of the entire 
cell-state transition, revealing expression changes of thousands of genes and extensive 
chromatin remodeling. A 3-step computational systems biology approach greatly simplified 
the complexity, and revealed that the whole adaptive process was controlled by a gene 
module activated within just three days of treatment, with RelA driving chromatin 
remodeling to establish an epigenetic program encoding long-term phenotype changes. From 
there a detailed mechanism connecting tumor epigenetic plasticity with non-genetic adaptive 
resistance to therapy was resolved. These findings were confirmed across several patient-
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derived cell lines and in melanoma patients under MAPK inhibitor treatment. Co-targeting 
BRAF and histone-modifying enzymes arrest adaptive transitions towards drug tolerance in 
epigenetically plastic melanoma cells and may be exploited therapeutically. (Chapter 2 has 
been adapted from a manuscript currently under review in Cancer cell, doi: 
10.1101/724740). 
From Chapter 3, the resolution of the investigation went a step further by moving from bulk 
study to single-cell analysis. The single-cell view further uncovered the fundamental 
biophysical nature of the cell-state transition as joint efforts from both cell state 
interconversion and phenotype-specific drug selection. It also pinpointed to signaling 
network hubs, RelA, as the driver molecule of the initiation of the adaptive transition. 
Targeting those hubs halted the transition and arrested resistance development. (Chapter3 
has been taken in part from PNAS, doi: 10.1073/pnas.1712064115). 
In Chapter 4, the various driving forces of phenotypic changes and evolution of melanoma 
cells during the resistance development process were further quantitatively modeled and 
validated via a thermodynamic inspired surprisal analysis and a modified Fokker-Planck-
type kinetic model. Joint experimental and computational approaches were employed, using 
either bulk or single-cell measurements as input, to interrogate the epigenetic landscape of 
the phenotypic evolution. the observed stable phenotypic equilibria of multiple drug-resistant 
subpopulations were found to be established via competition between state-dependent net 
proliferation rates and landscape potential. The results reveal how the tumor cells maintain a 
phenotypic heterogeneity that facilitates appropriate responses to external cues. (Chapter4 
has been taken in part from PLOS Computational Biology, doi: 
10.1371/journal.pcbi.1007034) 
Finally, in Chapter 5 of the thesis, using integrated single-cell proteomic and metabolic 
analysis of the early stage signaling and metabolic changes upon initial drug responses, two 
distinct paths connecting drug-naïve and drug-tolerant states were identified. Cells are shown 
to exclusively traverse one of the two paths depending on the level of a master transcription 
factor MITF before drug treatment. The two trajectories are associated with distinct signaling 
and metabolic susceptibilities. The results update the paradigm of adaptive resistance 
development in an isogenic cell population and offer insight into the design of more effective 
combination therapies. (Chapter5 has been taken in part from a manuscript that is currently 
under review in Nature Communications, doi: 10.1101/767988). 
Notably, in addition to the above contents mentioned in the thesis, two other exciting projects 
are future directions of the thesis. One of the projects analyzed the transcriptome of drug-
induced resistant cell populations with single-cell resolution. We discovered, in addition to 
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the well-known drug-resistant mesenchymal phenotype, there is a novel drug-resistant 
subpopulation co-existing, which has not been reported before. Detailed molecular-
mechanism associated with the drug-resistant subpopulations are discovered which guided 
the co-blocking of both resistant subpopulations as effective combination therapy. The other 
project utilized Raman-based single-cell sub-cellular metabolomics as an effective tool for 
investigating the metabolic features of the highly-aggressive mesenchymal phenotype by 
imaging the metabolomics phenotype of its subcellular organelle, which resolved the 
metabolic susceptibilities unique to this previously undruggable phenotype. 
In total, this thesis combines various physical science and systems biology approaches with 
many single-cell technologies and analyses to obtain a deep and thorough understanding of 
the fundamental nature and underlying mechanisms of non-genetic drug resistance in cancer. 
It provides several novel insights into the rational design of better and more effective 
combination therapies for overcoming drug resistance.  
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C h a p t e r  2  
KINETIC INFERENCE RESOLVES EPIGENETIC MECHANISM 
OF DRUG RESISTANCE IN MELANOMA 
We resolved a mechanism connecting tumor epigenetic plasticity with non-genetic adaptive 
resistance to therapy, with MAPK inhibition of BRAF-mutant melanomas providing the 
model.  These cancer cells undergo multiple, reversible drug-induced cell-state transitions, 
ultimately yielding a drug-resistant mesenchymal-like phenotype. A kinetic series of 
transcriptome and epigenome data, collected over two months of drug treatment and release, 
revealed changing levels of thousands of genes and extensive chromatin remodeling. 
However, a 3-step computational algorithm greatly simplified the interpretation of these 
changes, and revealed that the whole adaptive process was controlled by a gene module 
activated within just three days of treatment, with RelA driving chromatin remodeling to 
establish an epigenetic program encoding long-term phenotype changes. These findings were 
confirmed across several patient-derived cell lines and in melanoma patients under MAPK 
inhibitor treatment. Co-targeting BRAF and histone-modifying enzymes arrests adaptive 
transitions towards drug tolerance in epigenetically plastic melanoma cells and may be 
exploited therapeutically. 
This chapter includes content from our previously published article: 
[1] Su, Yapeng, Xiang Lu, Guideng Li, Chunmei Liu, Yan Kong, Jihoon W. Lee, Rachel Ng et al. "Kinetic 
Inference Resolves Epigenetic Mechanism of Drug Resistance in Melanoma." Cancer cell (Under 
revision). doi: 10.1101/724740 
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Introduction   
The acquisition of therapy resistance in cancer patients remains a major clinical 
challenge [1–4]. While various genetic mutations have been reported to cause resistance 
[5,6], recent literature also points to the importance of epigenetic modulations to drug-
tolerance that can precede the emergence of drug-resistant genotypes in a variety of tumor 
types [7–14]. For such epigenetic processes, tumor cells adapt to the drug treatment by 
orchestrating master transcription factors and chromatin remodelers within a regulatory 
network. The resultant changes of chromatin profile via histone modifications eventually 
establish specific gene expression programs of the drug-tolerant state [15–24]. Unlike genetic 
mechanisms, epigenetic cell-state transitions can be reversed upon drug removal [10,25,26]. 
Indeed, such reversibility has been observed in in vitro and in vivo tumor models [10,25–28] 
and increasingly reported in clinical settings [29–32]. Nevertheless, the mechanistic details 
of these epigenetic modulations remain incompletely understood, thus limiting the options 
for therapeutic interventions designed to arrest the non-genetic resistance.  
Accumulating evidence suggests that phenotypic plasticity is an essential characteristic 
associated with non-genetic resistance [15,33–35]. Phenotypic plasticity, defined as the 
ability of cells to reside in distinct phenotypes and switch between them without genomic 
alterations, is an intrinsic property of cells to survive stressful conditions. Cancer cells can 
also exploit plasticity to survive drug treatment by transitioning from a drug-sensitive 
phenotype to drug-tolerant phenotypes [15,36]. Paradigmatic examples include certain 
BRAF-mutant melanomas under MAPK pathway inhibitor (MAPKi) treatment. The drug-
naïve melanoma cells initially reside as drug-sensitive melanocytic phenotypes (MITFhigh 
and elevated pigmentation genes).  Upon continuous MAPK inhibition, they can evolve into 
a transient, slow-cycling, neural-crest-like phenotype (MITFlow/NGFRhigh) [25,37] and 
eventually towards a mesenchymal phenotype (MITFlow, SOX10low, and elevated 
mesenchymal markers) [25,35,38,39]. The mesenchymal phenotype is notorious for its 
resistance to MAPKi as well as many other treatment regimens including immunotherapy 
[9,40,41]. 
Several studies have explored the molecular markers associated with the drug-tolerant 
or drug-resistant phenotypes including: down-regulation of SOX10 [21,26] and upregulation 
of JNK/c-JUN [37,40,42] in the mesenchymal phenotype, as well as upregulation of KDM5 
[28,43] in a slow-cycling (likely neural crest) drug-tolerant phenotype. However, there 
remains a clear unmet need to identify the early-stage adaptive processes that are triggered 
immediately following the drug exposure to lead the transition towards drug-tolerant 
phenotypes. Such an understanding may unveil the molecular nature of phenotypic plasticity 
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and compelling drug targets that can arrest the entire adaptive resistance process prior to 
the establishment of resistant phenotypes. 
We sought to resolve the early-acting regulatory process of adaptive resistance through 
kinetic characterizations of the transcriptome and functional epigenome of patient-derived 
BRAF-mutant melanoma cell lines featuring varying degrees of phenotypic plasticity. 
Systems-level analysis of the transition dynamics, followed by experimental validations, 
discerned the critical transcription factors and chromatin remodelers within a regulatory 
network that initiated and drove the adaptive cell state transition. The mechanism informed 
the design of combination therapies to disrupt the chromatin remodeling and to arrest the 
adaptive transition at a very early stage. The phenotypic plasticity was found to correlate 
with the efficacy of the drug combinations across multiple melanoma cell lines, implicating 
that the plasticity may be epigenetically encoded in the baseline chromatin profiles. The 
signatures of the adaptive mechanism were also found in sequential patient biopsies. 
Together, our study resolved an early-acting epigenetic mechanism of non-genetic 
resistance, which may be exploited to prevent targeted therapy resistance in melanoma.  
Results 
Reversibility of the adaptive transition in patient-derived BRAF-mutant melanoma cell 
lines 
We used an epigenetically plastic BRAFV600E-mutant melanoma cell line M397 as a 
model system to interrogate the kinetics of the adaptive cell state transition in response to 
continuous BRAF inhibition. We treated the cells with a BRAF inhibitor (BRAFi) for a 
month, then separated them into two sets: one with an additional month of continuous drug 
treatment, and the other untreated for one month (Figure 1A). Cells were collected for a time-
series transcriptome and functional characterization (Figures 1 and S1; Table S1). The 
resultant gene expression data after 29 days (D29) of drug exposure showed significant 
enrichments of mesenchymal signatures, cellular invasiveness, migration, and loss of MITF 
targets (Figures 1C and S1D; Table S2). The adapted cells were slow-cycling, as evidenced 
by reduced proportion of cells in the S and G2/M phases (Figure 1E). An additional month 
of drug exposure maintained the cells in a steady state with a relatively stable transcriptome 
profile (Figures 1B and S1C). Drug removal (DR) triggered a reversion to a state with a 
transcriptome profile that resembled the untreated (D0) state (Figures 1B, S1C and S1D), as 
illustrated by the fact that the molecular signature enrichments of D29 vs. D0 and DR30 vs. 
D29 were essentially mirror images of each other (Figure 1C). Furthermore, the reverted 
cells recovered their proliferative and cell cycle characteristics, and were re-sensitized to 
BRAF inhibition (Figures 1D-1F). These results suggest a fully reversible adaptive transition 
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at the transcriptomic, phenotypic, and functional levels. We further confirmed the 
existence of such reversibility, at the functional level, in other BRAF-mutant melanoma cell 
lines with varying sensitivities to BRAFi (Figures 1D, 1F, S1A, and S1D). Therefore, the 
BRAFi-induced adaptive resistance is reversible at both transcriptomic and functional levels 
with generality across a panel of patient-derived BRAF-mutant melanoma cell lines. 
Information theoretic analysis of the transcriptome kinetics resolved two gene modules 
associated with the reversible transition 
To extract the underlying regulatory modules that change coordinately in the reversible 
transition, we applied information theory-based surprisal analysis to the time-course 
transcriptome data (Eq. 1). Surprisal analysis was initially formulated to understand the 
dynamics of nonequilibrium systems [44]. It has been extended, in multiple publications [45–
52], to characterize biological processes in living cells. It approximates quantum state 
distributions of molecular species within a cell’s molecular ensemble in order to assess the 
maximum entropy of those biomolecules. Particularly, for a system characterized by a kinetic 
series of transcriptome, Equation 1 from surprisal analysis can de-convolute the changes of 
thousands of genes into one unchanged gene expression baseline and a series of gene 
expression modules. Each module contains a group of genes that are coordinately changing 
together across time points (an example gene list for module-1 is visualized in dashed-line, 
circled regions in Figure 2A). We applied this analysis, and then used the resulting gene 
modules to computationally estimate and visualize cell-state transition trajectories (STAR 
Methods).  
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Specifically, in Equation 1,  ln Xi t , the natural logarithm of the measured level of 
transcript i at time t, is defined as the expression baseline of transcript i (
0ln i ), minus the 
sum of gene module alterations weighted by the relative contribution to each module by 
transcript i (  j ij
j
t G ). Each gene module is represented by a time-dependent module 
amplitude (or score λj(t)) that denotes the importance of the gene module j to the global 
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transcriptome at time t. Module-specific contribution scores from each transcript Gij 
denote weight of gene i on module j. Thus, the biological functions of each module j can be 
inferred from genes with higher positive or negative module-specific contribution scores Gij. 
The gene expression baseline is the reference point for the entire transition.  
The application of Eq. 1 to the time-series of transcriptome data de-convoluted them 
into two time-dependent gene modules plus the gene expression baseline. To visualize the 
kinetic changes of the entire transcriptome and each gene module, we plotted the time-series 
transcriptome profiles and de-convoluted gene modules as self-organizing mosaic maps 
(SOMs) (Figures 2A and S2A). The gene expression baseline calculated from the surprisal 
analysis (top row of SOMs in Figures 2A and S2A) shows no time dependence.  This 
demonstrates the validity of surprisal analysis in analyzing this system [51]. The second and 
third rows are plots of the two resolved, time-varying gene modules. The SOMs for D0 and 
DR30 appear nearly identical, reflecting the reversibility of the adaptive response at the 
transcriptome level as well as at the resolved gene module level. When the baseline state and 
the two regulatory gene modules are summed (the row labeled ‘sum’ in Figures 2A and S2A), 
the resultant SOMs from surprisal analysis closely matched the experimental transcriptome 
data (bottom row of Figures 2A and S2A). Thus, the expression change of thousands of genes 
during the reversible transition can be delineated by a time-invariant expression baseline, 
plus the changes of two time-varying gene modules. 
The reduction of the transcriptome kinetic series into two gene modules enables 
visualization of drug-adaptation trajectories taken by the cells.  This is achieved by projecting 
the time-series transcriptome onto the 2-D cell-state space defined by the gene modules, with 
each axis representing the module score of each gene module. The plot is a cyclic loop 
(Figure 2B) comprised of a forward trajectory (blue), and a drug-removal, reverse trajectory 
(green), which indicates that the cells undertake a different return path to the original drug-
sensitive state. This cyclic shape suggests that the two gene modules operate sequentially.  
The first module, Mearly, was fully activated within the first 3 days of drug treatment (y-axis 
of Figure 2B), while the second module, Mlate, (x-axis of Figure 2B) gradually activated 
between days 3 and 29 (D3 and D29).  Continued treatment beyond D29 caused minimal 
change in either module (blue dash line circled region of Figure 2B), in agreement with the 
stable transcriptome profile observed from D29 to D59 (Figures 1B and S2A). Interestingly, 
upon drug removal, there was an immediate reduction in the first module, followed by a 
gradual reversion of the second module to its original pre-treatment module score. The 
different operational dynamics of these modules resulted in the cyclic transition trajectories 
that the cells took. 
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To further investigate the biological meaning of the two gene modules, we conducted 
gene set enrichment analysis (GSEA) on genes ranked by their module-specific contribution 
scores (Gij). Mlate was positively associated with melanocytic signatures (e.g. MITF targets) 
and negatively correlated with mesenchymal signatures, cell invasiveness, and NFκB, TGFβ, 
and JNK signaling pathways (Figure 2B; Table S3). Consequently, the gradual change of the 
Mlate score from positive to negative values between D3 and D29 indicates that the drug-
treated cells de-differentiated towards neural-crest and mesenchymal phenotypes, with loss 
of melanocytic signatures, and an increase of NFκB, TGFβ, and JNK signaling. Similarly, 
Mearly was positively associated with HDAC1 activity and negatively associated with cell 
cycle regulation (Figure 2B), suggesting that the initial drug exposure led to an immediate 
histone deacetylation and cell cycle arrest. Therefore, the two gene modules resolved from 
surprisal analysis delineated the stepwise, reversible dynamic changes of cellular functions 
during the cyclic transitions associated with adaptive resistance development. 
Dynamic system modeling discerned the regulatory relationship between the early- and 
late-gene modules  
A possible implication of the sequential operation of Mearly and Mlate is that the biological 
processes associated with the two modules are coupled where the completion of the Mearly 
gene program triggers the expression of Mlate genes. This implies a co-dependency of these 
two modules. We tested this hypothesis by fitting the dynamic dependence of the two 
modules to a coarse-grained model resembling a simple two-gene feedback circuit (Eq. 2). 
This approximation yields an estimate for how the two gene modules are coupled (Figure 2C; 
see STAR Methods).   
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Here, the brackets denote the averaged expression level of module-associated genes at 
a given time point. Be and Bl represent the basal production of Mearly- and Mlate-associated 
genes, respectively. Coefficients Me-e and Ml-l reflect self-regulation of Mearly and the Mlate 
expression, respectively, while coefficients Ml-e and Me-l reflect the Mlate regulation over the 
expression of Mearly genes and vice versa.  
The ODE fitting of gene expression associated with Mlate and Mearly for both forward and 
reverse trajectories revealed that Mearly exerted significant control over both itself and Mlate.  
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This is evidenced by the significantly larger pre-factors Me-e and Me-l (Figures 2D and S3; 
Table S4). By contrast, Mlate yielded only minimal influence over itself or Mearly. The strong 
influence of Mearly applied to both the drug-treated forward and drug-release reverse 
trajectories (Figures 2D, 2E, S2B and S3). In other words, Mearly dominated the entirety of 
the forward D0-D29 transition path towards drug resistance as well as the drug removal 
trajectory back to the drug-sensitive state. Further, the dependence of Mlate on Mearly 
suggested an orchestrated process whereby certain important transcription factors associated 
with Mearly played a key role in regulating downstream genes associated with Mlate, ultimately 
driving the adaptive transition towards the drug resistant phenotype. Thus, dynamic system 
modeling revealed the strong influence of the early-acting gene module on the late-acting 
gene module, and implied that Mearly may contain the key regulators that initiated the adaptive 
cell state transition.   
Inference of critical early-acting upstream transcriptional regulators based upon the 
inter-dependence of the two gene modules 
Guided by the importance of Mearly module in driving the adaptive resistance (Figure 
2D), we hypothesized that certain key transcription factors (TFs) or co-factors within Mearly 
regulate the downstream genes within Mlate and thus drive the adaptive transition. To test this 
hypothesis, we used two complementary approaches to infer the early-acting TFs in M397. 
For the first approach (Figures 3A and S4A), we hypothesized that functionally relevant TFs 
associated with Mearly should have their target effector genes enriched in the gene set 
associated with the subsequent action of Mlate. Therefore, we first filtered out all the possible 
TFs and co-factors within Mearly and then acquired their downstream targets from the TF 
targets database, followed by assessing their enrichment in the genes associated with Mlate 
(STAR Methods). This identified that subset of Mearly-related TFs whose downstream targets 
are overrepresented within the genes associated with Mlate module. Five statistically enriched 
TFs and co-factors were identified, with Pearson correlation coefficients ρ > 0.9 (Figures 3B, 
panel i).  These include MEIS3, which is required for neural-crest invasion [53], NKX3-2, 
which mediates the epithelial-mesenchymal  transition in neural crest development [54], and 
LEF1 whose down-regulation is related to non-genomic MAPKi resistance in melanomas 
[9]. These enriched TFs may regulate the cancer cell phenotype changes associated with the 
forward and reverse transitions (Figure 3C). Most interestingly, the histone modifying 
enzyme KDM5B (H3K4 demethylase), whose expression displayed a sharp increase by D3, 
was also found to have many target genes overrepresented in Mlate (Figure 3D).  Importantly, 
this histone modifier has been previously associated with reversible drug-tolerant states in 
several tumor types, including melanomas [28,43,55].  
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For the second inference approach, we performed enrichment analysis of cis-
regulatory elements in the promoter regions of all genes strongly associated with Mlate 
(Figure S4B). We ranked these elements according to their statistical significance (Figure 
3B, panel ii).  The top one ranked element was the binding motif of the NFκB family member 
RelA, which was recently identified as an important regulator associated with this adaptive 
transition [25]. The expression kinetics of RelA was not associated with either Mlate or Mearly. 
Instead, the expression level of RelA gradually increased from the start of BRAF inhibition 
to D29, implying its consistent activity over the entire adaptive transition towards the 
mesenchymal state (Figure 3D). Interestingly, NFKBIE, which is highly anti-correlated with 
Mearly (ρ = -0.88) and represses NFκB activation by preventing RelA nuclear translocation, 
displayed a sharp drop by D3 (Figure 3D).  This suggests that activation of RelA and 
associated downstream genes in Mlate might be mediated by the immediate down-regulation 
of NFKBIE, thus releasing RelA into the nucleus. A second transcription regulator similarly 
identified was AP-2α, which has been reported to be involved in melanoma progression and 
metastasis [56]. Taken together, these analyses greatly simplified the interpretation of the 
kinetic transcriptome data by inferring a few controlling, early-acting TFs and co-factors 
(Figures 3B and S4B), including RelA and KDM5B, from the large numbers of transcripts 
altered during the course of BRAF inhibition and drug release (Figures S5A and S5B). 
Reversibility of chromatin accessibility and histone modification profiles shed light on 
downstream transcription factors associated with the adaptive transition 
Information theory analysis and dynamic ODE modeling of transcriptome kinetics 
pinpointed a few key early-acting TFs that likely trigger the initiation of the cell state 
transition towards resistance. To obtain a complete mechanistic picture, we seek to further 
identify the late-acting driver regulators that are the downstream targets of those early-acting 
TFs via cellular epigenome characterization at different stages of the reversible transition 
(Figure 5A).  
Since the previous inference and enrichment analyses pointed to the fast activation of 
histone modifiers KDM5B and HDAC1 in Mearly that represses activation histone marks 
(Figures 2B and 3B), we first accessed the regulatory regions associated with open chromatin. 
We accomplished this via transposase-accessible chromatin with high-throughput 
sequencing (ATAC-seq) and chromatin immunoprecipitation sequencing (ChIP-seq) against 
two activation histone marks, H3K4me3 and H3K27ac, which are targets of KDM5B and 
HDAC1. Similar to the transcriptome profiles, the overall chromatin accessibility displayed 
reversible changes during drug treatment and removal. That accessibility gradually decreased 
following BRAFi exposure, but after a month of drug removal reverted to a profile similar 
to that of untreated cells (Figures 4A, 4B and S5C). Overall modification levels of the two 
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histone marks displayed the same reversibility (Figure S5D and S5E).  However, the drop 
in these marks after 3-day BRAFi exposure was large relative to the corresponding small 
reduction of the ATAC-seq signal (Figures 4A and S5D), suggesting that these histone 
modifications may precede and perhaps drive the changes in chromatin accessibility. Further, 
the promoter region of many well-reported regulators for the adaptive resistance in 
melanoma also displayed reversible changes that aligned well with their reversible 
expression patterns (Figure S5E). We also tabulated the numbers of differential peaks of 
H3K4me3 and H3K27ac that changed between day 0 and subsequent time points (Figure 
4C). The differences between states at long-term drug removal (DR30) and at day 0 were 
minimal. This was especially true for H3K27ac, where only two peaks reflected acetylation 
differences between day 0 and long-term drug removal. These data demonstrated the 
genome-scale chromatin landscape underwent reversible changes upon drug treatment and 
removal, thus supporting a potential epigenetic mechanism of the reversible adaptive 
transition. 
To search for causal TFs driving the dynamic changes of the chromatin landscape, we 
used K-means clustering to analyze the genome-wide chromatin restructuring at four time 
points spread across the reversible transition (Figure 4B). We identified four clusters of 
chromatin accessibility peaks with unique kinetics, plus a fifth, time-invariant cluster. For 
these four clusters, we mined the underlying DNA sequences and searched for over-
represented TF binding motifs. The highly enriched motifs in the reversible transition (right 
side of Figure 4B) contain binding motifs of certain TFs reported previously to be involved 
in the adaptive resistance of melanomas, including MITF [57], SOX10 [26], Jun-AP1 
[37,40,42], and RelA [25].  Some of these TFs, such as RelA and AP-2, were overlapping 
with those inferred from the transcriptome data (Figure S4B). To further resolve whether 
these modifications were modulated by RelA whose motif is ranked top one in the common 
cis-regulatory element inference (Figures 3B and S4B), we quantified the H3K4me3 and 
H3K27ac ChIP-seq signals across all the RelA binding sites and found marked reduction 
after 3 days of drug exposure, with recovery upon drug removal (Figure 4D). It suggests that 
RelA binds primarily to distal sequences containing both activation histone marks H3K4me3 
and H3K27ac, and might regulate them through interactions with the KDM5B and HDAC1 
during the adaptive transition.  
In addition to confirming RelA as a critical early-acting regulator that may cause the 
epigenome changes, we further mined downstream regulators that may be the direct targets 
of RelA and showed consistent epigenome alteration patterns at the RelA binding region 
across the reversible transition. We achieved this by quantifying the changes in chromatin 
accessibility and two activation histone marks of all TFs/co-factors associated with Mlate that 
contain RelA binding motifs (STAR Methods). SOX10 was identified to display the most 
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significant changes across all three epigenome alterations at the RelA binding region 
(Table S5). Consider the importance of SOX10 in regulating mesenchymal phenotype in 
melanoma [21,26,58], we hypothesized that SOX10 is likely one key downstream regulator 
for the cell state transition towards resistance. Taken together, these data illustrated the 
reversibility of adaptive resistance at the level of the global chromatin landscape. The 
kinetics of the reversible epigenome profiles further pointed to a collection of early-acting 
and downstream-effector TFs, particularly RelA and SOX10, in regulating such adaptive 
epigenetic resistance. 
Mechanistic regulatory network of adaptive resistance 
Based on the transcriptional regulators inferred from gene module interactions and 
epigenome profiling, we tied these inferences together with prior knowledge and formed a 
mechanistic regulatory network (Figure 5A). We hypothesized that for drug-naïve cells, 
NFKBIE and SOX10 are both epigenetically activated and that downstream TGFβ signaling 
is repressed [26]. BRAF inhibition triggers a sharp drop in NFKBIE expression and a sharp 
increase in the expression of the histone demethylase KDM5B (Figure 3D). The reduction 
of NFKBIE would promote the nuclear translocation of RelA [59]. In the nucleus, RelA 
would then recruit KDM5B and HDAC1 to repress SOX10 and NFKBIE expression by 
erasing the activation histone marks in their promoter regions, consistent with the rapid 
decrease of activation histone marks at RelA binding sites (Figures 4D). The downregulation 
of SOX10 expression has been reported to promote BRAFi adaptive resistance through 
promoting the up-regulation of TGFβ signaling and mesenchymal transition (Figure 3C) 
[21,26]. Our mechanistic hypothesis provides a rationale for how this happens, and further 
indicates how the downregulation of NFKBIE promotes RelA nuclear translocation, thus 
establishing a positive feedback loop (Figure 5A). Drug removal reverses this process, 
starting with the gradual recovery of SOX10 expression (Figure 3D), the loss of 
mesenchymal signatures (Figure 3C), and the eventual re-opening of the chromatin (Figure 
4A).  We extensively tested this mechanism in the following ways.  
We first examined the change in overall chromatin accessibility and levels of the histone 
marks H3K4me3 and H3K27ac at the promoter regions of SOX10 and NFKBIE over the 
course of the adaptive transition. We found reduction of the overall chromatin accessibility 
and of the levels of both histone marks upon BRAF inhibition, and a recovery of these signals 
upon drug removal (Figure 5B). These observations confirmed the involvement of chromatin 
alterations in the gene expression changes of SOX10 and NFKBIE. We next explored the role 
of RelA in recruiting histone remodelers. We tested whether RelA, KDM5B and HDAC1 
simultaneously bind to the promoter regions of SOX10 and NFKBIE. We performed ChIP-
PCR experiments on untreated cells using primers targeting the promoter regions of SOX10 
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and NFKBIE. The results confirmed the co-localization of RelA, KDM5B, HDAC1, and 
the two histone marks (Figure 5C). Quantitative assessment of binding profiles via ChIP-
qPCR further revealed that BRAFi treatment elevated binding of RelA, KDM5B, and 
HDAC1 to the SOX10 and NFKBIE promoter sites and consequently diminished H3K4me3 
and H3K27ac histone marks (Figure 5D). These binding enrichment profiles reverted to the 
levels of the untreated cells after drug removal (Figure 5D). Co-immunoprecipitation (Co-
IP) assays confirmed the binding of RelA to KDM5B and HDAC1 (Figure 5E), suggesting 
that RelA can form a complex with either KDM5B or HDAC1. These findings support the 
role of RelA in recruiting histone remodelers in regulating the expression of SOX10 and 
NFKBIE.  
To further validate that SOX10 and NFKBIE are directly repressed by the recruitment of 
KDM5B and HDAC1 through RelA, we sought to perturb RelA with a drug that inhibits its 
nuclear translocation. According to our hypothesis, such inhibition should decrease the 
recruitment of the histone-modifying enzymes KDMB5 and HDAC1, which, in turn, will 
increase the H3K4me3 and H3K27ac levels at the promoter regions of SOX10 and NFKBIE. 
We first treated the M397 cells with BRAFi for 21 days to induce adaptive resistance with 
reduced SOX10 expression (Figure 5F). Under continued BRAFi treatment, we added a drug 
(JSH-23) to inhibit RelA nuclear translocation [60], and monitored short-term interval 
changes in SOX10 expression. SOX10 expression rapidly increased following JSH-23 
treatment and returned to the level originally observed at D0 after 24 hours of drug exposure 
(Figure 5F). Furthermore, we observed barely detectable binding of RelA, KDM5B, and 
HDAC1 and consequently increased binding of H3K4me3 and H3K23ac at the SOX10 and 
NFKBIE promoter regions after 24 hours of JSH-23 treatment (Figure 5G). The immediate 
increase of SOX10 expression and decrease of HDAC1 and KDM5B enrichment within 24 
hours of JSH-23 exposure further validated our hypothesis that the repression of SOX10 and 
NFKBIE is directly through RelA-mediated epigenetic silencing. 
We performed additional independent perturbations to validate the proposed molecular 
mechanism using genetically engineered M397 cells. We first triggered RelA nuclear 
translocation through CRISPR knockout (KO) of NFKBIE to release the cytoplasmic 
retention of RelA [61]. According to our proposed mechanism, this translocation should in 
turn enhance recruitment of the histone modifying enzymes HDAC1 and KDM5B, and thus 
diminish levels of activation histone marks H3K4me3 and H3K27ac at the promoter regions 
of SOX10. This prediction was confirmed by ChIP-qPCR result (Figure 5H).  The actual 
expression of SOX10 was consequently reduced in NFKBIE-KO cells relative to control cells 
(Figure 5I). Similarly, knockout of KDM5B partially upregulated H3K4me3 levels at the 
SOX10 and NFKBIE promoters (Figure 5J), thus increasing SOX10 and NFKBIE expression 
(Figure 5K). In addition, we also observed elevated H3K27ac at the SOX10 and NFKBIE 
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promoters, possibly through the decreased recruitment of HDAC1 by RelA due to the 
elevated NFKBIE expression. As a functional validation, we tested SOX10-KO and 
NFKBIE-KO M397 cells, expecting that both engineered cells would develop drug tolerance 
to BRAFi more rapidly than the wild type counterpart.  These engineered cell lines indeed 
behaved as expected according to our proposed mechanism (Figure 5L). Collectively, these 
experiments provide strong evidences for the proposed mechanism.  They validate the critical 
role of RelA as a rapid-acting regulator of resistance development by recruiting KDM5B and 
HDAC1 to epigenetically suppressed SOX10 and NFKBIE expression and consequently 
induce BRAFi drug tolerance (Figure 5A).  
Baseline epigenome states correlate with the phenotypic plasticity and drug response 
across melanoma cell lines  
We now turn towards understanding whether the mechanism of adaptive response of 
M397 cells to BRAF inhibition can be generalized to other BRAF-mutant melanoma cell 
lines that exhibit varying degrees of phenotypic plasticity and baseline level of resistance to 
BRAFi. We first tested the generality of Mearly and Mlate modules in other melanoma cell by 
evaluating the co-occurrence of gene sets associated with two modules across the CCLE 
melanoma cell lines. We observed higher co-occurrence score relative to random gene 
permutation (Figure S6A, see STAR Method), suggesting the various gene sets associated 
with two modules are not specific to the cell line we studied, but similarly modulated and co-
expressed across other cohorts of melanoma cells.  
Furthermore, we investigated the BRAFi-induced transcriptome changes in additional 
six patient-derived BRAF-mutant cell lines, each with a unique drug-naïve phenotypic 
composition that varies from largely mesenchymal (M381) to in-between neural crest and 
melanocytic (M263), to mostly melanocytic (M229) [25].  In order to permit comparisons 
between different cells, we projected the whole transcriptome kinetic data of each cell line 
onto the two-dimensional space defined by Mearly and Mlate, similar to the two-dimensional 
plot in Figure 2B (Figure 6A). Cell lines at the left side displayed much higher baseline IC50 
value than those at the right side, suggesting that cells at the BRAFi-induced dedifferentiated 
state are intrinsically resistant to BRAF inhibition. Similar trends were also observed across 
various BRAF-mutant melanoma cell lines from the GDSC database (Figure S6B), indicating 
cells with higher Mearly and lower Mlate scores are generally resistant to BRAFi. Similar to 
M397, upon BRAF inhibition, each cell line exhibited an initial change in the positive 
direction along Mearly, followed by a motion along the negative direction of Mlate (Figure 6A), 
which implied some mechanistic similarities between the cells. However, different cell lines 
also exhibited widely different amplitudes of motion along this 2D landscape, reflecting large 
variations in transcriptome plasticity (Figure 6A). Our hypothesis was that these different 
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amplitudes of transcriptome motion, particularly the motion along the controlling module 
Mearly, were related to the pre-treatment (baseline) epigenome state of the cells.  
Mearly was enriched with early-acting epigenetic modulations that dictate the subsequent 
adaptive transition in M397 (Figure 2B-2E).  Thus, for comparison across cell lines, motion 
along Mearly was chosen as a surrogate of transcriptome plasticity. We correlated the BRAFi-
induced motion along Mearly with the baseline epigenetic characteristics of the cells.  These 
correlations included the average chromatin accessibility (Figure 6B), the average levels of 
the two histone marks across all the enriched domains (Figures 6C, 6D, and S6C), and the 
levels of two histone marks on the TSS region of SOX10 (Figures 6E, 6F, and S6D). The 
strong correlations, particularly with SOX10-specific H3K4me3/H3K27ac signals, suggest 
that cellular plasticity is associated with the baseline chromatin state of the drug-naïve cells 
and implicate the generality of the chromatin remodeling mechanism in the adaptive 
resistance of melanoma cells. These findings also imply that cellular plasticity that permits 
adaptation to BRAFi may be encoded in cells before treatment through general and specific 
structural details of the chromatin.  
The relationships between cellular plasticity, chromatin accessibility (Figure 6G), and 
adaptive resistance to BRAFi suggest that drug targeting the chromatin remodeling 
machinery in combination with BRAFi would arrest the adaptive transition and inhibit the 
development drug resistance in the most plastic cell lines (e.g. M397 or M262) but should 
have little effect on the least plastic lines (e.g. M381). We used a recently-developed KDM5 
inhibitor CPI-455 [62] and a second generation HDAC1 inhibitor Quisinostat [63] to treat 
the cells in combination with BRAFi vemurafenib. We employed the minimal doses of CPI-
455 and Quisinostat that were sufficient to inhibit KDM5B and HDAC1 without significant 
cytotoxicity (Figures S6E and S6F). Clonogenic assays revealed that, in comparison with 
BRAFi monotherapy, both of the dual drug combinations (BRAFi + KDM5Bi or BRAFi + 
HDACi) could lead to a sustained growth inhibition across several epigenetically plastic 
melanoma cell lines, including M397 (Figure 6H). These results demonstrate the potential 
utility of co-targeting the driver oncogene BRAF along with chromatin-remodeling 
machinery to treat certain melanomas which demonstrate significant epigenetic changes 
upon BRAF inhibition. Importantly, the M381 and M233 cell lines, which exhibited the 
lowest levels of plasticity (Figure 6A) and chromatin accessibility (Figure 6G), did not 
respond to the therapy combinations (Figures 6H). Thus, the responsiveness towards 
combination therapy with epigenetic drugs can be predicted through the degree of cellular 
plasticity, which may be encoded by the baseline epigenome of cells prior to treatment. 
Collectively, the strong associations across different cell lines between transcriptome 
changes and the baseline chromatin permissiveness suggest both a generality and predictable 
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limitations of the molecular mechanism (Figure 5A), and also inform the use of epigenetic 
drugs across melanoma cells of different phenotypes.  
The presence of the epigenetic resistance mechanism in MAPKi-treated melanoma 
patients     
To determine whether the adaptive resistance mechanism identified in melanoma cell 
lines is present in melanoma patient samples, we collected paired tumor biopsies from 
patients bearing BRAFV600-mutant tumors prior to MAPKi treatment and at the onset of 
therapy resistance. Paraffin-embedded cross sections were stained for MITF, SOX10, 
NFKBIE, and KDM5B.  Prior to the therapy, these four protein markers showed relatively 
uniform spatial distributions (Figure 7A). After MAPKi exposure, some regions of the tumor 
tissues retained similar MITF, SOX10, and NFKBIE expression and loss of KDM5B, while 
other regions showed elevated KDM5B but loss of MITF and SOX10 (Figures 7A and 7B). 
The mutually exclusive spatial distribution of KDM5B and SOX10/MITF was consistent 
with the chromatin remodeling-mediated adaptive resistance mechanism observed (Figure 
5A), and suggested the presence of the adaptive resistance mediated by the epigenetic 
reprogramming in melanoma patients undergoing MAPKi treatments.  
To investigate the generality of our findings, we interrogated the expression levels of 
phenotypic markers and critical TFs using published transcriptome data of BRAF-mutant 
melanoma patients [9,64]. Gene expression levels from seven paired samples before and after 
MAPKi treatment were compared and enriched against curated gene sets (Figures 7C, and 
S7A; Table S6; STAR Methods). The reduced expression of MITF, NFKBIE, SOX10, and 
other melanocytic genes as well as the elevated expression of KDM5B, JUN, and other 
mesenchymal-related genes after treatment suggested the existence of the chromatin 
remodeling-mediated adaptive resistance in these patients. Furthermore, we also analyzed 
the published transcriptome data [64] of the paired melanoma patient samples by projecting 
them onto the two-dimensional plot defined by Mearly and Mlate and calculating the changes 
of Mearly and Mlate score upon MAPKi treatment. Like M397, Mearly score increased and Mlate 
score decreased after treatment, indicating the gene signatures associated with Mearly and Mlate 
displayed consistent changes with our cell line model (Figure S7B). In addition, we also 
evaluated the co-occurrence of gene sets associated with Mearly and Mlate modules across the 
TCGA melanoma patient samples (STAR Method). We observed higher co-occurrence score 
relative to random gene permutation (Figure S7C). This suggests that the various functional 
gene sets associated with two modules are not cell line specific, but similarly modulated and 
co-expressed across other cohorts of melanoma patient samples. We further performed 
Kaplan-Meier survival analysis using the melanoma dataset in TCGA (STAR Methods). 
Consistent with our mechanism, patients with either low baseline expression level of KDM5B 
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or higher level of NFKBIE are less likely to develop adaptive resistance to MAPK 
inhibition and consequently have longer overall survival (Figure 7D). Taken together, these 
results confirmed the existence of adaptive resistance in melanoma patients, and validated 
the clinical relevance of the epigenetic mechanism. 
Discussion 
Epigenetic plasticity is precisely titrated during normal development to stabilize cell fate 
commitment and facilitate appropriate cellular responses to external cues [15,17,65]. Cancer 
cells with dysfunctional epigenome homeostasis can exploit this built-in chromatin plasticity 
to survive drug challenges and other stressful conditions [24,66–68]. Accumulating evidence 
indicates that epigenetic dysregulation can vary across different tumor cells and can also give 
rise to all the classic hallmarks of cancer [15]. For example, for epigenetically plastic cancer 
cells, a highly permissive epigenetic landscape allows them to rapidly adapt to drug 
challenges by reversibly transitioning into a drug-tolerant state that fuels malignant 
progression. Such adaptive transitions have been recently observed in clinical biospecimens 
of glioblastoma [23], breast cancer [69], and many other tumor types [18,28,70]. Despite the 
strong influence of epigenetic plasticity on therapy resistance, the mechanistic underpinnings 
of the drug-induced epigenetic reprogramming that initiates the adaptive transition are less 
clear. A systems-level characterization aimed at capturing the dynamic drug adaptation is a 
pressing need for solving this mechanistic puzzle. 
Our goal was to establish a firm mechanistic link between epigenetic plasticity and the 
development of adaptive drug resistance in BRAF-mutant melanomas. Using BRAFi-treated 
patient-derived melanoma cell lines as models, our study revealed several properties of 
cellular plasticity. First, the drug-induced cell state changes were completely reversible upon 
drug removal at the transcriptome, epigenome, and functional levels. Second, the cell state 
changes proceeded via the sequential operations of two distinct gene expression programs, 
with the early-acting gene module setting in motion epigenetic and transcriptional programs 
that encode for longer-term changes associated with the late-acting gene module, ultimately 
yielding the drug-resistant mesenchymal-like phenotype. Finally, the activation of the early-
acting module upon BRAF inhibition is extremely rapid. For M397 cells, activation involves 
nuclear translocation of the key transcription factor RelA, aided by rapid down-regulation of 
NFKBIE and coupled with the rapid recruitment of histone modifiers.  These cells are thus 
poised with a ‘hair-trigger’ response to drug challenge.  
A mechanistic link between epigenetic plasticity and the development of adaptive drug 
resistance was successfully established through a systems-level, multi-omics approach that 
focused on the kinetics of the adaptive response. We first acquired time-resolved 
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transcriptome and epigenome data to track the kinetics of the reversible cell state transition 
over a two-month period. Critical regulators that underlie the adaptive transition were 
distilled from thousands of candidate TFs/co-factors through the sequential application of 
two distinct systems biology approaches followed by bioinformatics inferences. First, a top-
down information theoretic analysis [44,46,51,52,71] simplified the transcriptome changes 
into the changes of two gene modules, one of which (Mearly) was fully activated within the 
first 3 days of BRAF inhibition. Next, dynamic ODE modeling [72] precisely identified co-
dependencies between two modules and uncovered the dominating influence of Mearly over 
both itself and the second module, Mlate. Guided by these gene module relationships, 
bioinformatic inference further identified key TFs and epigenetic regulators from which we 
extracted and experimentally validated a mechanistic regulatory network for the adaptive 
resistance. Such mechanistic understanding would be difficult to uncover without the 
synergistic integration of this three-part systems-level computational analysis. This analytic 
methodology could potentially be adapted for the understanding of cell state changes in other 
biological contexts. 
We find that the adaptive response was not truly reversible, in that the trajectory that the 
cancer cells took upon drug exposure was not retraced following drug removal. Although 
drug release reversed the transcriptional changes, it did not reverse the order of the two 
modules, so that Mearly was deactivated first upon drug removal. Therefore, the cells took a 
cyclic route as they traversed from drug-naïve to drug-resistant and back (Figure 2B). Similar 
to the adaptive response to drugging, this finding implicates the involvement of Mearly-
associated epigenetic reprogramming in regulating the first step of the reverse transition as 
well. It emphasizes the importance of those epigenetic regulations that manifest as an early-
acting transcriptional program for the rapid adaptation to therapeutic challenges in 
melanomas. Indeed, the sequential operation of Mearly and Mlate modules associated with cell 
state regression was generally observed across several other melanoma cell lines, although 
with different magnitudes of motion (Figure 6A). By interpreting that magnitude of motion 
as a metric of transcriptome plasticity, we found that the plasticity was strongly correlated 
with baseline chromatin accessibility and with the levels of activation histone marks of 
untreated melanoma cell lines (Figure 6B-6F). These findings imply that transcriptome 
plasticity may be epigenetically encoded prior to drug exposure. The sequential operations 
of Mearly and Mlate also resemble observations of sequential transcriptional waves that guide 
cell differentiation in other biological systems [73–76]. The molecular causes of the 
differences in baseline epigenome profiles across cell lines are unclear. Deciphering the 
causes of the intertumoral epigenetic heterogeneity provides an important area for future 
investigation.  
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A distinct chromatin state was observed in the drug-induced resistant cells compared 
with untreated or long-term drug removal cells. We identified histone remodelers KDM5B 
and HDAC1 as important players for establishing the resistant epigenetic state. However, 
other epigenetic remodelers may also contribute to the cell state changes. In fact, the SIRT6 
and BET protein families have been reported as regulators of MAPKi resistance in other 
melanoma systems [20,37]. Histone remodelers are generally recruited by TFs to regulate 
specific downstream genes. While other TFs could potentially recruit histone remodelers to 
regulate downstream resistance-associated genes, we identified RelA as a key player in 
regulating SOX10, whose repression is well-documented to trigger the resistant 
mesenchymal phenotype in melanomas [21,26]. In fact, the immediate recovery of SOX10 
expression levels after inhibition of RelA nuclear translocation in drug-tolerant cells 
confirmed the critical role of RelA as a key upstream TF in regulating SOX10 expression and 
associated resistance development (Figure 5F). In addition, the rapid recruitment of histone 
remodelers by RelA to the promoter regions of SOX10 within as early as 3 days after BRAF 
inhibition confirmed the critical role of RelA for initiating the adaptive resistance early on. 
The question of how BRAF inhibition induces the subsequent RelA-dependent molecular 
circuit was not resolved. The elevated level of reactive oxygen species (ROS) in melanoma 
cells upon BRAF inhibition [11] might be relevant, since ROS is known to activate the 
proinflammatory NFκB signaling pathway [77]. Phosphoproteomics that can resolve early 
signaling events immediately after BRAF inhibition may prove useful for such endeavor 
[78,79]. 
One of the most exciting aspects of epigenetic therapy is the ability to potentiate 
responses to existing therapies, which effectively multiplies the drug arsenal against cancer 
progression [80]. The intimate role of epigenetic dysregulation in therapy resistance 
development suggested that the epigenetic regulators KDM5B and HDAC1 would be 
attractive targets for combining with BRAFi for arresting the development of adaptive 
resistance at least in epigenetically plastic melanoma cells. This hypothesis was validated in 
clonogenic assays (Figure 6H). It is worth noting that BRAF and HDAC inhibitors were 
reported to be used in sequential order to eliminate the melanoma cells that acquired 
resistance to BRAF inhibition by exploiting the lethal ROS levels [11]. However, our results 
pointed to an alternative therapeutic strategy that using them in combination at the very 
beginning could retain tumor cells in the drug-sensitive stage and thus lead to sustained 
growth inhibition. While in vitro models may not fully recapitulate the cellular behavior in 
vivo, evidence of our epigenetic mechanism was also observed in melanoma tissue samples 
from patients under MAPK inhibitor treatments. This implies a potential role for these 
combination therapies in treating BRAF-mutant melanomas, with the provocative goal of 
disrupting the development of adaptive resistance against MAPKi (Figure 7A). In an 
interesting parallel, the adaptive regression in melanoma towards the drug-tolerant state has 
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also been reported to contribute to resistance development in various immunotherapy 
regimens [9,25,33,81]. Indeed, by analyzing transcriptome data of melanoma patients from 
a recent trial of PD-1 checkpoint blockade [41], we observed lower Mlate module score in 
non-responders than responders (Figure S7D), implying the more dedifferentiated melanoma 
phenotype was less likely to respond to PD-1 checkpoint blockade. With the increasing 
options of immunotherapy in treating metastatic melanomas in the clinic, combinations of 
epigenetic drugs with drugs targeting immune modulations may warrant further exploration. 
Moreover, how to sensitize the melanoma cells with minimal epigenetic plasticity (e.g. 
M381) to combinatory targeted inhibitions also requires further studies. 
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Experimental Model and Subject Details 
Cell culturing 
M-series patient-derived cell lines used in this study were generated under UCLA 
institutional review board approval # 11–003254. Cells were cultured in a water-saturated 
incubator at 37 °C with 5% CO2 in RPMI 1640 with L-glutamine (Life Technologies), 
supplemented with 10% fetal bovine serum (Omega), and 0.2% antibiotics (MycoZapTM 
Plus-CL from Lonza). The cell lines were tested for mycoplasma and were periodically 
authenticated to its early passage using GenePrint 10 System (Promega). BRAF inhibitor 
(vemurafenib), KDM5B inhibitor (CPI-455), HDAC inhibitor (Quisinostat) and RelA 
translocation inhibitor (JSH-23), all from Selleck Chemicals LLC, were dissolved in DMSO 
at designated concentrations before applying to cell culture media. Cells were plated in 10 
cm tissue culture plate at 60% confluency and treated with certain drugs for the specified 
numbers of days. M397 cells were treated with 3 µM of vemurafenib for 59 days or for 29 
days followed by drug removal removed and cell culture with normal medium for another 
35 days. Gender of the patients from whom the cell lines were derived: M397, female; M229, 
male; M262, female; M249, female; M263, female; M233, male; M381, male. 
Patient samples 
Melanoma samples before treatment were obtained from surplus biopsies stored in the 
melanoma biobank at the Peking University Cancer Hospital and Institute (Beijing, China). 
The patient #1 received vemurafenib and patient #2 received dabrafenib and trametinib 
combinations. Both patients exhibited partial response (PR) to these MAPK inhibitors. The 
secondary biopsies were performed when patients showed progressive disease (PD). The 
patients consented to the use of their biopsy materials for scientific studies and all research 
was conducted in accordance to the guidelines and protocols approved by the institutional 
ethics review committee and abiding by all local laws for research on human derived tissue. 
Gender of the reported patient samples: patient#1, female; patient#2, female. 
Method Details 
RNA-seq 
Total RNA was extracted from cell pellets using RNeasy Mini Kit (Qiagen). RNA 
sequencing libraries were prepared with Kapa RNA mRNA HyperPrep kit (Kapa 
Biosystems) according to the manufacturer's protocol. Briefly, 100 ng of total RNA from 
each sample was used for polyA RNA enrichment using magnetic oligo-dT beads. The 
  
37 
enriched mRNA underwent fragmentation using heat and magnesium, and the first-strand 
cDNA was made using random priming. The combined 2nd cDNA synthesis with dUTP and 
A-tailing reaction generated the resulting ds cDNA with dAMP to the 3’ ends.  The barcoded 
adaptors (Illumina) finally were ligated to the ds cDNA fragments.  A 10-cycle of PCR was 
performed to produce the final sequencing library. The libraries were validated with the 
Agilent Bioanalyzer DNA High Sensitivity Kit and quantified with Qubit. 
ATAC-seq 
A previously published protocol [82] was used for cell lysis, tagmentation, and DNA 
purification. The Tn5 treated DNA was amplified with a 5-cycle PCR in 50µl reaction 
volumes. The tubes were removed from thermocycler and used 5 µl of a partially amplified 
library to perform qPCR to determine how many additional PCR cycles were needed. For 
the samples in this study, an additional 4-5 cycles of PCR was performed on the remaining 
45ul of each partially amplified product. 1.8X AmpurXP beads purification was used for the 
final PCR cleanup. The libraries were validated with the Agilent Bioanalyzer DNA High 
Sensitivity Kit, and quantified with qPCR. 
ChIP-seq, ChIP-PCR, and ChIP-qPCR 
H3K4me3, H3K27ac, NFkB p65, KDM5B, and HDAC1 ChIP were performed by using 
Magna ChIP A/G Chromatin Immunoprecipitation Kit. Briefly, cells were cultured to ~80% 
confluency in a petri dish containing 10 mL of growth media and then fixed in 1% 
formaldehyde by adding 275 μl of 37% formaldehyde for 10 minutes to cross-link protein–
DNA complexes at room temperature. The unreacted formaldehyde was quenched by adding 
glycine to a final concentration 0.125 M. Gently swirl dish to mix. The nuclear pellet was 
isolated with Cell Lysis Buffer. The pellet was resuspended with 500 μl SDS Lysis Buffer 
containing 1X Protease Inhibitor Cocktail II before sonication for 4 min (10 s on, 30 s off, 
10% strength in a Bioruptor to yield DNA fragments of 0.2-1.0 kb in length. The lysates 
were cleared by centrifugation (12,000g for 10 min at 4 °C) and diluted tenfold in ChIP 
dilution buffer to decrease the concentration of SDS. After keeping 10% of the sample as 
input, 500 μl supernatant was incubated overnight at 4 °C with antibody and 20 μL of fully 
resuspended protein A/G magnetic beads. The washing, elution, reverse cross-linking, and 
purification steps were performed according to the manufacturer’s description. Eluted DNA 
was quantified by Qubit dsDNA HS Assay Kit, and used for further PCR, qPCR or ChIP-
seq library preparation.  
ChIP-seq libraries were prepared with Kapa DNA HyperPrep Kit (Kapa, Cat KK 8700) 
according to the manufacturer's protocol. Briefly, 5-10 ng of immunoprecipitated DNA was 
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underwent end-repaired, A tailing and adaptor ligation. A 10 cycles of PCR was performed 
to produce the final sequencing library. The libraries were validated with the Agilent 
Bioanalyzer DNA High Sensitivity Kit and quantified with Qubit.  
ChIP-PCR was performed by using KAPA Taq ReadyMix PCR Kit on CFX96 Real Time 
PCR Detection System without adding plate read. ChIP qPCR was performed by using 
SsoAdvanced Universal SYBR Green Supermix on CFX96 Real-Time PCR Detection 
System. In each PCR/qPCR reaction, 2 μl eluted DNA was added. 
Sequencing of RNA-seq, ChIP-seq, and ATAC-seq library 
RNA and ChIP-seq library templates were prepared for sequencing using Illumina HiSeq SR 
Cluster V4 Kit. Sequencing runs were performed on Illumina Hiseq 2500 in the single read 
mode of 51cycle of read1 and 7 cycles of index read with SBS V4 Kits. ATAC-seq library 
templates were prepared for sequencing with Illumina HiSeq PE Cluster V4 Kit, sequencing 
runs were performed in the paired-end mode of 101cycle on Illumina HiSeq 2500 with HiSeq 
SBS V4 Kits. Real-time analysis (RTA) 2.2.38 software was used to process the image 
analysis and base calling. 
CellTiter-Glo 
5000k cells were seeded onto each well of a 96well plate and were treated with indicated 
drug concentrations for 72hours. ATP-based CellTiter-Glo (Promega) luminescent cell 
viability assay was utilized to quantify the cell number for constructing dose-response 
curves. IC50 values were calculated as standard from at least three biological replicates. 
Cell cycle and apoptosis assays 
For cell cycle analysis, 500k cells were plated and were then treated with EdU. After 
treatment, cells were washed with PBS and fixed. Next, cells were processed for EdU 
detection using the Click-iT EdU Alexa Fluor 488 Flow Cytometry Assay Kit (Thermo 
Fisher) according to the manufacturer’s protocol. DNA content was visualized using SYTOX 
AADvanced (Thermo Fisher). Gates were determined using an unstained control. All 
experiments were performed with at least two biological replicates. 
Cell apoptosis assays were performed by treating indicated cell lines cultured under 
respective conditions. Cells were stained with Annexin V–FITC and propidium iodide for 
15 minutes at room temperature before flow cytometry analysis. Gates were determined 
using an unstained control. All experiments were performed with at least two biological 
replicates. 
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Fluorescence imaging of cell lines 
Fluorescent micrographs of cells were acquired with a Nikon C2plus confocal microscope 
(Ti) using Plan Apo λ 20× objective (Nikon Inc., Melville, NY) controlled by NIS elements 
AR software (4.51.00) with the following settings: 30 μm pin hole, 12-bit acquisition, 25-30 
PMT gain, and laser power of 0.7% (405 nm), 1.0% (488 nm), or 0.4% (640 nm). The cells 
adhered on gelatin-coated glass surfaces in 96-well glass bottom plates (Greiner Sensoplate 
Plus, Cat# 655892). To prepare the surface, 100 µL of 0.1% gelatin solution was incubated 
in each well at room temperature for 10 minutes. After incubation, the solution was removed, 
and the wells were air-dried for at least 15 minutes. Typically, 10,000 cells were seeded per 
well in 100 µL culture media and grown to ~70% confluency. To fix the cells, equal volumes 
of 4% PFA solution was gently added to each well. After fixing for 20 minutes at room 
temperature, the cells were washed twice in wash buffer (0.1% BSA in PBS), and blocked 
and permeabilized in blocking buffer (10% normal donkey serum, 0.3% Triton X-100 in 
PBS) for 45 minutes at room temperature. After removing blocking buffer, cells were 
incubated in mouse anti-MITF primary antibodies (Thermo Fisher Scientific, Cat# MA5-
14154) diluted to 5 μg/mL in antibody diluent (1% BSA, 1% normal donkey serum, 0.3% 
Triton X-100 in PBS) for 4 hours at room temperature. After washing twice in wash buffer, 
cells were incubated in donkey anti-Mouse IgG, Alexa Fluor 647 secondary antibody 
(Thermo Fisher Scientific, Cat# A31571, RRID:AB_162542) diluted to 4 μg/mL in antibody 
diluent for 1 hour at room temperature. After washing twice in washer buffer, cells were 
counterstained for 20 min at room temperature with Alexa Fluo 488 Phalloidin (Thermo 
Fisher Scientific Cat# A12379), as per manufacturer’s instructions. After washing twice in 
wash buffer, cells were further counterstained for 5 min with 4',6-Diamidino-2-Phenylindole 
(DAPI) (Thermo Fisher Scientific Cat# D1306) diluted to 1 μg/mL in PBS. Finally, after 
washing twice in PBS, the wells were filled with 78% glycerol. 
Western blotting 
Histone proteins were extracted using the Histone Extraction Kit (ab113476). The Invitrogen 
precast gel system NuPAGE was used for SDS-PAGE. The 4–12% Bis-Tris gels were loaded 
with samples. After blotting, the membranes were blocked in 5% BSA with TBS + 0.1% 
Tween-20 (TBST) mix for at least 1 hour at room temperature. Membranes were then 
incubated overnight with the primary antibody in 5% BSA with TBST at 4°C. The next day, 
membranes were washed three times for 5 min in TBST, incubated with a suitable HRP-
coupled secondary antibody for 1 hour at room temperature, and washed three times and 
proteins were visualized with SuperSignal™ West Pico PLUS Chemiluminescent Substrate 
(Cat.No.34577) using the ChemiDoc™ XRS+ System. 
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RT-qPCR 
For quantitative reverse transcription-polymerase chain reaction (qRT-PCR), total RNA was 
extracted by TRIzol™ Plus RNA Purification Kit (Cat.No.12183555) and reversed to 
cDNAs. Real-time PCR was performed with gene-specific primers on the two-color real-
time PCR detection system (BIO-RAD) using the SsoAdvanced™ Universal SYBR® Green 
Supermix (Cat.No.1725272) to represent the relative expression levels. 
Co-IP and protein detection 
For cell lysis, cells were cultured to ~80% confluency in a petri dish containing 10 mL of 
growth media and were washed with ice-cold PBS three times. Then the cells were collected 
with a scraper in 1 mL ice-cold PBS supplemented with 1X proteinase inhibitor cocktail 
(Cell Signalling) and centrifuged. The cell pellets were resuspended in cell lysis buffer 
containing 50 mM Tris-HCl pH 7.5, 250 mM NaCl, 1 mM EDTA, 0.5% Triton X-100, 10% 
glycerol, and 1X proteinase inhibitor cocktail (Cell Signalling). The resuspended cell pellets 
were incubated in a cold room (4°C) for 30 min and sonicated in ice-water bath three times 
for 5-second pulses each. Then the cell lysates were cleared by 10,000 × g centrifuge at 4°C 
for 10 min. The protein was quantified by Qubit Protein Assay Kit (Invitrogen). 
For cross-linking antibody to magnetic beads, 20 μl magnetic protein A/G beads (Millipore) 
were washed with cell lysis buffer twice and resuspended in 100 μl cell lysis buffer without 
glycerol. 5 μg Anti-NFkB p65 (RelA) antibody was coupled to Magnetic protein A/G beads 
by incubation at 4°C overnight on a rotator. The RelA antibody-coupled Protein A/G beads 
were washed three times in 200 µL Conjugation Buffer (20 mM Sodium Phosphate, 0.15M 
NaCl, pH 7.5). Then the RelA antibody-coupled beads were suspended in 250 µL 5 mM BS3 
with conjugation buffer and incubated at room temperature for 30 min with rotation. The 
cross-linking reaction was quenched by adding 12.5 μl 1M Tris-HCl (pH 7.5) and incubated 
at room temperature for 15 min with rotation. The RelA antibody conjugated protein A/G 
beads were washed with Cell Lysis buffer three times.  
For co-immunoprecipitation (Co-IP) experiment, 200 μl pre-cleared cell lysates were added 
to RelA antibody conjugated protein A/G beads and incubated overnight at 4°C with rotation. 
The beads were then washed 5 times with 500 μl cell lysis buffer without glycerol. The pellet 
beads were collected by a magnetic stand and resuspended in 65 μl SDS buffer (50mM Tris-
HCl pH6.8, 2% SDS, 10% glycerol, 1% β-mercaptoethanol). 
For immunoblotting, the elutes were boiled for 10 min at 95 °C. The 20 μl boiled elutes were 
electrophoresed on 10% Mini-PROTEAN TGX Precast Gels with running buffer containing 
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SDS. Then the gels were transferred on the PVDF membranes in Bio-Rad Wet Blotting 
Systems. The membranes were blocked with 5% non-fat dried milk (Bio-Rad) dissolved in 
PBS for 1 h at room temperature and incubated at 4 °C overnight with the following primary 
antibodies: JARID1B/KDM5B (Bethyl Lab #A301-813A), NFkB p65 (Millipore # 17-
10060), HDAC1(Millipore # 17-608). After incubating with secondary Goat anti-
Mouse/Rabbit antibodies coupled with HRP (Thermo), membranes were visualized by 
ChemiDoc XRS+ Imaging Systems. 
CRISPR engineering of cell lines   
LentiCRISPR v2 plasmids targeting the coding sequence of KDM5B or NFKBIE, and control 
LentiCRISPR v2 plasmid were purchased from GenScript.  Lentiviruses were produced in 
HEK-293T cells by transient transfection of LentiCRISPR v2 plasmid and their packaging 
vectors psPAX2 and pMD2.G as previously described [83]. The virus was collected, filtered 
through a 0.45µm syringe filter after 48 hours and the M397 cells were spin-infected with 
viral supernatant supplemented with 10 µg/mL polybrene at 2,500 rpm and 30°C for 90 min. 
The transduced cells were selected using puromycin, starting at 3 days post-transduction. 
Genome editing in the respective locus was examined using a surveyor assay, which was 
performed according to the manufacturer’s instructions (Integrated DNA Technologies) [84]. 
Clonogenic assay 
Melanoma cells were plated onto six-well plates with fresh media at an optimal confluence. 
The media (with drug or DMSO) were replenished every two days. Upon the time of staining, 
4% paraformaldehyde was applied onto colonies to fix the cells and 0.05% crystal violet 
solution was used for staining the colonies.  
Patient multiplexed IHC and quantification 
Multiplexed IHC staining was performed on FFPE tissue samples from melanoma primary 
tumors and metastatic lesions. Multiplexed IHC staining and antibody validation were 
performed by PerkinElmer. Briefly, the slides were firstly deparaffinized in xylene, followed 
by treatment with microwave for epitope recovery. Hematoxylin and eosin (H&E) staining 
was performed for histopathological evaluation and multiplexed IHC staining was then 
conducted on the slides via an Opal 7-Color IHC Kit (NEL811001KT, PerkinElmer) and a 
panel of antibodies including anti-KDM5B (Sigma-Aldrich), anti-MITF (Sigma-Aldrich), 
anti-SOX10 (Sigma-Aldrich) and anti-NFKBIE (Sigma-Alrich). The protocol was based on 
the manual of PerkinElmer Opal staining Kit and previous studies [85]. Finally, DAPI 
(PerkinElmer) was stained to visualize cell nuclei. Images were acquired using a Vectra 
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Polaris Multispectral Imaging System (PerkinElmer) for whole-slide scanning. inForm 
Image Analysis software (inForm 2.4, PerkinElmer) was used to process and analyze all 
images. Image J was employed to quantitate the fluorescence intensities of cells in the 
designated areas.  
Quantification and Statistical Analysis 
RNA-seq analysis 
Reads were aligned against the human genome (hg19) using TopHat2 [86].  Read counts 
were quantified using htseq-count [87], with known gene annotations from UCSC [88] with 
anti-sense (AS) genes removed.  Fold-change values were calculated from Fragments Per 
Kilobase per Million reads(FPKM) [89] normalized expression values, which were also used 
for visualization (following a log2 transformation). Aligned reads were counted using 
GenomicRanges [90].  Separate comparison p-values were calculated from raw counts using 
limma-voom [91], and false discovery rate (FDR) values were calculated using the method 
of Benjamini and Hochberg [92].  Prior to p-value calculation, genes were filtered to only 
include transcripts with an FPKM expression level of 0.1 (after a rounded log2-
transformation) in at least 50% of samples [89].  Genes were defined as differentially 
expressed if they had a |fold-change| > 1.5 and FDR < 0.05. Candidate genes were selected 
based upon the inverse overlap between the early and late time series. The “Early Drug” time 
series included 5 samples from Day 3 to Day 29 (with active drug treatment).  The “Late No-
Drug” had 6 time-points after drug removal at Day 29 (4-35 days post-drug removal). There 
were also 3 samples with active drug treatment after Day 29, but no genes were differentially 
expressed for that comparison consistent with the expectation of similar gene expression 
patterns after developing resistance; however, those 3 late drug samples (along with an 
untreated control sample) were used for visualization in a heatmap of candidate genes 
(defined as genes with an significant increase in expression with drug treatment and a 
significant decrease in expression after drug removal, or a significant decrease in expression 
with drug treatment and a significant increase in expression after drug removal). 
A heatmap of log2(FPKM + 0.1) standardized expression (mean of 0, standard deviation of 
1, per-gene) was visualized using the ‘ggplots’ package in R.  More specifically, standardized 
expression was limited to be within the range of -2 and 2 (so, all values less than -2 were set 
to -2, and all values greater than 2 were set to 2), and clustering was only performed by genes 
(with samples ordered by time, within each category).  Hierarchical clustering was performed 
using Euclidian Distance as the distance metric. 
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Consensus clustering of M397 transcriptome 
To inspect the similarity of the transcriptome of M397 in different time points, we applied 
consensus clustering using the R package of ConsensusClusterPlus [93] to define clusters. 
The top 3,000 most varying genes were used for consensus clustering with the hierarchical 
clustering method.  
Analysis of differentially expressed transcription factors 
To annotate differentially expressed transcription factors/co-factors, the differential 
expression analysis was performed by Cuffdiff among D0, DR30, DR35, D29, and D33 
(FDR ≤ 0.05). Then we downloaded TFs/co-factors list from AnimalTFDB 3.0, and got the 
up/down-regulated TFs/co-factors by screened from the differential expression analysis. The 
result was visualized by a volcano plot. 
ChIP-seq analysis 
Reads were mapped to the human genome hg19 by bowtie2 [94]. The identical aligned reads 
were deduplicated to avoid PCR duplicates. Peaks were called on the merged set of all ChIP-
seq reads of M397 using MACS2 with the following parameters: --nomodel, --broad [95]. 
Peaks were assigned to the gene with closest TSS. Differential analysis between D0 and any 
other samples( D3, D32, DR) were performed using diffReps with a window size 1000.[96]. 
Differential binding regions were called if the absolute log value of the fold change was more 
than 1 and FDR <0.05. Then the differential binding regions were compared and merged to 
ChIP peaks called form MACS2 To visualize peaks in each sample, bed graph file was 
generated using MACS2 with following parametes: --nomodel, --broad, --bdg, --SPMR. 
Then the generated bed graph file was converted into bigwig file by bedGraphToBigWig 
tool. The average of ChIP-seq signal was calculated and visualized by deepTools v3.0.2 [97]. 
The read counts were normalized by RPKM. RPKM (per bin) = number of reads per bin / 
(number of mapped reads (in millions) * bin length (kb)). To assess how H3K4me3 and 
H3K27ac signal of differential binding regions in the cyclic transition of M397 changed in 
multiple cell lines, we calculated the normalized read counts around the differential binding 
peaks(+/- 1kb) at the window size of 10bp. The different peaks are called from the time-
series ChIP-seq data we generated at this paper. To evaluate the average H3K4me3 and 
H3K27ac signal at SOX10, we slid the 10bp window size from -3Kb to +10Kb around the 
TSS to counts the normalized reads and calculated the average value for 520-780 bins. 
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ATAC-seq analysis 
All experiments were performed once. First, adaptor sequences were trimmed form the reads 
using Cutadapt. Then Reads were aligned to hg19 with bowtie2 with standard parameters 
and a maximum fragment length of 2,000. [94]. The identical aligned reads were 
deduplicated to avoid PCR duplicates. These de-duplicated reads were then filtered for high 
quality (MAPQ ≥ 30). Peaks were called on the merged set of all ATAC-seq reads of M397 
using MACS2 with following parameters: --nomodel, -broad, -q 1e-5 [95] and filtered to 
remove putative copy number varied regions [98]. Differentially accessible regions between 
D0 and any other samples( D3, D32, DR) were identified using diffReps with a window size 
500. (Shen et al., 2013)). Differential binding regions were called if the absolute log value of 
the fold change was more than 1 and FDR <0.05. Then the differential binding regions were 
compared and merged to ChIP peaks called form MACS2.  To visualize peaks in each 
sample, the same routine in ChIP-seq analysis was applied. ATAC-seq profile of 
differentially accessible region in samples of M397 were generated by using ngs.plot.r with 
following parameters: -G hg19 -R bed -L 1000 -GO km -KNC 4 -SC 0,3.5.The profile of 
unchanged ATAC-seq peaks in samples of M397 was plotted by using ngs.plot.r with 
following parameters; -G hg19 -R bed -L 1000 -GO total -SC 0,3.5. HOMER was used to 
find over-represented motifs in the set of differentially accessible peaks by using a 
background set of peaks that did not significantly change, and using the parameter “-size 
given -len 6,8,10,12 -mset vertebrates -bg” [98]. The average of ATAC-seq signal was 
calculated and visualized by deepTools v3.0.2 [97]. The read counts were normalized by 
RPKM. RPKM (per bin)=number of reads per bin / (number of mapped reads (in millions) 
* bin length (kb)). For the calculation of the average ATAC-seq signal, we constructed the 
meaningful value around the different peaks (+/- 1Kb) at the window size of 10bp and 
calculated the average value for 140-160 bins. The different peaks are called from the time-
series ATAC-seq data we generated at this paper. 
Inference of RelA downstream transcription factors  
To identify RelA-binding TFs/co-factors in the Mlate process, we downloaded TF/co-factor 
list from AnimalTFDB 3.0. HOMER was used to annotate RelA-binding motif (HOMER 
Motif 208) at the whole genome level with the following parameters: annotatePeaks.pl tss 
hg19 -size -1800,400. Then, TF/co-factors containing RelA-binding-motif were selected out. 
Within this list of TF/co-factors, RelA-motif overlapped H3K4me3, H3K27ac and ATAC-
seq peaks were analyzed by bedtools v2.27.1. Thirty-six TFs showed changes in the RelA-
motif overlapped peaks across the adaptive transition (D32 vs D0). However, only two TFs, 
SOX10 and DNAJC1, displayed significant changes (p < 0.05) for all three epigenome 
alterations (Table S5). 
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Surprisal analysis and SOM visualization 
In order to analyze the dynamic transcriptome changes across all time points, we assume that 
many of them are coordinately changing together as a group (or gene module). Surprisal 
analysis has been well documented in deconvoluting the change of thousands of genes into 
the change of a couple of gene modules and one unchanged gene expression baseline 
[46,51,52,99]. 
When applied here, surprisal analysis simplified the transcriptome dynamics into two major 
gene modules and one unchanged gene expression baseline. Briefly, the natural logarithm of 
the measured level of a transcript i at a specific time point t, ln 𝑋𝑖(𝑡), is expressed as a sum 
of a log-transformed gene expression baseline, term ln 𝑋𝑖
0, and several gene modules 𝜆𝑗(𝑡) ×
𝐺𝑖𝑗, representing deviations from the common expression baseline. Each deviation term is a 
product of a time-dependent module score 𝜆𝑗(𝑡), and the time-independent module-specific 
contribution score 𝐺𝑖𝑗 of the gene i.  Gene i that displays large positive or negative 
contribution to a module j (high positive or negative Gij value) represents a gene that is 
functionally positively or negatively correlated with the module j. In other words, the 
biological function of the module j could be inferred by functional enrichment analysis of 
genes with positive and negative Gij values. 
To implement surprisal analysis, we first computed the singular value decomposition (SVD) 
of the matrix 𝑙𝑛 X(𝑡). As described previously [51], the SVD factored this matrix in a way 
that determined the two sets of parameters that are required in the surprisal analysis: the 
Lagrange multipliers (𝜆𝑗(𝑡)) for all gene modules at a given time point and for all times, as 
well as the module-specific contribution scores (𝐺𝑖𝑗)  for all transcripts i at each gene module 
j. Further enrichment analysis of the functions associated with each module were performed
based on the module-specific contribution scores of the genes associated with that module. 
The module-1 and module-2 scores of other published datasets on melanoma cell lines [25] 
or melanoma patients’ biospecimens [9,41] were calculated as ∑ (𝑙𝑛 𝑋𝑖 ) ∙ 𝐺𝑖𝑗𝑖  which
considered the both the gene expression as well as the respective gene contribution towards 
each gene module. 
Natural log-transformed transcriptome dataset and contributions from each gene module 
(𝜆𝑗(𝑡)𝐺𝑖𝑗 ) calculated from surprisal analysis were visualized using self-organized maps 
(SOMs). Here, the SOMs plotted individual sample as a single 2-dimensional heatmap and, 
at the same time, displayed high-resolution patterns. Thousands of input genes were assigned 
to 625 rectangular “tiles” (SOM nodes), each of which represented a mini-cluster of genes, 
arranged to form a pattern within a 2-dimensional mosaic map on the SOM grid. Each mini-
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cluster of genes was mapped onto the same tiles in each map, and the color of each tile 
represented the relative average expression of the gene mini-cluster within that tile. Most 
similar clusters were placed adjacent to each other in the mosaic map. Tiles at the same 
location represented the same group of genes across different conditions. Gene Expression 
Dynamics Inspector (GEDI) package was utilized to implement the SOM visualization [100]. 
Dynamic system modeling of two gene modules 
In order to more precisely infer the mathematical inter-regulation relationship between two 
gene modules, we performed dynamic systems modeling with regards to the average gene 
expression of the top 500 genes that have the highest positive or negative G values (weights). 
More specifically, for drug treatment condition, we have G1 positive genes and G1 negative 
genes (genes that are positive or negatively correlated with Mlate), which are paired with G2 
positive and G2 negative genes (genes that are positive or negatively correlated with Mearly) 
respectively. Therefore, we have 4 different scenarios for drug treatment condition. 
Similarly, we also have 4 different scenarios for the drug removal condition. 
We started with a system of first-order mass equations that can consider all possible 
interaction relationships between the two modules. This system initially included terms for 
baseline, constant basal regulation (Bl and Be) on each gene module, first-order 
autoregulation from itself (Me-e and Ml-l), and first-order regulation by the genes from the 
other module (Me-l and Ml-e). We simultaneously fitted all coefficients through unbiased 
search using Markov Chain Monte Carlo (MCMC) in Python 3.0 and Gaussian distribution 
of coefficient probability. Initial coefficients were set on random uniform distributions. We 
also constrained coefficients such that the resulting fit would not lead to artificial oscillations 
with a frequency beyond the Nyquist frequency of our experimental sampling. Using the 
fitted parameters, our simulated trajectories of module1 (Mlate) and module2 (Mearly) can 
recapitulate the original experimental data.  
Gene set enrichment analysis  
Gene Set Enrichment Analysis (GSEA) was conducted based on GSEA v2.2.3 software with 
1000 permutations and weighted enrichment statistics. Normalized enrichment score (NES) 
was assessed across the curated Molecular Signatures Database (MSigDB) Hallmark, C2 
curated gene sets, and MITF signature [34]. To calculate the single-sample gene set 
enrichment, we used the GSVA program [101] to derive the absolute enrichment scores of 
previously experimentally validated gene signatures. The normalized log2 RPKM values 
were utilized as input for GSVA in the RNA-seq mode. The patient transcriptomic data was 
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based on the patient transcriptomic data was obtained from [64]. GSEA v3.0 was used 
with the same parameters described above. 
Transcription factor target and motif enrichment analysis 
Two different approaches were utilized to identify driving transcription factor in module2 
(Mearly) process. For the first approach, we filtered the TF that are associated with module2 
(Pearson correlation with module2 amplitude (λ2) bigger than 0.8 or less than -0.8) and 
define them as module2 associated TFs. We then acquired the downstream targets genes for 
all module2 associated TFs using public database TFtargets 
(https://github.com/slowkow/tftargets). The KDM5B gene targets were manually verified by 
ChIP-seq data (GSE101045). We then further filter the module2-associated TFs based on the 
overlap of their downstream target gene with certain module1 (Mlate). More specifically, for 
a certain TF in module2 (Mearly), if its’ downstream-targeted genes are over-represented in 
module1 (Mlate) process (Hypergeometric test with Bonferroni correction, FDR<=0.05), then 
this TF is selected as a candidate for driving TF in module2. For the second approach, we 
use HOMER to find enriched motifs in the promoter sequence of module1 associated gene 
set (Pearson correlation with module2 amplitude (λ2) bigger than 0.8 or less than -0.8) with 
following parameters: -len 6,8,10,12 -start -1800 -end 100 -b -mset vertebrates. Then, we 
infer the potential TFs based on the enriched motif information.  
GDSC data analysis 
Cell lines from skin cutaneous melanoma (SKCM) samples, containing the BRAFV600E 
genetic mutation from the GDSC project, were selected to analyze the association between 
the transcriptional states before drug treatment and their drug responses [102]. Gene 
expression levels of the selected cell lines were projected to two gene modules (Mearly and 
Mlate). BRAF inhibitors Dabrafenib is selected to analyze the association of transcriptome 
state and drug response. Pearson correlation analysis and linear regression modeling for the 
two gene modules and the log-transformed IC50 values (Drug concentration that reduces 
viability by 50%) or AUC (area under the dose-response curve) values were carried out. 
CCLE and TCGA analysis  
GSVA analysis was utilized to analyze the pathway enrichment scores across RNA-seq data 
of melanoma patient from TCGA database [103] and from melanoma cell line data from 
CCLE [104] database. The enrichment score of Mearly and Mlate associated genesets across all 
samples within the (patient or cell line) dataset were utilized as input to calculate pairwise 
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Pearson correlations, and the average Pearson values of all possible pairwise correlations 
are used as co-occurrence score of Mearly and Mlate genesets within each dataset. 
Patient data analysis  
Paired patient data before and after the MAPKi treatments were used to evaluate relevant 
gene expression levels and gene sets enrichment. These data were collected from two 
published papers. The gene expression levels and associated patient identification numbers 
in the original papers were provided in Table S6. Patient survival analysis was performed 
with high expression vs. low expression of selected genes from the TCGA melanoma 
(SKCM) data set including all stage III and IV patients. Kaplan-Meier method was used to 
estimate the survival rate, along with a log-rank statistical test comparing the survival 
distribution. All tests were two-sided, and p values less than 0.05 were considered 
statistically significant. 
Data and Software Availability  
The accession number for the gene expression, ATAC-seq and ChIP-seq data reported in this 
paper is GEO: GSE134459. 
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Figures. 
Figure 1. Adaptive drug resistance and reversibility across a panel of melanoma cell 
lines. (A) An illustration of the melanocyte-to-mesenchymal transition and the experimental 
timeline. Cells were treated with BRAF inhibitor (BRAFi) vemurafenib for 29 days (D29). 
BRAFi treatment continued for some cells up to D59, while other cells were followed over 
a 35 day period of drug removal (DR35). Cells were harvested for RNA-seq at the time points 
specified. (B) Heatmap of differential expressed genes (DEGs) at a series of time points of 
drug treatment and drug removal for M397 cells. Sidebars denote consensus clustering 
results of the variated genes from the samples (6 clusters) and their treatment conditions. 
DR30 and DR35 fall into the same cluster with the control sample. (C) Enriched molecular 
signatures associated with the adaptive transition in M397 cells. (D) Increased drug tolerance 
and reversed drug sensitivity across multiple melanoma cell lines with varying baseline 
sensitivities to BRAF inhibition evaluated by IC50 values of vemurafenib. LT: long-term; 
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DR: drug release. Mean ± SD. (E) Cell cycle distribution across the reversible transition 
of M397 cells. (F) Cell viability and apoptotic profiles of untreated cells (Ctrl) and reverted 
cells (upon 30 days drug removal) after 3-day BRAFi exposure. DR: drug removal. See also 
Figure S1 and Table S1 
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Figure 2. Information theoretic analysis and dynamic systems modeling of the 
reversible adaptive transition in M397 cells. (A) Application of surprisal analysis to the 
time-series transcriptome data over the transition. The transcriptome data, decomposed into 
a time invariant gene expression baseline plus two time-dependent gene modules, are 
illustrated as self-organizing maps (SOMs). Adding the baseline and first 2 gene modules 
recapitulates the experimentally measured transcriptome profiles. (B) The cyclic trajectory 
of the reversible transition plotted in the landscape defined by the first two gene modules. 
The blue and green dash lines circled the milieu of the mesenchymal-like drug-resistant state 
and drug naïve state, respectively. Selected enriched molecular processes (nominal p < 0.05) 
associated with each gene module are listed. NES: normalized enrichment score. (C) 
Schematic illustration of the simplified model for two gene module interactions. (D) The 
module-module interaction coefficient in the ordinary differential equations (ODEs) 
determined by fitting the model to the average expression level of the top 500 genes 
associated with each gene module. (E) Experimentally measured and ODE fitted average 
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expression levels of genes associated with the two modules in the forward and reverse 
directions of the cyclic transition. See also Figures S2, S3 and Tables S2, S3, S4. 
 
Figure 3. Bioinformatic inference of the critical regulators that drive the initiation of 
the reversible adaptive transition. (A) A scheme showing the target gene inferences. (B) 
Bioinformatic inferences based on the dynamic relationships between the two gene modules.  
(i) The list of enriched transcription factors (TF) and co-factors from target gene enrichment 
are ranked according to their absolute correlation coefficients with Mearly scores with relative 
expression levels (z-score) shown as a heatmap. The target gene number and statistical 
significance (p values) for each enriched element are listed to the right. (ii) Enriched motifs 
from the cis-regulatory elements of genes highly correlated (ρ > 0.8) with Mlate. Top two 
significantly enriched motifs are listed. -Log2 p values are shown to the right. (C) Relative 
expression levels of cell-state specific genes over the course of the adaptive cyclic transition 
(D) Gene expression levels, normalized to D0, of the critical TFs/co-factors involved in the 
adaptive transition. See also Figure S4.   
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Figure 4. Epigenetic reversibility of the adaptive transition. (A) Chromatin accessibility 
change assessed by average peak signal of ATAC-seq across the entire genome. The x-axis 
shows flanking regions of +/- 1kb around the peak center. (B) Heatmap of chromatin 
accessibility changes assessed by average ATAC-seq peak signal across all peaks, at selected 
time points over the transition. K-mean clustering of rows identifies five chromatin regions 
that grouped into D3 enriched (group 1), D0/DR30 enriched (group 2), and independent of 
drug treatment (group 3). Color corresponds to the normalized ATAC-seq signal. Relevant 
transcription factor binding motifs are indicated for cluster groups 1 and 2. (C) Venn 
diagrams showing the numbers and overlaps of differential ChIP-seq peaks for H3K4me3 
and H3K27ac. Each circle represents changes in those peaks between two time points, while 
the intersection of the circles represent changes that are shared between circles. (D) ChIP-
seq profile plots show the average H3K4me3 (left) and H3K27ac (right) ChIP-seq signal 
across peaks identified by RelA ChIP-seq, with heatmap representation of each peak shown 
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below. The x-axis shows flanking regions of +/- 4kb around the peak center. See also 
Figure S5 and Table S5. 
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Figure 5. Molecular mechanism that underlies the reversible adaptive transition. (A) 
Illustration of the mechanism of epigenetic regulation before and after BRAF inhibition.  Left 
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panel: retention of RelA in the cytoplasm and open chromatin at the promoter regions of 
SOX10 and NFKBIE. Right panel: BRAFi induces translocation of RelA into the nucleus, 
allowing RelA to recruit histone modifiers KDM5B and HDAC1 to the target genes to reduce 
chromatin accessibility and epigenetically repress of SOX10 and NFKBIE expression. 
Functional consequences, such as increased TGFβ signaling and adaptive drug resistance, 
result in turn. The illustrations of the cell cycle reflect the measured cell cycle arrest observed 
upon short-term BRAF inhibition. (B) ATAC-seq and ChIP-seq profiles at the promoter 
regions of NFKBIE and SOX10, at selected time points across the reversible transition. (C) 
ChIP-PCR data illustrates the binding and co-localization of RelA, KDM5B, HDAC1, 
H3K4me3, and H3K27ac to promoter regions of SOX10 and NFKBIE (labeled NP1 and SP1, 
respectively). (D) ChIP-qPCR assessment of the binding profiles of RelA, KDM5B, 
HDAC1, H3K4me3, and H3K27ac on the promoter regions of NFKBIE and SOX10 at a 
series of time points across the reversible transition. (E) Co-immunoprecipitation of RelA 
with KDM5B and HDAC1, confirming the binding between RelA and the two histone 
modifiers (*P<0.05 compared to respective D0). (F) The recovery of SOX10 gene expression 
levels of M397 cells pretreated with BRAFi for 21 days (D21), and then co-treated for 0-24 
hours with BRAFi and JSH-23 (*P<0.05 compared to D0) (G) ChIP-qPCR assessment of 
the binding profiles of RelA, KDM5B, HDAC1, H3K4me3, and H3K27ac on the prompter 
regions of NFKBIE and SOX10 for control and JSH-23 24h-treated cells (*P<0.05 compared 
to respective control). (H) ChIP-qPCR of the binding profiles of H3K4me3 and H3K27ac on 
the promoter region of SOX10 from NFKBIE KO M397 cells (*P<0.05 compared to 
respective WT). (I) SOX10 expression levels after NFKBIE KO compared to wild type (WT) 
(*P<0.05 compared to WT) (J) ChIP-qPCR of the binding profiles of H3K4me3 and 
H3K27ac on the promoter regions of NFKBIE and SOX10 from KDM5B KO M397 cells 
(*P<0.05 compared to WT) (K) Expression levels of SOX10 and NFKBIE after KDM5B KO 
compared to WT (*P<0.05 compared to WT). (L) Clonogenic assays of NFKBIE KO or 
SOX10 KO cells related to respective controls.   
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Figure 6. The generality and molecular underpinning of the phenotypic plasticity of 
patient-derived melanoma cell lines in response to BRAF inhibition. (A) Quantification 
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of phenotypic plasticity upon BRAF inhibition across a panel of melanoma cell lines. The 
transcriptome data are projected to the 2D plane defined by the two gene modules (Mearly and 
Mlate) and connected by smooth lines. The data points denote 0-day (D0), D3, and D21 
BRAFi treatment in counterclockwise order, respectively. The color of the line encodes the 
baseline IC50 value of the cell line. (B-F) The correlation between short-term plasticity 
(motion along Mearly) and the (B) average ATAC-seq signal, (C) average H3K4me3 (D) and 
H3K27ac ChIP-seq signal across all peaks, as well as (E) average H3K4me3 and (F) 
H3K27ac ChIP-seq signal on the transcription start site (TSS) region of SOX10 across all 
cell lines with Pearson correlation coefficients and p-values as shown. The shaded regions 
of panels B-F denote 95% CIs of each linear fitting. (G) The chromatin accessibility of a 
panel of melanoma cell lines quantified by the average ATAC-seq signal across all peaks 
with heatmap view of each peak shown below. The x-axis includes flanking regions of +/- 
4kb around the peak center. (H) Clonogenic assays for BRAFi monotherapy and combination 
therapies simultaneously targeting the driver oncogene BRAF and histone modifiers 
KDM5B and HDAC1. The cell lines are ordered from left to right with increased plasticity. 
See also Figure S6.  
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Figure 7. The clinical relevance of the drug-induced chromatin remodeling mechanism. 
(A) Immunohistochemical (IHC) staining of melanoma tissue biopsies from two patients 
bearing BRAF-mutant melanoma before and after MAPKi treatment. Hematoxylin and eosin 
(H&E) staining shown in left column followed by a staining panel from pre-treatment or 
post-treatment biopsies. Post-treatment tissue was collected at the onset of tumor recurrence. 
The stains are DAPI nuclear stain (blue), NFKBIE (green), KDMB5 (yellow), SOX10 (red), 
MITF (cyan), and merge. The region highlighted by white dashed lines in the post-MAPKi 
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tissues display reduced MITF, NFKBIE, and SOX10 expression and elevated KDM5B 
expression, consistent with the adaptive resistance mechanism. The region highlighted by 
red dashed lines retained the MITF, NFKBIE, and SOX10 expressions but with loss of 
KDM5B after treatment. (B) Digitized mean fluorescence intensity (MFI) of the areas 
highlighted by white dashed lines for the selected markers in two patients. Data are 
represented as mean ± SD (*P<0.05 compared to respective pre-MAPKi). (C) Log-fold 
change in the expression of relevant genes (post-treatment vs baseline), collated from 
published datasets of BRAF-mutant melanoma patients treated with MAPK inhibitors 
(STAR Method). (D) Kaplan-Meier plots assembled using TCGA data sets of tumors from 
patients with stages III and IV melanomas with log-rank P values shown. See also Figure S7 
and Table S6. 
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Supplementary Information 
 
Supplementary figures 
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Figure S1. Reversible adaptive resistance across melanoma cell lines. Related to 
Figure 1. 
A. Stacked bar plot shows the fraction of cells viable in G0/G1, S, and G2/M phases 
(y-axis) for different melanoma cell lines. Each cell line has two different assay 
conditions: observed either before treatment, or after pretreated with BRAFi for 30 
days and drug removal in normal medium for another 30 days. Cells in both 
conditions underwent cell cycle analysis at both drug-naïve condition and 
retreatment with BRAFi for another 3 days. Cells that have gone through drug 
treatment and drug removal have the same cell cycle distribution as cells that never 
receive drug treatment. 
B. Immunostaining of M397 cells at different stages of reversible adaptive drug 
resistance. M397 cells before treatment (D0, first row), after treatment with BRAFi 
for 59 days (D59, second row), and pretreated with BRAFi for 29 days and then 
cultured with normal medium for another 35 days (DR35, third row) were used for 
immunostaining of MITF (red), actin (green), and DAPI (blue). The cell 
morphology at D0 is very similar to that at DR35. Cell morphology at D59 is very 
different from the ones at the other two conditions. Left panel scale bar 100um, 
right panel scale bar 20um. 
C. Two-dimensional self-organizing maps (SOMs) of overall transcriptome profiles 
of cells collected at different stages across the reversible adaptive drug response.  
D. Enrichment scores of representative gene sets across different stages of the 
reversible adaptive response. Enrichment scores at different time points are shown 
as dots connected with solid lines. The scores stabilize after prolonged drug 
treatment (after 21 days of BRAFi, blue line) and return to the enrichment score of 
day 0 after long-term drug removal (green line). 
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Figure S2. Surprisal analysis of the reversible adaptive transition in M397. Related to 
Figure 2. 
(A) Application of surprisal analysis to the kinetic transcriptome profile with respect to the 
reversible adaptive transition. The transcriptome data, decomposed into a time-invariant gene 
expression baseline plus two time-dependent gene modules, are illustrated as self-organizing 
maps (SOMs). Adding the expressions of the baseline gene module and time-dependent 
module-1 and module-2 recapitulates the experimentally measured transcriptome profiles 
visualized by the fact that the patterns of the SOMs in the last row (experimentally measured 
transcriptome profiles) are almost identical to those at second last row (predicted 
transcriptome profiles from surprisal analysis by adding first three rows). 
(B) ODE predictions (smooth line) are consistent with the average expression levels of genes 
associated with module-1 and module-2 from experimental measurements (dots) in the 
forward and reverse directions of the adaptive transition. More specifically, for drug 
treatment conditions, we have G1 positive genes (genes that positively contribute to module-
1 or Mlate) and G1 negative genes (genes that negatively contribute to module-1 or Mlate), 
which are paired with G2 positive and G2 negative genes (genes that positively and 
negatively contribute to module-2 or Mearly) respectively. Therefore, we have four different 
scenarios for drug treatment and four different scenarios for drug removal.   
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Figure S3. Best fitted parameters from dynamic system modeling of the reversible 
adaptive transition in M397. Related to Figure 2. The module-module interaction 
coefficients in the ordinary differential equations (ODEs) determined from fitting the ODE 
model to the average expression level of the top 500 genes associated with each gene module. 
More specifically, for drug treatment condition, we have G1 positive genes (genes that 
positively contribute to module-1 or Mlate) and G1 negative genes (genes that negatively 
contribute to module-1 or Mlate), which are paired with G2 positive and G2 negative genes 
(genes that positively and negatively contribute to module-2 or Mearly), respectively. 
Therefore, we have four different scenarios for drug treatment. Similarly, we also have 
another four different scenarios for the drug removal. 
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Figure S4. Strategies for inference of the critical regulators that drive the initiation of 
the reversible adaptive transition. Related to Figure 3. 
(A) Target gene inference based on the dynamic relationships between the two gene 
modules. The TFs/co-factors whose expression kinetics are correlated with the 
module scores of Mearly (left panel) are mapped to their target genes, followed by 
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assessing the target gene enrichments in the genes correlated with Mlate scores 
(middle panel). The inferred transition-driving TFs/co-factors whose target genes 
are significantly overrepresented in Mlate are ranked by their absolute correlation 
coefficients with Mearly scores. The top-5 elements were listed.  
(B) Common motif inference to extract enriched motifs from genes highly correlated 
with Mlate (left panel) and to identify the TFs that bind to these motifs and regulate 
cell state regression (right panel). Seven significantly enriched motifs with p <0.01 
(i.e. -log2P > 6.64) were identified and listed. 
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Figure S5. Epigenetic reversibility of the adaptive transition. Related to Figure 4. 
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(A) Graphical illustration of our methodology that integrates systems biology, 
bioinformatics and molecular biology approaches for investigating the molecular 
mechanism of the adaptive resistance. 
(B) A volcano plot showing the transcription factors/co-factors that display significant 
alterations between the drug-resistant state and the drug-sensitive state. 
(C) Differential peaks of the ATAC-seq profiles between two different time points. D0, 
D3, D32, and DR30 denote day-0, day-3, day-32, and drug removal day-30 across 
the adaptive transition, respectively. 
(D) Average H3K4me3 (left) and H3K27ac (right) ChIP-seq signal at the transcription 
start sites (TSS) across all genes with heatmap representation of each peak shown 
below. The x-axis shows flanking regions of +/- 3kb around the TSS. 
(E) ATAC-seq and ChIP-seq profiles at the promoter regions of some representative 
cell state marker genes, at selected time points across the reversible transition 
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Figure S6. The generality and molecular underpinning of the phenotypic plasticity of 
patient-derived melanoma cell lines in response to BRAF inhibition. Related to Figure 
6. 
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(A) Co-occurrence score of Mearly-related gene sets (G2+ and G2- gene sets) and 
Mlate-related gene sets (G1+ and G1- gene sets) in comparison with randomly 
selected gene sets calculated from the transcriptome data across all melanoma cells 
from the CCLE database. 
(B) Correlations between Mearly or Mlate module scores and BRAFi resistance levels 
across BRAFV600E-mutant melanoma cell lines in the GDSC database. The BRAFi 
resistance levels are quantified by natural log-transformed IC50 (µM) values and 
AUC. 
(C) Average H3K4me3 (left) and H3K27ac (right) ChIP-seq signal across promoter 
regions of all genes for a panel of melanoma cell lines, with heatmap view around 
TSS shown below. The x-axis shows flanking regions of +/- 1kb around each peak 
center. The y-axis of the top panel represents the read counts normalized by RPKM.  
(D) Average H3K4me3 (left) and H3K27ac (right) ChIP-seq signal at the transcription 
start site (TSS) region of SOX10.  
(E) Short-term clonogenic assay of KDM5 inhibitor (left) and HDAC inhibitor (right) 
across a panel of melanoma cell lines showing no significant toxicity to the cells at 
the dose used. 
(F) Left, western blot of lysates from melanoma either untreated control (CT) or treated 
with KDM5B inhibitor (CPI) and HDAC inhibitor (Q). H3 is used as loading 
control. 
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Figure S7. Generality and clinical relevance of adaptive epigenetic mechanism in 
melanoma patients. Related to Figure 7. 
(A) Gene set enrichment analysis (GSEA) on published transcriptome data from a 
melanoma patient (P2 in Table S6) before and after MAPKi treatment for selected 
gene sets relevant to the reversible transition observed in our system. NES, 
normalized enrichment score. 
(B) The change in Mearly and Mlate module scores calculated by published transcriptome 
data from melanoma patients before and after MAPKi treatment.  
(C) Co-occurrence scores of Mearly-related gene sets (G2+ and G2- gene sets) and Mlate-
related gene sets (G1+ and G1- gene sets) relative to randomly selected gene sets 
calculated from transcriptome data across all melanoma patients from the TCGA 
database.  
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(D) Average Mlate module scores of responders and non-responders to PD-1 
checkpoint blockade calculated by published transcriptome data of melanoma 
patients under PD-1 checkpoint inhibitor treatment (see STAR Methods) 
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Supplemental Tables 
Table S1: RNA-seq data (in RPKM) for time-course experiments of M397 and relevant 
gene module scores from information theory analysis. Data are provided as Excel 
spreadsheets. (https://www.biorxiv.org/content/10.1101/724740v1) 
 
Table S2. GSEA analysis for selected gene sets between different time points. 
Statistically significant positive enrichments are highlighted in yellow and negative 
enrichments in blue. 
 
Table S3. GSEA analysis of the genes associated with Mearly (G2) and Mlate (G1) gene 
modules for selected gene sets. Statistically significant positive enrichments are highlighted 
in yellow and negative enrichments in blue. 
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Table S4. Fitting parameters used in the ODE modeling. 
 Input genes for ODE parameter fitting 
Basal 
term 
Influence on 
M
late
 
Influence on 
M
early
 
 M
early
 input M
late
 input B
l
 B
e
 M
e-l
 M
l-l
 M
l-e
 M
e-e
 
Drug 
ON 
M
early
_positive_genes M
late
_positive_genes 8.39 6.33 0.49 -0.05 0.09 0.38 
M
early
_negative_genes M
late
_positive_genes -9.6 7.59 -0.68 -0.15 -0.15 0.52 
M
early
_positive_genes M
late
_negative_genes -3.12 6.83 -0.17 -0.01 -0.09 0.25 
M
early
_negative_genes M
late
_negative_genes 2.75 1.49 0.31 -0.048 0.14 0.41 
         
Drug 
OFF 
M
early
_positive_genes M
late
_positive_genes 5.47 5.35 0.38 0.16 -0.12 0.53 
M
early
_negative_genes M
late
_positive_genes -3.46 6.2 -0.18 0.03 -0.05 0.22 
M
early
_positive_genes M
late
_negative_genes -1.83 0.93 -0.48 0.14 -0.01 0.15 
M
early
_negative_genes M
late
_negative_genes 10.23 3.23 0.45 0.03 0.04 0.16 
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Table S5. The statistical significance of the alterations of chromatin accessibility and 
histone marks across the adaptive transition. The epigenetic alterations were evaluated in 
the RelA binding regions of a list of TFs and co-factors that are strongly associated with Mlate 
and contain RelA binding motifs. The TFs/co-factors that show statistically significant 
changes across all three epigenome alterations are shown in black. 
 
TF name 
H3K4me3 H3K27ac ATAC-seq 
P values 
SOX10 3.2 × 10
-11
 1.7 × 10
-4
 5.9 × 10
-5
 
DNAJC1 5.9 × 10
-5
 1.2 × 10
-3
 9.5 × 10
-3
 
ACTN1 3.4 × 10
-9
 4.0 × 10
-5
 0.13 
MMS19 3.0 × 10
-9
 1.2 × 10
-4
 6.1 × 10
-2
 
REPIN1 7.0 × 10
-9
 7.3 × 10
-4
 0.18 
IKZF5 7.0 × 10
-7
 1.2 × 10
-4
 0.15 
SIX4 5.1 × 10
-8
 6.9 × 10
-4
 0.42 
VEGFA 5.8 × 10
-7
 5.5 × 10
-4
 0.48 
KLF10 1.1 × 10
-6
 8.8 × 10
-4
 0.73 
E2F3 5.4 × 10
-6
 1.3 × 10
-3
 0.16 
HIVEP2 2.1 × 10
-6
 6.5 × 10
-4
 0.95 
IRX3 1.9 × 10
-6
 1.4 × 10
-3
 0.60 
SGK1 4.1 × 10
-5
 3.1 × 10
-4
 0.14 
TADA3 1.1 × 10
-6
 4.0 × 10
-3
 0.97 
SERTAD3 7.0 × 10
-5
 3.8 × 10
-4
 0.44 
MAF 3.1 × 10
-5
 5.8 × 10
-3
 0.17 
SOX5 3.1 × 10
-6
 1.3 × 10
-2
 0.89 
PHTF1 3.2 × 10
-5
 4.2 × 10
-3
 0.32 
SATB2 6.3 × 10
-5
 2.6 × 10
-3
 0.49 
HOXA13 5.3 × 10
-5
 2.8 × 10
-3
 0.68 
ZBTB24 3.5 × 10
-5
 9.4 × 10
-3
 0.32 
FHIT 3.5 × 10
-5
 8.5 × 10
-3
 0.53 
IRF1 4.9 × 10
-5
 1.3 × 10
-2
 0.58 
ZNF670 3.2 × 10
-4
 2.6 × 10
-3
 0.53 
VDR 9.8 × 10
-5
 1.5 × 10
-2
 0.79 
YAF2 9.5 × 10
-5
 2.9 × 10
-2
 0.47 
RNF25 4.7 × 10
-4
 2.1 × 10
-2
 0.67 
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ZNF280B 1.3 × 10
-2
 3.4 × 10
-3
 0.55 
ETS1 1.9 × 10
-2
 4.1 × 10
-3
 0.36 
CTDSP1 4.5 × 10
-3
 1.7 × 10
-2
 0.85 
TAF10 2.0 × 10
-2
 7.5 × 10
-3
 0.89 
RFX2 6.1 × 10
-3
 0.12 0.53 
FOXP1 4.0 × 10
-3
 0.37 0.53 
STAT1 9.4 × 10
-2
 0.22 0.75 
TARBP1 0.18 0.14 0.94 
ZNF280A 0.16 0.61 0.53 
 
 
Table S6. Relevant gene expression levels (RPKM) of selected patients before and after 
the MAPKi treatments from published data. Data are provided as Excel spreadsheets. 
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C h a p t e r  3  
SINGLE CELL ANALYSIS RESOLVES THE CELL STATE 
TRANSITION AND SIGNALING DYNAMICS ASSOCIATED WITH 
MELANOMA DRUG-INDUCED RESISTANCE 
Continuous BRAF inhibition of BRAF mutant melanomas triggers a series of cell state 
changes that lead to therapy resistance, and escape from immune control, prior to 
establishing acquired resistance genetically. We used genome-wide transcriptomics and 
single-cell phenotyping to explore the response kinetics to BRAF inhibition for a panel of 
patient-derived BRAFV600-mutant melanoma cell lines. A subset of plastic cell lines, 
which followed a trajectory covering multiple known cell-state transitions, provided 
models for more detailed biophysical investigations. Markov modeling revealed that the 
cell state transitions were reversible and mediated by both Lamarckian induction and non-
genomic Darwinian selection of drug tolerant states. Single cell functional proteomics 
revealed activation of certain signaling networks shortly following BRAF inhibition, and 
prior to the appearance of drug resistant phenotypes. Drug targeting those networks, in 
combination with BRAF inhibition, halted the adaptive transition and led to prolonged 
growth inhibition in multiple patient derived cell lines.  
This chapter includes content from our previously published article: 
[1] Su, Yapeng, Wei Wei, Lidia Robert, Min Xue, Jennifer Tsoi, Angel Garcia-Diaz, Blanca Homet Moreno 
et al. "Single-cell analysis resolves the cell state transition and signaling dynamics associated with 
melanoma drug-induced resistance." Proceedings of the National Academy of Sciences 114, no. 52 (2017): 
13679-13684. doi:10.1073/pnas.1712064115 
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Introduction 
The high rate of both response and resistance to BRAF inhibitors (BRAFi) has made 
BRAF mutant melanomas and derived cell lines into paradigmatic models for exploring the 
challenges of targeted inhibitors. Epigenetic alterations and associated cell state transitions 
along the melanocytic lineage towards drug tolerant states appear to precede the emergence 
of clones that are genetically resistant to BRAF inhibition [1-5]. Specifically, brief BRAFi 
exposure (1-3 days) can trigger melanocytic differentiation in certain cell lines. This is 
accompanied by increased MITF (a melanocytic transcription factor) and upregulation of 
downstream melanosomal antigens MART-1 and gp100 [1, 2]. Slightly longer exposure (2-
9 days) can induce de-differentiation towards a slow-cycling neural crest-like phenotype, 
with a characteristic increase of Nerve Growth Factor Receptor (NGFR) and loss of MART-
1 [5]. Extended exposure (>2 weeks) can yield an invasive mesenchymal-like state with both 
MART-1 and NGFR loss [3]. The kinetics and molecular details of these cell state changes 
depend upon the drug treatment duration and dose, and the plasticity of the cancer cells [3-
5]. For some patient-derived cell lines, these drug-induced cell state transitions are reversed 
upon drug release [5, 6]. Observations on patient-derived cells have been shown to correlate 
with what is seen in patient tumors [3-5].  
Several studies have explored the biology of non-genetic BRAFi resistance in BRAF 
mutant melanomas [1-5], but the biophysical picture of this process is less resolved. 
Biophysical studies can yield predictive insights, but may lack the mechanistic detail of a 
biological investigation. Of particular interest here are the nature of the cell-state changes 
observed over the course of drug resistance development. We consider two scenarios. The 
first involves the enrichment of drug resistant cancer cell genotypes, or epigenotypes, with 
growth advantage upon drug exposure, akin to the Darwinian-type selection [7]. The second, 
Lamarckian induction [8], is when the drug treatment itself induces cell state changes 
towards a more drug tolerant state that can persist across cell generations through 
transcriptional reprogramming and signaling network rewiring. The second scenario is often 
loosely (and imprecisely) termed as an adaptive response to drugging.  
In principle, experimental measures of the trajectories of many single melanoma cells 
would discriminate between the different scenarios for drug resistance development. 
However, such trajectories are not feasible for the full, few month, reversible melanocyte to 
mesenchymal transition, although sub-regions of this cell state space may be so mapped [5]. 
Here, we utilize whole transcriptome analysis and single cell phenotype profiling to 
investigate the responses of a series of patient-derived BRAF mutant melanoma cell lines to 
BRAFi. Certain cell lines exhibit the full range of adaptive responses, and data from those 
cells is computationally modeled to investigate the transition kinetics and the nature of the 
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BRAFi-triggered cell-state changes. We further explore the signaling pathways associated 
with the induction of various sub-phenotypes via a kinetic single cell functional proteomic 
study [9]. These single cell assays uncover the emergence of drug-activated signaling, prior 
to the appearance of drug-tolerant phenotypes, and identify strategies for arresting the cell-
state transitions and prolonging cell growth inhibition. We demonstrate that our findings 
extend to less-plastic cell lines.  
Results 
The cellular transition trajectories of phenotypically plastic melanoma cells in 
adaptation to BRAFi.  
We interrogated 18 patient-derived BRAFV600E mutant melanoma cell lines by exposing 
them to BRAFi (vemurafenib) for periods of 3 days and 3 weeks at a concentration of 2×IC50 
for each cell line (SI Appendix, Table S1). Phenotypic changes were characterized by flow 
cytometry using well-established markers for melanocytic (MART-1) and neural crest-like 
cells (NGFR), respectively (SI Appendix, Figs. S1 and S2, and Table S2) [5, 6, 10]. Clustering 
of flow cytometry data classified the 18 cell lines into 4 clusters according to their phenotypic 
plasticity to BRAFi. Cluster C cells exhibited the highest plasticity upon drug treatment (SI 
Appendix, Fig. S1A).  
We further characterized these phenotypic changes at the whole transcriptome level. We 
randomly selected 9 cell lines from the 4 clusters for RNA-seq analysis at baseline, plus after 
3 days and 3 weeks of drug exposure (Fig. 1 and SI Appendix, Fig. S1B). Consistent with 
previous findings, the most drug resistant cell lines (defined by IC50>1μM) showed a 
relatively low melanocytic signature, elevated expression of neural crest and mesenchymal 
related genes, and activated signaling in JNK and NFκB pathways [3, 5]. AXL and c-JUN 
strongly correlate with the IC50 values while LEF1 and MITF are anti-correlated [3, 11, 12]. 
A clustering analysis of genome-wide expression of the 9 cell lines yielded partitions 
identical to those generated from two-marker flow cytometry data (SI Appendix, Fig. S1B). 
This confirmed NGFR and MART-1 as robust markers for characterizing the BRAFi-
induced phenotype transitions. The differentially expressed genes (DEGs) upon BRAFi 
treatment, as analyzed using Gene Expression Dynamic Inspector (GEDI) [13], pointed to 
cluster C again that exhibited the largest transcriptional alterations upon drugging (Fig. 1C). 
A common group of proliferation-related genes showed varying degrees of down-regulation 
in all clusters (SI Appendix, Fig. S3).  
We selected the highly plastic Cluster C cell lines (M397, M229, and M263) for a time-
course analysis for either a brief (3 days) to a prolonged (71-90 days) BRAF inhibition. The 
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three lines followed similar trajectories on the flow cytometry plots (Fig. 1B), starting with 
transient melanocytic differentiation (increased MITF/MART-1 expression) for 3 day 
treatment (Figs. 1B and SI Appendix, Table S2), followed by the appearance of the slow 
cycling neural crest-like (NGFRhigh/MART-1neg) state after 1-3 weeks of drug treatment. 
Prolonged BRAF inhibition yielded a double negative (NGFRlow/MART-1neg) state 
characterized by a sharp increase in cell proliferation [5]. The interpretation of these 
trajectories (Fig. 1B) was validated at the transcriptional level by scoring MITF activity [14] 
and neural crest signatures [15] of each cell line using curated gene sets (Fig. 1D and SI 
Appendix, Fig. S4 and Table S3). The trajectories also correlated with the development of 
adaptive resistance (SI Appendix, Fig. S5). Similarly, Gene Set Enrichment Analysis (GSEA) 
on the averaged gene expression of the three cell lines revealed significant enrichment in 
neural crest stem cell and EMT related genes with elevated invasiveness and migration 
signatures. Meanwhile, TNF/NFκB, JNK, and p38 MAPK signaling related genes were 
significantly enriched upon continuous BRAFi exposure (Fig. 1E), with down-regulation of 
MITF signature (Fig. 1E and SI Appendix, Fig. S6). These findings were confirmed by 
inspecting the expression levels (SI Appendix, Fig. S7A) and mining the GO terms of these 
DEGs (SI Appendix, Fig. S7B). The enrichment of neural crest-related genes was 
insignificant after prolonged drug exposure while the enrichment of EMT-associated genes 
held steady (Fig. 1E). Thus, the double negative state carried mesenchymal signatures, and 
exhibited the loss of neural crest state signatures. Analysis of other clusters showed similar 
enrichment in neural crest and mesenchymal signatures except for Cluster A, which 
contained innately resistant cells with MART-1neg/NGFRneg baseline expression (SI 
Appendix, Fig. S8). Similar enrichment patterns of the transcriptional programs were also 
found in published transcriptomic datasets involving 39 patient samples from pre-treatment, 
on-treatment, and/or emergence of acquired resistance to RAF/MEK inhibitors [16]. This 
suggests similar adaptive resistance in these BRAFi-treated patient tumors (SI Appendix, Fig. 
S9). Moreover, when cells were treated with BRAFi for 3 weeks or longer, we identified 
significant enrichment in most innate anti-PD-1 resistance (IPRES) signatures [17] (SI 
Appendix, Table S4), pointing to a potential rise of resistance to PD-1 blockade for cells 
adapted to the run-in BRAFi therapy. The BRAFi-induced cell state changes in Cluster C 
cells reflected a summation of the various types of adaptive transitions reported for 
melanomas in response to BRAFi [3-6]. Thus, Cluster C cell lines were carried forward for 
a detailed biophysical investigation of BRAFi-induced cell state transitions.  
Adaptive transition proceeds through drug-mediated cell state interconversion and 
phenotypic selection.  
Three factors can account for the drug-induced cell-state transition kinetics. The first is 
a deterministic factor that arises from cell state changes determined by the underlying 
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causative gene regulatory networks. The second factor arises from the stochastic nature of 
gene expression. Stochastic cell-state changes may be considered as a random walk diffusion 
process across the epigenetic landscape [18]. The third factor accounts for phenotype-
specific cell proliferation and survival upon drug exposure. To account for all three factors, 
we modified a published Markov kinetic framework [19] to model the BRAFi-induced cell 
state transitions (Fig. 2). Our model assumed that the cell population is comprised of four 
discrete cell states (Fig. 2A), and contains a non-symmetric cell state interconversion matrix 
to account for both deterministic (Lamarckian induction) and stochastic cell state transitions. 
For drug treated cells, a drug susceptibility matrix is introduced to quantify the third factor 
(See SI Appendix, Materials and Methods). Experimental inputs into the model are short-
time measures of the cell-state composition dynamics. Computational outputs are state-to-
state transition probabilities (Fig. 2B), and, for drug treated samples, state-dependent drug 
susceptibility (Fig. 2C).  
We sorted NGFRpos and NGFRneg subpopulations of two Cluster C cell lines (M397 and 
M229) at baseline, and seeded them separately in petri-dishes for in vitro expansion (Fig. 2A 
and SI Appendix, Figs. S10-S12), with and without BRAFi, thus providing 4 initial conditions 
for each cell line. For untreated samples, flow cytometry analysis of the phenotype 
compositions over the first 3 cycles of expansion provided input into the Markov model. The 
fitted Markov model parameters (Fig. 2C) were then used to predict longer-term phenotypic 
evolution. Without BRAFi, the NGFRpos and NGFRneg subpopulations of both cell lines were 
predicted and experimentally shown to return to their original unsorted phenotypic 
composition after several cell cycles (SI Appendix, Fig. S10B) [5, 18-20].  
BRAFi clearly altered the cell-state interconversion probabilities (Figs. 2B and SI 
Appendix, Fig. S13). The Markov model fits from phenotype dynamics of sorted populations 
(Fig. 2B) under BRAFi were used to predict the drug susceptibility of each cell state. The 
neural crest-like and double negative states were predicted, and experimentally shown, to be 
more resistant to drug treatment compared to melanocytic and double positive states (Fig. 
2C). We further used the interconversion and drug susceptibility matrices inferred from the 
cell-state kinetics of segregated populations to predict the phenotypic evolution of unsorted 
cells upon prolonged BRAFi exposure. The model predictions were in good agreement with 
the experiments (Fig. 2D and SI Appendix, Fig. S13C, Tables S5 and S6). Furthermore, the 
Markov model suggests that, upon drug removal, the cells should return to the original 
phenotypic compositions characteristic of drug naive cells. In fact, such a reversible 
transition was observed in both the Cluster C cells and the less plastic Cluster B cells (SI 
Appendix, Fig. S14A), and the reverted cells also exhibited a similar IC50 to BRAFi as the 
untreated cells (SI Appendix, Fig. S14B).  
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The Markov model predictions provide evidence for Lamarckian induction, since they 
show that BRAFi influences the specific rates of cell-state interconversion. The predictions 
also provide evidence of phenotype-dependent Darwinian selection, since cell states with the 
lowest drug susceptibility eventually win out. If only the drug susceptibility matrix is 
included in the Markov model, the resultant prediction is in poor agreement with the 
experiments (SI Appendix, Fig. S13D). Therefore, the combined actions of both cell state 
interconversion and drug selection contribute to the observed phenotypic kinetics.  
Single cell functional proteomics reveals the emergence of drug-activated signaling at 
the initiation of the adaptive transition.  
We utilized the microfluidics based SCBC technology to carry out single cell analysis 
of the M397 cells so as to interrogate those signaling pathways directly targeted by BRAFi 
[9]. Guided by the transcriptional analysis, we designed a protein panel that covers critical 
phenotypic markers, transcription factors and signaling effectors involved in the adaptive 
transition (SI Appendix, Tables S7 and S8). Each SCBC has 320 microchambers (1.5 
nanoliter volume) engineered for cell lysis, and each equipped with an antibody array for 
protein capture. Following cell lysis, specific proteins are captured, and each array element 
is developed as a sandwich immunofluorescent assay (SI Appendix, Fig. S15).  
Scatter plots of single cell data are shown in Fig. 3A with averaged protein abundance 
indicated by the black horizontal lines. The time-series data are projected onto a two-
dimensional plane using the t-SNE algorithm (Fig. 3B) [21]. SCBC assays from different 
time points cluster into different groups. The dispersion within a group and the distance 
between groups provide functional measures of how different the single cells are. Such 
dispersion can be quantified by the functional heterogeneity index (FHI) defined in our 
previous study [9]. Notably, BRAFi treatment increases the cellular heterogeneity in days 3 
and 6, indicating an elevated plasticity (Fig. 3C). This is reflected in the sharply increased 
dispersion of day-6 cells in the t-SNE plane. This increase in heterogeneity between days 3 
and 6 is reminiscent of the attractor destabilization and bifurcation prior to a cell-state 
transition in other systems [22, 23].  
We used the SCBC data to assess protein-protein correlations at each time point (SI 
Appendix, Fig. S16). The emergence of strong negative correlations between NGFR and 
MITF/MART-1 at day-3 points to the initiation of the cell state transition towards the neural 
crest-like phenotype with elevated NGFR and loss of MITF/MART-1. The overall activity 
of the network may be quantified by the signaling network activity index (SNAI) that 
accounts for both the numbers and strengths of statistically significant correlations (See SI 
Appendix, Materials and Methods). The SNAI is highest at day-6 (Fig. 3D), with particularly 
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strong signaling participation of p-ERK and p-NFκB p65 (SI Appendix, Fig. S16), 
suggesting a potential gain of function through MEK/ERK and NFκB p65 signaling that 
might lead to BRAFi drug tolerance by promoting the adaptive transition. The SNAI drops 
sharply between day 6 and day 10, but then recovers to an activity similar to that seen for 
untreated cells (Fig. 3D), albeit with altered active network components (SI Appendix, Fig. 
S16). This general behavior is reminiscent of cell-state transitions seen in other model 
systems [23], and indicates a possible cell-state switch between days 6 and 10. 
To quantify the influence of the functional proteins on the overall signaling coordination 
at the initiation of the transition, we performed Principal Component Analysis (PCA), using 
an analytical approach previously reported [9]. We calculated the correlations between the 
assayed proteins and first principal component (PC1) for untreated and 6 days BRAFi treated 
samples. PC1 captures the most essential feature of the signaling network, and thus identifies 
those proteins that participate most strongly in the signaling coordination. For the untreated 
sample, PC1 is populated by p-ERK, p-NFκB p65, p-JNK, and p-P38α (Fig. 3E). At day 6, 
these four proteins bifurcate into 2 groups, with the influence of p-JNK and p-P38α (blue 
group) signaling repressed, and MEK/ERK and NFκB p65 signaling (red group) elevated 
(Fig. 3E). This behavior suggests that combining BRAFi with MEK and NFκB p65 inhibition 
that might arrest the adaptive cell-state transition towards drug resistant phenotypes. 
Combined MEK/ERK and NFκB p65 inhibition with BRAFi arrests the adaptive 
transition and induced a sustained growth inhibition.  
The single cell analysis suggests that inhibiting the NFκB p65 and MEK/ERK signaling 
axes might keep the cells in the BRAFi sensitive state. To test this hypothesis, we used 
trametinib (T, MEK inhibitor) and JSH-23 (J, NFκB p65 translocation inhibitor) [24] in 
combination with vemurafenib (V) to treat the M397 cells in vitro, and compared the results 
against mono-therapies (V, T, and J) or dual combinations (V+T and V+J) over 23 days. 
Consistent with our prediction, all combination therapies induced considerable cell growth 
inhibition (Fig. 4A). The monotherapies T and J were much less potent compared to V, but 
both dual combinations and the triple combination significantly outperformed the 
monotherapies. Consistent with previous finding [5], while V+T yielded enhanced 
therapeutic effect relative to V, it did not halt the phenotypic transition towards the neural 
crest-like drug tolerant state (Figs. 4B, and SI Appendix, Fig. S17), and therapy resistance 
emerged after prolonged treatment (Fig. 4C, SI Appendix, Fig. S19A). However, both V+J 
and V+T+J successfully arrested the transition and kept the cells in the drug sensitive state 
(MART-1pos) (Figs. 4B), indicating NFκB p65 nuclear translocation is necessary for the 
adaptive transition towards the drug tolerant phenotypes. Drug dose-response assay under 
the Bliss independence assumption further confirmed that the sustained growth inhibition of 
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the triple combination was not simply a result of drug synergy, but due to the arrest of cell 
state transition (SI Appendix, Fig. S18). We further performed colonogenic assays to assess 
if the combination can induce sustained growth inhibition on four other BRAFV600E mutated 
melanoma cell lines. The results indicated that the V+T+J combination outperforms V+T 
over prolonged periods for all cell lines tested, while treatment with J alone showed no 
significant cytotoxicity (Fig. 4C and SI Appendix, Fig. S19).  
Discussion 
Adaptive resistance resulting from transcriptomic reprogramming permits BRAF 
mutant melanoma cells to survive BRAF inhibition. BRAFi exposure triggers a transient 
melanocytic differentiation program, followed by multiple de-differentiation programs that 
terminate in a drug-resistant mesenchymal-like state. Cells with distinct innate drug 
sensitivities may follow all or part of this transition trajectory upon BRAFi exposure (SI 
Appendix, Fig. S2). The full transition trajectory was observed within a highly plastic set 
of patient derived cells (SI Appendix, Fig. S1A, Cluster C), accompanied by an elevated 
IPRES gene signature associated with anti-PD-1 therapy-resistant melanomas [17]. These 
results challenge the notion of protocols with a run-in period of targeted BRAFi therapy 
followed by immune checkpoint therapy, as the adaptive response to BRAFi may also 
create a less friendly environment to immunotherapies in certain BRAFi sensitive tumors 
[25].  
The kinetics of the cell state transitions that occur from the drug naïve, melanocytic 
state to the drug resistant mesenchymal state was well-captured by a Markov model. This 
analysis revealed the critical role of drug induction, relative to the selection of drug tolerant 
phenotypes, in the adaptive response to BRAFi. Drug induction can enable the de novo 
generation of new cell states, while selection accelerates the enrichment of the drug tolerant 
states. The cell state interconversion probabilities over long periods of drug treatment were 
inferred from snapshots of flow cytometry data. However, the Markov model does have 
limitations. For example, the phenotype-dependent drug susceptibility determined from the 
Markov model is incomplete, as it groups the net effect of cell proliferation and cell death 
of each phenotype into a single diagonal term in the matrix. The relative contribution of 
each factor is not distinguished [20, 26]. Similarly, upon drug removal, the relative 
contribution of the cell state reversion versus regrowth of specific cellular phenotypes is 
also not resolved. Additionally, the Markov model oversimplifies the continuous cell state 
transitions by categorizing cells into discrete phenotypes based on their marker expression 
levels. Continuous kinetic models [18], coupled with experimental measures of single cell 
trajectories [26], may prove attractive for investigating these transitions at finer resolution.  
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Transcriptional analysis revealed several critical signaling pathways associated with 
cellular adaptation to BRAFi. This, in turn, informed the design of a second kinetic 
investigation of the transition via single cell functional proteomics. That study unveiled the 
BRAFi-induced activation of MEK/ERK and NFκB p65 signaling, prior to the emergence 
of the drug-resistant phenotype. NFκB can synergize with c-Jun in the transcriptional 
response to TNF-α [12]. Further, the c-Jun/JNK signaling axis has been reported to play a 
critical role in melanoma adaptive resistance to BRAFi [3, 4], and was also found here to 
be associated with the emergence of adaptive resistance when the cells were transitioning 
to the neural crest or mesenchymal-like states (SI Appendix, Fig. S20). However, 
TNF/NFκB signaling was activated at the beginning of the adaptive transition (prior to the 
c-Jun/JNK activation), implying that TNF/NFκB signaling might enable the neural crest 
transition program. This is further supported by the report that neural crest de-
differentiation can be triggered by pro-inflammatory cytokine TNF-α secreted from tumor 
infiltrating lymphocytes [10]. It echoes the observation that the MITFlow/NFκBhigh 
transcriptional state of melanomas is resistant to inhibition of BRAF and MEK, singly or 
in combination [11]. NFκB inhibitors are normally used as adjuvant to chemo- or targeted- 
therapies in clinical trials [27]. However, due to the host toxicity, identifying more 
clinically actionable targets downstream of the NFκB pathway may be an appealing option 
[28] for arresting BRAFi adaptive resistance. As similar enrichment patterns were recurrent 
in more than half of the on-treatment patient biopsies (SI Appendix, Fig. S9), we anticipate 
that combined therapy with inhibitors of this pathway may improve the durability of 
BRAFi therapy.  
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Materials and Methods 
Human melanoma cell lines (M series) were established from patient’s biopsies under 
UCLA IRB approval # 11–003254. Please refer to SI Appendix, SI Materials and Methods 
for cell lines and reagents used, experimental protocols and statistical analysis.  
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Figures. 
 
Fig. 1. Phenotypic and transcriptomic characterization of a panel of patient-derived 
melanoma cell lines while adapting to BRAF inhibition. (A) Heat map of baseline 
expression levels for critical genes involved in the adaptive BRAFi resistance across a 
panel of melanoma cell lines, ordered by averaged IC50 to BRAFi. An IC50 of 1 µM was 
set to be the threshold for resistant lines. Correlation coefficients between each gene’s 
expression and IC50 across cell lines were evaluated with statistically significant 
correlations listed in bold font (*p<0.05 and **p<0.005). (B) Phenotypic kinetics screened 
by flow cytometry shows how the three plastic cell lines from Cluster C experienced a 
phenotypic transition following a counter-clockwise trajectory over a 73 days BRAF 
inhibition. (C) Visualization of differentially expressed genes for all the cell line clusters 
relative to control by GEDI. Each mosaic map represents averaged genome-wide 
expression profile for a specific cluster of cell lines at a time point as labeled. Each pixel 
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in the same location within the mosaic maps represents the same minicluster of genes 
(red: up-regulation, blue: down-regulation, green: no change). (D) Plot of signature scores 
of MITF and neural crest for the 3 plastic cell lines across different time points upon BRAFi 
treatment. Counter-clockwise trajectories appear for all three lines (VC: DMSO control). 
(E) GSEA normalized enrichment scores (NES) show significant enrichment of curated 
gene sets in the relevant categories associated melanoma adaptive cell state transition for 
21 days and 73-90 days (NOM p values: *p<0.05, **p<0.005, ***p<0.0005, NS: not 
significant). 
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Fig. 2. Markov model of cell state transition predicts phenotypic evolution of 
melanoma cells upon BRAF inhibition. (A) Schematic illustration of phenotypic 
segregation and treatment conditions in Markov model. The cells were sorted to NGFR+ 
and NGFR- subpopulations and treated with or without vemurafenib. (B) Cell state 
transition probabilities of M397 at untreated and vemurafenib treated conditions. (C) 
Relative viability of different phenotypes for M397 inferred by the model (up), and 
measured IC50 values (normalized to control) at different time points (down) across the 
transition at which one phenotype is enriched as indicated by its respective color code 
(error bars: ±SD). (D) Model prediction of the phenotypic kinetics (solid lines) versus 
experimental data (dots connected with dash lines) for M397 with continuous exposure to 
vemurafenib.  
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Fig. 3. Single cell proteomic profiling of the M397 cell line during the course of 
adaptive cell state transition. (A) Background subtracted SCBC data represented as one-
dimensional scatter plot (mean ± SEM was overlaid for each protein by the black horizontal 
bar). Statistical uniqueness is evaluated by Kruskal-Wallis test comparison among multiple 
time points. All 13 markers are statistically significant with P < 0.0005. (B). Application 
of t-SNE algorithm to the single cell data separates the cells into spatially distinct clusters 
based on their proteomic profiles. Each point in the t-SNE plane represents a single cell 
measurement and its color is coded by a time point. (C) Quantification of the functional 
heterogeneity (FHI) of M397 cells across different time points along with the transition. 
(D) The Signaling Network Activity Index (SNAI) across different time points along with 
the transition, extracted from single cell proteomic measurements of M397 cells. (E) 
Change in signaling coordination quantified as correlations between key functional 
proteins and the first principal component for control and day-6 in which a bifurcation of 
signaling proteins is identified.  
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Fig. 4. In vitro validation of the mono- and combination therapies predicted by SCBC 
analysis. (A) In vitro cell proliferation assay of M397 for the mono- and combination 
therapies based upon the predictions from the SCBC data analysis. At each time point, cell 
number of each test condition is normalized to the number of vemurafenib monotherapy 
and plotted as Log 10 fold change (Error bars: ±SD). (B) Flow cytometry analysis of 
MART-1 and NGFR levels at single cell resolution for mono- and combination therapies 
on both M397 (23 days treatment) and M229 (28 days treatment). (C) Clonogenic assays 
of long-term drug treated samples confirm V+T+J induced a sustained growth inhibition. 
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SI Appendix 
 
Supplementary Materials and Methods 
Cell lines, reagents and cell culture 
Human melanoma cell lines (M series) were established from patient’s biopsies under UCLA 
IRB approval # 11–003254. Cells were cultured in RPMI 1640 with L-glutamine (Mediatech, 
Inc, Manassas, VA), 10% fetal bovine serum (Omega Scientific Tarzana, CA), and 1% 
penicillin, streptomycin and fungizone (Omega Scientific Tarzana, CA). Cultures were 
incubated in a water-saturated incubator at 37°C with 5% CO2. Cells were maintained and 
tested for mycoplasma as described before [1, 2]. Cell lines were periodically authenticated 
to their early passages using GenePrint® 10 System (Promega, Madison, WI). Presence of 
mutations in the genes of interest was checked by OncoMap 3 or Iontrone, and was confirmed 
by PCR and Sanger sequencing as previously described [1, 2].  
Vemurafenib (NC0621949, Selleck Chemicals LLC), trametinib (NC0592237, Selleck 
Chemicals LLC), and JSH-23 (S7351, Selleck Chemicals LLC) were dissolved in DMSO at 
designated concentrations before applying to cell culture media. All cell lines were plated in 
T-75 plates at 60% confluency and treated with vemurafenib at twice the 50% inhibition 
concentration (2 × IC50) of each cell line using their previously described IC50 (Table S1). 
The DNA-antibody conjugates were synthesized with previous protocols reported [3]. The 
list of ssDNA and antibodies used in this work is shown in Tables S6 and S7.  
Phenotype tracking by flow cytometry. 
Cell suspensions were stained for flow cytometry with PE conjugated anti human NGFR 
antibody from Biolegend (San Diego, CA). All cells were then fixed with Fix-Perm buffer 
from BD Bioscience (San Jose, CA) and stained for intracellular FITC conjugated anti 
human Melan-A antibody from Santa Cruz (Dallas, TX). Isotypes for mouse IgG1k and 
mouse IgG1 respectively were used to enable correct gating and to confirm antibody 
specificity. Blue live-dead staining from Life technologies (Waltham, MA) was used to 
discriminate alive. 10000 alive events were collected for each sample. Flow cytometry 
analysis was conducted using LSR-II from BD Biosciences (San Jose, CA), and the data was 
analyzed using FlowJo software (Tree Star, Inc., San Carlos, CA). The hierarchical clustering 
from the 18 cell lines, was performed using the expression levels in flow cytometry, with 
complete linkage and Euclidean distance metric. Gating of NGFR and Mart1 for defining 
cell states are all based on the staining of isotype controls. 
MITF Reporter Cell Line 
The human Tyrosinase Promoter (TP) was subcloned from pLightSwitch Prom S700747 
(SwitchGear Genomics, Carlsbad, CA), which was first digested with MluI (New England 
Biolabs; Ipswich, MA). Blunt ends were generated using T4 Polymerase (New England 
Biolabs) and the resulting fragment was digested again with Bgl II (New England Biolabs). 
Resulting 1057 bp Tyrosinase promoter insert was then cloned by standard methods [4] into 
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the BamH1 and HpaI sites of the lentiviral vector backbone Lenti-D-EN-fLUC, driving 
the expression of the firefly luciferase gene.  
Lentivirus particles were generated as previously described [5] to stably transduce M229, 
M263 and M397. Generated stable reporter cell lines M229TP, M263TP and M397TP from 
different conditions were trypsinized and seeded at a density of 100.000 cells per well in 96-
well white-bottomed plates. Luciferase activity was read out from white-bottomed plates 
using luciferin directly (1:10 Final dilution) and signal was normalized according to viability 
calculated using CellTiter-Glo (Promega, San Luis Obispo, CA) (1:2 final dilution), also 
plated in white-bottomed plates. Bioluminescence imaging was carried out with a Xenogen 
IVIS 200 Imaging System (Xenogen/Caliper Life Sciences). 
RNA-Seq 
RNA extraction was performed using AllPrep DNA/RNA Mini kit from Qiagen in 18 human 
melanoma cell lines samples and also in samples from M229, M263 and M397 treated under 
different conditions. Bioanalyzer confirmed correct integrity, library was constructed and 
Illumina 50 bp single-end RNA-seq data was collected for the samples described. RNA 
sequencing was performed using 50 bps single end sequencing on the Illumina HiSeq 2500 
platform. Libraries were prepared using the IlluminaTruSeq RNA sample preparation kit per 
the manufacturer’s instructions. Reads were mapped and aligned to the Homo sapiens NCBI 
build 37.2 reference genome using TopHat2 v2.0.9 [6]. Expression values in fragments per 
kilobase of exon per million fragments mapped (FPKM) were generated using Cufflinks 
v2.2.1 program and Cuffnorm to quantify and normalize aligned reads using the geometric 
library size normalization method [7].  
The stochastic cell transition model 
The stochastic cell-state transition model is built by assuming a time-homogeneous Markov 
chain process as described in a previous publication [8]. Two basic assumptions are made 
for the model: First, cells at four designated subpopulations transition randomly between 
states per certain unit time. Second, the transition probabilities depend only on a cell's current 
state, regardless of its prior states. The governing equations are listed below. 
  
Proportions of various states are listed as column vectors. The 4×4 state transition probability 
matrix with each element denoting the transition probability from one cell state to other states 
per unit time is pre-multiplied with a diagonal drug sensitivity matrix. The four diagonal 
elements of this matrix encode the relative viability of the two melanocyte, neural crest and 
double negative states in the presence of drug treatment. The calculated 4-element vector is 
normalized to have a summation of 1 to generate the new proportions vector. 
Kinetic flow cytometry data (Table S5) of segregated cell populations at different time points 
are used as input. Monte Carlo simulation is performed by random sampling differential 
transition probability and viability vectors to quantitatively infer the most probable values in 
the matrices that best recapitulate the experimental observations of sorted cells. The values 
Time
original treatment State transition new
proportions sensitivity matrix probability matrix proportions
        
        
        
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inferred from sorted cells are then utilized to predict the cell state dynamics and final 
steady-state composition of unsorted cells under drug treatment (Fig. 2D). 
Transcriptomic data analysis 
Heatmap and clustering analysis of transcriptomic dataset for all 9 cell lines was performed 
via MATLAB. Genes are pre-filtered by RPKM value with criteria of average value greater 
than1 and coefficient of variance greater than 0.3. Filtered gene expression values were 
standardized across each row (normalized for each individual gene) and represented by 
redblue colormap. Hierarchical clustering was performed with average linkage and 
Euclidean distance metric. Whole transcriptomic dataset for each cell line upon drug 
treatment was also plotted as self-organized mosaic maps with respective to its control via 
Gene Expression Dynamics Inspector (GEDI) [9]. Each tile in the maps represents a 
minicluster of genes with similar expression kinetics. Gene clusters with related expression 
kinetics are placed close together, while clusters exhibiting very different kinetic trajectories 
are placed far apart. The tile color encodes the average expression level of the genes in that 
minicluster at a given time point. By extracting genes in interesting regions (e.g. common 
regions that are changing in the same direction across all cell line clusters or unique regions 
that are only changing in only one cluster, etc.), one could further investigate their biological 
functions. Genes in regions of interest are further enriched in the Gene Ontology Biology 
Process database using Enricher [10].  
For generating the phenotypic trajectory in Figs. 1D and S4, the MITF activity and neural 
crest signature scores were determined by using genes identified as MITF targets [11] and 
chicken embryo neural crest genes from Gallus EST in situ hybridization analysis – 
GEISHA- [12] (Table S3) respectively. Signatures scores were calculated by taking the sum 
of all log2 fold changes from DMSO control for all signature genes and divided by the square 
root of the total number of genes. 
Gene Set Enrichment Analysis (GSEA) was performed using GSEA v2.2.3 software with 
1000 permutations and weighted enrichment statistics. For correlation enrichment, we used 
Pearson correlation of relevant pathways with MITF, L1CAM, NGFR, NFκB1, CCL2, and 
AXL expression across patient samples. For the pre-ranked option with log2 fold changes 
were used as the ranking metric. Normalized enrichment score (NES) was assessed across 
the curated Molecular Signatures Database (MSigDB) Hallmark, C2 curated gene sets, and 
MITF signature [11]. 
Using Database for Annotation, Visualization and Integrated Discovery (DAVID) 6.8, we 
looked at relevant Gene ontology (GO) terms for differentially expressed genes for M229, 
M263 and M397 at 21 days and 73-90 days of drug treatment with respect to DMSO control 
(Fig. S7).  
 
Microchip fabrication and single cell proteomic assay 
The fabrication of the SCBC devices and the protocol of the single cell proteomic assays 
were extensively discussed in our previous publications [13, 14]. Briefly, the DNA 
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microarrays at each microchamber were converted to antibody microarrays by flowing 
the DNA-antibody conjugate cocktail solution immediately prior to use. Cells were randomly 
loaded into the 310 microchambers of the SCBC. Each microchamber has an assay 
component, and a separate reservoir of lysis buffer, and was photographed after cell loading. 
The SCBC was then cooled on ice for cell lysis. Following a 2-hour protein capture period 
at room temperature, the microchambers were flushed and the antibody arrays were 
developed using a cocktail of detection antibodies. The developed antibody barcode arrays 
were digitized by a Genepix scanner. Each array is matched with the micrograph of that array 
for preparing a table that contains the microchamber address, the numbers of cells, and the 
measured fluorescence levels of each assayed protein. 
Clonogenic assay 
Clonogenic assays were performed by plating melanoma cells in six-well plates with fresh 
media at an optimal confluence. The media (with drug or DMSO) were replenished every 
2 days. Upon the time of staining, 4% paraformaldehyde was applied onto colonies to fix 
the cells and 0.05% crystal violet solution was used for staining the colonies.  
Drug dose-response SRB assay 
The 3 cell lines were pre-seeded into 96-well plates for 48 hours before the addition of drug. 
After that, cells were treated with drug for 72 hours, and cell viability was determined using 
In Vitro Toxicology Assay Kit (TOX6, SIGMA-ALDRICH) following the manufacturer's 
instruction. A Bliss independence model was used to evaluate the effect of drug combination 
[15].  
 
Statistical analysis of SCBC data 
The SCBC readouts from the microchambers with a single cell were collected to form a data 
table. Each row of the table corresponds to a measurement of a panel of functional proteins 
from a single cell and each column contains digitized fluorescence intensities that provide 
readout of the levels of each of the assayed proteins. Protein-protein Spearman’s rank 
correlation coefficients can be directly calculated from single cell data. Protein correlation 
networks were generated by running the calculation through all the protein pairs in panel 
(Fig. S12). Bonferroni corrected p-value was used to define the statistical significance level 
for the entire panel and only those significant correlations were shown in the networks.  
The t-SNE dimensionality reduction analysis was performed on SCBC dataset following a 
previous published algorithm [16].  
A normalized PCA was used to peel off layer after layer of systematic co-variations from 
the data, in terms of principal components (PCs). The correlations between functional 
protein levels and PCs were calculated to quantify the dominative protein pattern of the 
signaling network coordination and its response to external perturbations such as drug 
treatment. The signaling network activity index (SNAI) is a metric of the overall strength 
of the protein signaling coordination at a given condition, and is defined as the reciprocal of 
the determinant of the protein-protein correlations 
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Supplementary Figures 
 
 
Fig. S1. Phenotypic clustering of 18 BRAFV600 mutant melanoma cell lines upon 
BRAF inhibition. (A) Clustering of 18 cell lines based upon their partition percentages 
(color coded in red) in four phenotypic quadrants (inset) at baseline and upon BRAFi 
response identifies 4 groups. The quadrants are defined by the gate setting of NGFR and 
MART-1 expression levels for each cell line in the flow cytometry analysis. Cluster C cells 
show highest phenotypic plasticity upon BRAF inhibition. Hierarchical clustering is 
performed with complete linkage and Euclidean distance metric (ST: 3 days vemurafenib 
treatment, LT: 3 weeks vemurafenib treatment). (B) Heat map of the genome-wide 
expression levels of 9 cell lines randomly selected from each cluster at control, 3 days, and 
3 weeks vemurafenib treatment. Clustering is performed with average linkage by Euclidean 
distance metric. Four clusters are identified to be wholly consistent with the clustering results 
using MART-1 and NGFR markers in panel A. The clusters are labeled in lower case font, 
indicating that these cells represent a subset of those analyzed in panel A.  Up-regulated 
genes are colored in red and down-regulated genes in blue. 
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Fig. S2. Flow cytometry analysis of NGFR and MART-1 expression levels for 18 
BRAFV600 mutant melanoma cell lines treated with DMSO control and vemurafenib 
for 3 days and 21 days. The average NGFR and MART-1 levels across treatment conditions 
are as bar graphs on the right (mean ± SEM). The cell lines are ordered according to their 
respective clusters identified in Fig. S1A. 
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Fig. S3. Enrichment analysis of commonly down-reglated genes across all the cell line 
clusters and uniquely up-regulated genes in cluster C upon BRAFi exposure. (A) GEDI 
visualization of differentially expression genes relative to control for all the cell line clusters 
upon 21 days of vemurafenib treatment. Gene miniclusters circled in blue denote commonly 
down-regulated genes across all the cell line clusters at varying degrees. Gene miniclusters 
circled in red denote genes that are uniquely up-regulated in Cluster C cells. (B and C) Gene 
Ontology enrichment using Enricher for genes circled in blue (or red). The top 10 ontology 
terms with highest enrichment scores are listed from top to buttom with decreasing p values.  
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Fig. S4. Plot of MITF activity signature scores vs neuron differentiation (Molecular 
Signatures Database C5 Collection) signature scores for the 3 plastic cell lines across 
different time points upon vemurafenib treatment. Counterclockwise trajectories appear 
for all three lines (VC: DMSO control). 
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Fig. S5. Cell growth kinetics of M397, M229 and M263 under DMSO control or BRAFi 
treatment overlaid with phenotypic profiles (M397 only). BRAFi exposure moderately 
inhibited the cell growth for a short-term followed by a drug tolerant exponential growth 
phase characteristic of the adaptive resistance to BRAFi (data are shown as mean ± SD). 
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Fig. S6. MITF activity analyzed using a bioluminescence tyrosinase promoter (TP) 
reporter system through different time points of vemurafenib for M229TP, M263TP 
and M397TP. Each condition is normalized for 100,000 cells and viability. Data is 
representative of duplicate wells, and representative of an experiment done in two 
independent experiments. Error bars are standard deviation of the two wells. Luciferase 
representative images are shown underneath. 
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Fig. S7. Transcriptional signatures of three plastic cell lines in Cluster C. (A) Heat map 
of expression levels for critical genes involved in the adaptive BRAFi resistance at baseline 
(DMSO) as well as upon 3 days, 21 days, and 73-90 days of vemurafenib exposure. (B) Gene 
Ontology analysis of differentially expressed genes for the three plastic cell lines following 
21 days and 73-90 days drug treatment with respect to DMSO control. Relevant GO terms 
are listed with respective p-values, analyzed by DAVID. Blue terms denote GO term 
enrichment for down-regulated genes and red terms denote GO term enrichment for up-
regulated genes. 
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Fig. S8. GSEA shows enrichment of curated gene sets associated with the cell state 
regression towards neural-crest like and mesenchymal-like states upon 21 days 
vemurafenib exposure in other cell line clusters (NOM p values: *p<0.05; **p<0.005, 
***p<0.0005).  
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Fig. S9. Transcriptional signatures of the cell state transition associated with the 
adaptive resistance in melanoma patient biopsies (transcriptomes from ref. 16 in the 
main text). (A) Heat map of GSEA normalized enrichment scores (NES) of relevant curated 
gene sets involved in the adaptive transition for 11 paired pre-treatment and on-treatment 
patient biopsies. More than half of patient samples show acquisition of neural crest-like and 
mesenchymal phenotype signatures with up-regulated NFκB and JNK signaling as identified 
in the cell line studies. (B) Correlation of critical regulatory genes with relevant 
transcriptional signatures associated with the adaptive resistance across 39 melanoma patient 
biopsy samples. Genes involved in the ECM reprogramming, focal adhesion, collagen 
formation, stemness, EMT signatures were negatively correlated with MITF and positively 
correlated with NGFR, NFκB, CCL2 and AXL. Gray shadow denotes an insignificant 
enrichment with a p value > 0.05. (C) Gene expression levels of patient samples at baseline 
(pre-treatment), on-treatment and resistant stages for three curated gene sets for invasiveness, 
stem cell and mesenchymal transition signatures. It revealed that the genes involved in 
cellular invasiveness, stem cell signature and EMT were consistently up-regulated at on-
treatment stage and descending at acquired resistant stage, implying the existence of cellular 
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regression towards neural crest-like and mesenchymal-like phenotypes as a non-genomic 
adaptive response in these on-treatment patient biopsies prior to the disappearance of these 
signatures when cells acquired robust therapy resistance potentially genetically. 
 
Fig. S10. The Markov model prediction and the experimental validation of cell state 
kinetics for segregated M229 and M397 cells. (A) Experimental flow for sorting cells to 
obtain NGFR+ and NGFR- subpopulations, and culturing each subpopulation in fresh 
growth media with or without BRAFi treatment. (B) For both M397 and M229 cell lines, 
unsorted cells or sorted NGFR+ or NGFR- subpopulations are cultured with or without drug, 
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and their phenotype composition are monitored using flow cytometry until they reach to 
an equilibrium composition. The final equilibrium composition from unsorted, NGFR+/- 
subpopulations and model prediction are presented as bargraphs. DN – double negative 
mesenchymal-like state (NGFR-/MART-1-), NC – neural crest-like state (NGFR+/MART-
1-), DP – double positive plastic state (NGFR+/MART-1+), melanocytic state (NGFR-
/MART-1+).  
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Fig. S11 Experiments setting and flow cytometry plots of sorted M397 NGFR+ and 
NGFR- subpopulations under treatment naïve and drug treatment conditions. Time-
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series flow cytometry phenotyping of M397 sorted subpopulations cultured without 
BRAFi (A) and with BRAFi (B) treatment. The cell cycle for M397 is 3 days. 
 
Fig. S12. Experiments setting and flow cytometry plots of sorted M229 NGFR+ and 
NGFR- subpopulations under treatment naïve and drug treatment conditions. Time-
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series flow cytometry phenotyping of M229 sorted subpopulations cultured without 
BRAFi (A) and with BRAFi (B) treatment. The cell cycle for M229 is 1 day. 
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Fig. S13. Markov model of stochastic cell state transition predicts phenotypic 
evolution of melanoma cells upon BRAF inhibition. (A) Cell state transition 
probabilities of M229 at untreated and vemurafenib treated conditions. (B) Treatment 
sensitivity of different phenotypes for M229 inferred by the model. (C) Model prediction 
of the phenotypic kinetics (solid lines) versus experimental data (dots connected with dash 
lines) for M229 with continuous exposure to vemurafenib. (D) Model prediction of the 
phenotypic kinetics (solid lines) versus experimental data (dots connected with dash lines) 
for M397 and M229 when only drug selection is considered.  
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Fig. S14. Reversibility of the adaptive transition upon drug removal (A) Phenotypic 
reversibility for the plastic M397 cell line in Cluster C and less plastic M233 cell line in 
Cluster B. While starting at different baseline phenotypic composition, both M397 and M233 
cell lines follow the transition trajectory towards double negative state (NGFR-/MART-1-) 
upon drug exposure and return to their original composition upon drug removal. DR: drug 
removal. (B) The IC50 values for M397 cells at untreated, upon long-term drug exposure (46 
days), and after long-term drug removal (treatment discontinued for 33 days), confirming the 
reverted cells are re-sensitized to BRAF inhibition.  
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Fig. S15. The optical pictures of SCBC and its microchamber units: valves for chamber 
formation (red), valves for lysis buffer control (green), cell chamber compartment (blue), and 
lysis buffer reservoir (yellow) are delineated by food dyes. The sandwich 
immunofluorescence detection scheme with a scanned image is listed below the optical 
images. In the scanned image, the green stripes are used as alignment markers of a 
microchamber; each red stripe represents a functional protein measured and the fluorescence 
signal denotes the protein level from the single cells. 
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Fig. S16. Protein-protein correlation networks of M397 cells at different time points, 
extracted from SCBC data. The correlation (orange) / anti-correlation (blue) strength were 
reflected in the thickness of the edges (see keys). 
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Fig. S17. Immunofluorescence and flow cytometry analyses of NGFR and MART-1 
markers to BRAF inhibition. (A) Fold change of NGFR and MART-1 levels for mono- 
and combination therapies (23 days treatment) with respect to DMSO control on bulk M397 
and M229 populations quantified by sandwich immunofluorescence assay. The predicted 
effective combinations (V+J and V+T+J) keep the MART-1 and NGFR levels unchanged, 
while V or V+T induces significant NGFR up-regulation and loss of MART-1 (error bars: 
±SD). (B) Cell phenotype marker histograms from flow cytometry analysis of MART-1 and 
NGFR levels for mono- and combination therapies on both M397 (23 days drug treatment) 
and M229 (28 days drug treatment). 
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Fig. S18. Synergy effects of combining vemurafenib (V) and trametinib (T) with JSH-
23 (J). Percentage of excess activity over that expected under the Bliss independence 
assumption for each of the various dose combinations. Red indicates synergy; blue indicates 
antagonism. The red boxes outline the concentration ranges used in the long-term clonogenic 
assays in Fig. 4. *p<0.05 under Student's t-test. 
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Fig. S19. Clonogenic assays for long-term combination therapy and short-term 
monotherapies in a cohort of melanoma cell lines. (A) Clonogenic assays of long-term 
drug treated samples were quantified using ImageJ software and normalized to V+T. The 
statistical significance is evaluated by Student's t-test. **p<0.005, ***p<0.0005. Error bars: 
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±SD). (B) The same doses used in long-term combination treatments were used for 
monotherapies here. No significant toxicity to the cells was observed for using JSH-23 alone 
(treatment time: M263, 7 days; M229: 11 days; M308: 10 days; M249: 7 days).   
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Fig. S20. Change in signaling coordination quantified as correlations between key 
functional proteins and the first principal component for control, day-6 (initiation of 
the adaptive transition), and day-23 (establishment of adaptive resistance). The up-
regulation of JNK and p38α signaling axes is identified when the cells develop adaptive 
resistance to BRAFi. 
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Supplementary Tables 
Table S1. Characterization of 18 melanoma cell lines used in this study, where 9 
randomly selected cell lines from each cluster for transcriptomic studies are shadowed 
in red. 
 
Cell line Sensitivity IC50 (nM) Mutational Status   
M370 R >10000 BRAFV600E mutant 
Cluster A M381 R >10000 BRAFV600E mutant 
M410 R 3510 BRAFV600E mutant 
M233 R >10000 
BRAFV600E mutant   
3 copies BRAF   
AKT1 amplification   
CCN31 amplification    
EGFR amplification   
CDKN2A deletion   
PTEN deletion 
Cluster B M238 S 243 
BRAFV600E mutant        
2 copies BRAF   
CDKN2A deletion    
PTEN deletion 
M255 I 1625 
BRAFV600E mutant    
2 copies BRAF   
AKT2 amplification   
CCND1 amplification   
EGFR amplification   
CDKN2A deletion 
M395 S 131 BRAFV600E mutant 
M406 S 645 BRAFV600E mutant 
M409 I 1018 BRAFV600E mutant 
M411 S 171 BRAFV600E mutant 
M229 S 282 
BRAFV600E mutant   
4 copies BRAF  
MITF amplification   
AKT1 amplification   
PTEN deletion 
Cluster C 
M263 I 839 
BRAFV600E mutant    
2 copies BRAF   
CDKN2A deletion 
M397 S 132 BRAFV600E mutant 
M399 I 1155 BRAFV600E mutant 
M403 S 450 BRAFV600E mutant 
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M249 S 273 
BRAFV600E mutant   
3 copies BRAF    
MITF amplification   
AKT2 amplification  PTEN deletion 
Cluster D 
M262 S 150 
BRAFV600E mutant       
2 copies BRAF   
AKT1 mutation&amp   
CDKN2A deletion 
M308 R >10000 
BRAFV600E mutant   
3 copies BRAF   
MITF amplification   
AKT2 amplification   
EGFR amplification    
CDKN2A deletion 
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Table S2. Color coded table comparing normalized median fluorescence intensity 
values for  MART-1 and NGFR upon 3 days and 21 days of vemurafenib exposure with 
respect to DMSO control. The data are extracted from flow cytometry analysis (Fig. S2) 
across 18 cell lines. Fold changes are listed and color coded (red: increase, blue: decrease). 
 MART1 NGFR 
Cell lines Vem 3d Vem 21d Vem 3d Vem 21d 
M370 1.05 1.01 0.90 1.13 
M381 0.89 1.07 1.04 1.56 
M410 0.85 0.84 0.82 0.96 
M233 0.94 0.66 1.05 7.20 
M238 0.47 0.67 33.89 47.89 
M255 0.29 1.13 1.51 2.07 
M395 0.84 0.64 27.70 11.20 
M406 0.87 0.87 2.04 4.85 
M409 0.77 1.16 2.52 4.66 
M411 0.70 0.77 5.98 26.00 
M229 2.10 0.16 0.48 127.17 
M263 2.15 2.25 7.38 6.10 
M397 1.71 0.33 0.82 4.42 
M399 5.04 2.79 4.04 1.54 
M403 1.77 1.25 0.00 1.47 
M249 1.61 1.88 0.05 1.82 
M262 1.01 0.77 0.02 0.89 
M308 0.89 0.60 6.50 27.03 
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Table S3. Complete chicken neural crest gene set list from Gallus Expression in situ 
Hybridization Analysis (GEISHA) (12). 
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Chick_neural_crest	(GEISHA)
AARS HDAC2 PDGFD
ABCF2 HES1 PDGFRA
ACVR2B HES5 PEBP1
ADAM12 HES6 PENK
ADAM33 HEY1 PGK1
ADAMTS1 HEY2 PITX2
ADAMTS3 HK2 PLEKHG1
AGR2 HNRNPM POU3F4
AHCYL1 HOXA3 PTK7
ALK HOXB7 RAC1
ALX1 HS2ST1 RARA
ANGPTL4 HS3ST3A1 RARB
ANK3 HTRA1 RAR-GAMMA2
ANKRD6 ID2 RCC2
ANXA6 IPO9 RELT
AP2A2 IREB2 RERE
ARHGAP15 ISL1 RET
ARHGAP28 KDM4A RHOB
ASCL1 KIF4A RHOU
AUTS2 KLF10 RND3
B-G KTN1 ROBO1
BLNK LAMA5 ROBO2
BMP4 LECT1 RSPO3
BMP7 LFNG RXRA
BMPER LGR4 SALL4
BTBD11 LIMS1 SEMA3D
BTG2 LMNB2 SEMA7A
CADM3 LMO4 SIX1
CDH11 LOC100858038 SIX4
CDH6 LOC420041 SLC7A3
CRABP1 LZTS1 SLIT1
CXCL14 MAFA SMO
CXCR4 MAFB SNAI1
CYP26C1 MAFK SNAI2
DACH1 MAP3K5 SOX10
DACT2 MATN4 SOX2
DAD1 MCAM SOX8
DKC1 MECOM SOX9
DLL1 MEF2C SPRY2
DLL4 MKRN1 SREBF2
DLX3 MMP2 STOX1
DLX5 MOXD1 TBX1
DRGX MSX1 TBX3
DSC2 MSX2 TCF3
DSG2 MXI1 TFAP2A
EBF2 MYC TIAM1
EDNRB MYCN TIAM2
EFNB2 NCOA1 TIMP2
EGR4 NES TPD52L2
ELK3 NET1 TRIO
ENAH NEUROD4 TSHZ2
EPCAM NEUROG1 VSX1
ETS1 NHLH1 WIF1
EYA2 NKX2-5 WNT-1
FGF13 NOG WNT16
FGF3 NOLC1 WNT8A
FGFR2 NR6A1 ZEB2
FGFR3 NRP2 ZIC1
FLT4 OLFM1 ZRANB1
FOXD3 OSBP2
FRZB PALLD
FZD1 PAX3
GATA1 PAX7
GFRA2 PCDH15
GLG1 PCDH18
GTF2E2 PCDH8
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Table S4. GSEA enrichment across innate anti-PD-1 resistance (IPRES) signature 
at 3 days and 21 days of BRAFi exposure using averaged gene expression levels of the 
3 plastic cell lines. NES stands for normalized enrichment score. 
 
  
  
144 
Table S5. Cell state composition measured by flow cytometry across time, while 
being with or without BRAF inhibition. DN – double negative mesenchymal-like state 
(NGFR-/MART-1-), NC – neural crest-like state (NGFR+/MART-1-), DP – double positive 
plastic state (NGFR+/MART-1+), melanocytic state (NGFR-/MART-1+). 
     NGFR+   NGFR-  
    Cycle DN NC Melanocytic DP Cycle DN NC Melanocytic DP 
M397 
tr
ea
tm
en
t 
n
a
ïv
e 
co
n
d
it
io
n
 
0 0.0% 2.4% 0.0% 97.6% 0 0.5% 0.0% 99.5% 0.0% 
1 0.3% 29.4% 0.7% 69.7% 1 3.3% 7.7% 32.1% 57.0% 
3 0.2% 28.1% 0.9% 70.8% 3 2.4% 22.0% 18.1% 57.5% 
6 0.3% 34.8% 2.9% 62.0% 6 3.3% 30.0% 17.7% 49.0% 
10 0.3% 34.0% 2.5% 63.2% 10 1.4% 26.9% 11.7% 60.0% 
15 0.4% 22.3% 3.8% 73.5% 15 2.9% 11.7% 31.7% 53.7% 
d
ru
g
 t
re
a
tm
en
t 
co
n
d
it
io
n
 0 0.0% 2.4% 0.0% 97.6% 0 0.5% 0.0% 99.5% 0.0% 
1 0.2% 9.1% 1.3% 89.6% 1 2.1% 2.9% 55.3% 39.7% 
3 0.1% 15.3% 1.7% 82.9% 3 1.6% 8.2% 33.0% 57.3% 
6 0.2% 30.1% 4.1% 64.0% 6 16.3% 14.9% 18.2% 50.6% 
10 30.1% 44.0% 3.8% 22.1% 10 50.7% 13.9% 19.4% 16.0% 
15 65.2% 27.7% 3.7% 3.4% 15 82.0% 11.9% 4.4% 1.7% 
                        
M229 
tr
ea
tm
en
t 
n
a
ïv
e 
co
n
d
it
io
n
 
0 0% 59% 0% 41% 0 39% 0% 61% 0% 
7 20% 49% 19% 12% 7 34% 10% 55% 2% 
10 19% 46% 24% 12% 10 17% 12% 69% 2% 
15 38% 37% 20% 6% 15 28% 12% 58% 1% 
20 29% 25% 40% 5%           
d
ru
g
 t
re
a
tm
en
t 
co
n
d
it
io
n
 
7 6% 68% 3% 23% 7 10% 27% 35% 28% 
16 2% 82% 1% 16% 16 5% 51% 8% 37% 
38 10% 83% 0% 6% 38 25% 69% 1% 5% 
60 17% 72% 3% 8% 60 32% 56% 2% 11% 
71 38% 61% 0% 1% 71 68% 26% 5% 1% 
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Table S6. Phenotype proportion for M397 and M229 unsorted cells under drug 
treatment condition. 
 
Cell Line Cycle DN NC Melanocytic DP 
M
3
9
7
 
0 0% 7% 17% 76% 
2.3 0% 9% 25% 66% 
7 1% 44% 8% 46% 
14.3 53% 39% 1% 7% 
20.6 64% 32% 0% 4% 
22 76% 20% 0% 4% 
26 74% 21% 5% 1% 
 
     
M
2
2
9
 
0 6% 7% 76% 12% 
11 2% 28% 25% 46% 
21 2% 63% 2% 32% 
30 1% 62% 2% 34% 
38 3% 75% 1% 22% 
60 25% 59% 16% 0% 
71 42% 52% 5% 1% 
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Table S7. The sequences of the oligonucleotides used in the protein immunoassays. 
All oligonucleotides were synthesized by Integrated DNA Technology (IDT) and 
purified via high performance liquid chromatography (HPLC). The DNA coding 
oligomers were pre-tested for orthogonality to ensure that cross-hybridization between non-
complementary oligomer strands was negligible (<1% in photon counts).  
 DNA sequence used for pattering ssDNA microarray 
A 5'-AAAAAAAAAAAAAATCCTGGAGCTAAGTCCGTA-3' 
B 5'-AAAAAAAAAAAAAGCCTCATTGAATCATGCCTA-3' 
C 5'-AAAAAAAAAAAAAGCACTCGTCTACTATCGCTA-3' 
D 5'-AAAAAAAAAAAAAATGGTCGAGATGTCAGAGTA-3' 
E 5'-AAAAAAAAAAAAAATGTGAAGTGGCAGTATCTA-3' 
F 5'-AAAAAAAAAAAAAATCAGGTAAGGTTCACGGTA-3' 
G 5'-AAAAAAAAAAAAAGAGTAGCCTTCCCGAGCATT-3' 
H 5'-AAAAAAAAAAAAAATTGACCAAACTGCGGTGCG-3' 
I 5'-AAAAAAAAAAAAATGCCCTATTGTTGCGTCGGA-3' 
K 5'-AAAAAAAAAAAAATAATCTAATTCTGGTCGCGG-3' 
L 5'-AAAAAAAAAAAAAGTGATTAAGTCTGCTTCGGC-3' 
M 5'-AAAAAAAAAAAAAGTCGAGGATTCTGAACCTGT-3' 
N 5'-AAAAAAAAAAAAAGTCCTCGCTTCGTCTATGAG-3' 
 Complementary ssDNA Sequence for antibody conjugation 
A' 5'NH3-AAAAAAAAAAAAATACGGACTTAGCTCCAGGAT-3' 
B' 5'NH3-AAAAAAAAAAAAATAGGCATGATTCAATGAGGC-3' 
C' 5'NH3-AAAAAAAAAAAAATAGCGATAGTAGACGAGTGC-3' 
D' 5'NH3-AAAAAAAAAAAAATACTCTGACATCTCGACCAT-3' 
E' 5'NH3-AAAAAAAAAAAAATAGATACTGCCACTTCACAT-3' 
F' 5'NH3-AAAAAAAAAAAAATACCGTGAACCTTACCTGAT-3' 
G' 5'NH3-AAAAAAAAAAAAAAATGCTCGGGAAGGCTACTC-3' 
H' 5'NH3-AAAAAAAAAAAAACGCACCGCAGTTTGGTCAAT-3' 
I' 5'NH3-AAAAAAAAAAAAATCCGACGCAACAATAGGGCA-3' 
J' 5'NH3-AAAAAAAAAAAAACCTGCTCGACAACTAGAAGA-3' 
K' 5'NH3-AAAAAAAAAAAAACCGCGACCAGAATTAGATTA-3' 
L' 5'NH3-AAAAAAAAAAAAAGCCGAAGCAGACTTAATCAC-3' 
M' 5'Cy3-AAAAAAAAAAAAAACAGGTTCAGAATCCTCGAC-3' 
N' 5'NH3-AAAAAAAAAAAAACTCATAGACGAAGCGAGGAC-3' 
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Table S8. List of antibodies used for the SCBC multiplex protein assays.  
Antibody Manufacture 
 Human NGFR DuoSet R&D DY367 
 Human sTNF DuoSet R&D DY225 
 Human S100B Mab Mouse IgG2A R&D MAB1820 
 S100B Rabbit mAb Cell Signaling 9550 
 Melan-A Monoclonal  Sigma-Aldrich M6570 
 Human Melan-A/MART-1 Sheep IgG R&D AF8008 
 Human Phospho-JNK2 DuoSet R&D DYC2236 
 Human MITF Goat IgG R&D AF5769 
 MITF abcam ab80651 
 Human/Mouse/Rat Phospho-ERK1 R&D DYC1825 
 Human NFκB1 Mouse IgG R&D MAB2697 
 NFκB1 p105/p50 Cell Signaling 3035 
 Human/Mouse NFκB p65 Mouse IgG2B R&D MAB5078 
 Phospho-NFκB p65 Rabbit mAb Cell Signaling 4025 
 Phospho-IκB alpha (Ser32) ELISA Kit Cell Signaling 7343 
 Phospho-p38 alpha DuoSet R&D DYC869B 
 Slug (SNAI2) mouse IgG 
Sigma-Aldrich 
SAB1412527 
 Slug Rabbit mAb Cell Signaling 9585 
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Dataset S1. Kinetic RNA-seq data of the 9 randomly selected melanoma cell lines. 
(See “Dataset_S01 (XLSX)” from 
https://www.pnas.org/content/suppl/2017/12/06/1712064115.DCSupplemental). 
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C h a p t e r  4  
PHENOTYPIC HETEROGENEITY AND EVOLUTION OF 
MELANOMA CELLS ASSOCIATED WITH TARGETED THERAPY 
RESISTANCE 
Phenotypic plasticity is associated with non-genetic drug tolerance in several cancers. Such 
plasticity can arise from chromatin remodeling, transcriptomic reprogramming, and/or 
protein signaling rewiring, and is characterized as a cell state transition in response to 
molecular or physical perturbations. This, in turn, can confound interpretations of drug 
responses and resistance development. Using BRAF-mutant melanoma cell lines as the 
prototype, we report on a joint theoretical and experimental investigation of the cell-state 
transition dynamics associated with BRAF inhibitor drug tolerance. Thermodynamically 
motivated surprisal analysis of transcriptome data was used to treat the cell population as 
an entropy maximizing system under the influence of time-dependent constraints. This 
permits the extraction of an epigenetic potential landscape for drug-induced phenotypic 
evolution. Single-cell flow cytometry data of the same system were modeled with a 
modified Fokker-Planck-type kinetic model. The two approaches yield a consistent picture 
that accounts for the phenotypic heterogeneity observed over the course of drug tolerance 
development. The results reveal that, in certain plastic cancers, the population 
heterogeneity and evolution of cell phenotypes may be understood by accounting for the 
competing interactions of the epigenetic potential landscape and state-dependent cell 
proliferation. Accounting for such competition permits accurate, experimentally verifiable 
predictions that can potentially guide the design of effective treatment strategies. 
This chapter includes content from our previously published article: 
[1] Su, Yapeng, Marcus Bintz, Yezi Yang, Lidia Robert, Alphonsus HC Ng, Victoria Liu, Antoni Ribas, 
James R. Heath, and Wei Wei. "Phenotypic heterogeneity and evolution of melanoma cells associated 
with targeted therapy resistance." PLoS computational biology 15, no. 6 (2019): e1007034. doi: 
10.1371/journal.pcbi.1007034. 
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Introduction 
The phenotypic plasticity of many tumors can confound the identification of effective 
therapeutic strategies [1-4]. For such tumors, even if the cancer cells are isogenic, the 
cellular composition can be a heterogeneous mix of different cell states (phenotypes) that 
exhibit the capacity for dynamic interconversion. Each phenotype can have a characteristic 
gene expression profile, drug susceptibility, proliferation rate, and metastatic potential [5]. 
When this heterogeneous population is challenged with a physical or molecular 
perturbation, the cell states can rapidly evolve [6] to form a new population distribution 
better suited to survive the challenge. This adaption may proceed without genetic changes 
[7-9]. Removal of the challenge can lead to recovery of the original population distribution 
[5, 10, 11]. This behavior bears similarities to that of ‘phenotypic equilibria’ [1, 12, 13]. In 
those systems, if a subset of this population of microstates is physically separated from a 
stable, heterogeneous population and allowed to expand in culture, the phenotypic 
heterogeneity of the original culture will recover. This facile adaptability makes plastic 
tumors challenging to drug-target, and it highlights the importance of quantitative models 
that can provide predictive and mechanistic insights into the underlying driving force 
controlling such behaviors.  
Similarities between steady states in nonequilibrium biological systems and 
perturbation/relaxation scenarios in classical thermodynamics equilibria have prompted 
investigations into applying physicochemical models for describing phenotype dynamics 
within an epigenetic landscape [13-16]. Qualitative descriptive models have been explored 
for many years, but quantitative and predictive models have only been recently explored 
[14-20]. In one class of studies, epigenetic landscape models are explored, wherein stable 
cell states are described as local minima (attractors) within a metaphoric energy (or 
potential) cell-state landscape. In such models, the driving forces that influence the cellular 
composition and population dynamics are the gradients on that surface. As a result, cells 
tend to gravitate and remain in the local minima of such landscapes. However, in many 
other cases, this potential landscape does not predict the observed phenotypic heterogeneity 
[16], implicating other important factors that can influence the population dynamics are at 
play.  
To address this puzzle, we studied highly plastic patient-derived BRAFV600E mutant 
melanoma cell lines as models of cancer cell phenotypic plasticity. The high rate of both 
response [21] and resistance development [10] of BRAF-mutant melanoma patients to 
BRAF inhibitor (BRAFi) treatment has made such cell lines important models for 
understanding challenges associated with targeted inhibitors [9, 10]. BRAFi can trigger a 
series of nongenetic cell state changes along the melanocytic lineage towards drug-tolerant 
and eventually drug resistant states through epigenetic reprogramming. These include the 
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transition of drug-sensitive melanocytic cancer cells into a drug-tolerant neural crest-
like phenotype, which, under continued BRAF inhibition, can eventually transition into a 
fully drug-resistant, invasive mesenchymal-like phenotype [5, 9-11]. The cell biology of 
this BRAFi-induced phenotypic evolution has been extensively characterized [5, 22], and 
shown to correlate with what is observed in patient biopsies [9-11, 22]. However, a 
quantitative biophysical understanding of this type of epigenetic plasticity has not been 
fully explored.  
To this end, we carried out two sets of experiments, integrated with two theoretic 
approaches, on phenotypically plastic BRAFV600E mutant melanoma cell lines. At the 
macroscopic level, we measured a kinetic series of bulk transcriptomes over a 2.5-month 
course of low dose BRAF inhibition, during which time the cells evolve from a mostly 
melanocytic, drug-sensitive phenotype to a mesenchymal, drug-tolerant phenotype. This 
data set provides input into an information-theoretic surprisal analysis [23], which is used 
to identify the relative free energy-like potential over the entire course of cell state 
transition from drug response to drug tolerance. We also utilized microscopic inputs from 
flow cytometry to profile, at the single-cell level, the phenotypic evolution of the same 
system. These phenotypic evolution dynamic data cannot be described with conventional 
Fokker-Planck equation but can be well recapitulated using a modified Fokker-Planck-type 
(FP-type) kinetic model [17, 18, 24] which considered cell-state dependent proliferation 
differences. The model resolves relative cell state potential and cell-state proliferation 
differences were quantitatively validated through experiment. We further show that both 
approaches provide a self-consistent picture in which the combined effects from the 
relative stability of cellular phenotypes, together with the phenotype-specific net-
proliferative rate, act as the drivers to predictably influence the cell population dynamics 
of drug-induced phenotypic evolution over time. The results provide conceptual guidance 
for considering effective therapy combinations [5].  
Results 
Surprisal analysis of bulk transcriptome data resolves steady state and time-dependent 
constraints in the melanocytic to mesenchymal transition 
 We used two patient-derived BRAFV600E mutant cell lines (M397 and M229) with a 
prominent melanocytic to mesenchymal phenotypic evolution induced upon BRAF 
inhibition (Fig 1A and S1 Fig) [5]. We characterized this process by both a bulk 
transcriptome profiling (S1 Table) and a flow cytometry phenotyping using two protein 
markers (MART-1 and NGFR) that are established cell phenotype markers for this system 
[5, 9, 25]. The transcriptome was measured at Day 0 (D0), which served as an untreated 
control, and at a set of time points following BRAFi (vemurafenib) treatment (S2 Fig.). 
Following drug exposure, the relative location of the binning of cell populations expressing 
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different levels of the two markers followed a counterclockwise transition trajectory 
around the flow cytometry plots (S1(A) Fig), moving from the melanocytic phenotype 
(MART-1pos) towards a transiently enriched slow-cycling neural crest 
(MART1neg/NGFRhigh) population around day15 to day20 (D15–D20), and eventually 
terminating at a mesenchymal (MART1neg/NGFRneg) phenotype at around day62 (D62) with 
elevated expression of the mesenchymal marker N-cadherin (Fig 1A). This drug-resistant 
population stably persisted with extended drug treatment beyond D62 (S1(A) Fig). A similar 
transition trajectory was also observed for M229 (S1(B) Fig). These drug-induced 
phenotypic transitions agree with previous literature [5, 22]. 
 To assess the overall stability and transcriptomic eigenpatterns associated with the cell 
population distributions at various time points across the drug-induced phenotypic evolution, 
we first applied surprisal analysis (Eq. 1) to the transcriptome time series. Surprisal analysis 
extends the principles of maximum entropy and was initially formulated to understand the 
dynamics of nonequilibrium systems [26]. Using the method of Lagrange multipliers, it seeks 
the maximum entropy of molecules and identifies the global steady state with minimal free 
energy, as well as a series of time-dependent constraints that prevent the nonequilibrium 
system from reaching the global steady state [16, 23, 26, 27]. Surprisal analysis has been 
extended to characterize biological processes in living cells, where it assesses the maximum 
entropy of the biomolecules within the cell ensemble through using a simplified 
approximation of quantum state distributions of the molecular species [23]. Consequently, 
for a system with kinetic transcriptome data as input, it can extract the time-independent gene 
expression baseline (the global steady state), as well as a series of gene expression modules 
(constraints) that evolve with time [16, 23, 26, 28]. A full derivation and thermodynamic 
interpretation of Eq. 1 is provided within the supplementary materials of previous reports 
[23, 28]. 
 
state variable of contribution
constraint  at of transcript 
time t
0
measured expression global steady state
level of transcript expression level of
at time t transcript 
ln ( ) ln ( ) ( )
j i
i i j ij
i
i
t t t G   
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deviation terms from 
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of transcript  (contrainsts)
j
j
i
     (1) 
In Eq. 1, is the measured level of transcript i at time t. This is considered to be the 
global steady-state level of transcript i (   0 0 0ln i iX t G  ), modified by the sum of the 
contributions arising from the constrained processes. The global steady state resolved by 
surprisal analysis is the cellular state with maximum entropy. If there were no constraints 
acting upon the cells, then Eq.1 predicts that the cells would be in the global steady state. 
However, there are non-zero constraints (with amplitudes given by the j values), which are 
iX (t)
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biological processes that move the system away from the global steady state. Transcripts 
associated with a constraint are identified through Eq. 1 as lowering the entropy of the 
system, presumably to maintain one or more biological functions. Data mining the set of 
transcripts associated with a given constraint can provide insight into those biological 
functions. Although we do not impose the condition that λ0 is time-independent, we neither 
expect nor find time-dependence (the λ0 variation is <0.7%) (Fig 1B).  
To capture the time evolution of the drug-treated cells, each constrained process is 
represented by a time-dependent amplitude λj(t) and constraint-specific contributions from 
each transcript Gij. In principle, analysis of the transcriptomic data across the time series from 
D0 to D73 could resolve several constraints, but we resolve only three for M397 (S3 and S4 
Figs). This is illustrated in Fig 1C, where we represent the whole transcriptome data as a self-
organized map (SOM) [29]. The map structure is determined using all data sets. Each tile 
represents a minicluster of genes with similar expression kinetics. Gene clusters with related 
expression kinetics are placed close together, while clusters exhibiting very different kinetics 
are placed far apart. The tile color encodes the average expression level of the genes in that 
minicluster at a given time point. For SOMs representing a specific constraint, that average 
gene expression level is also weighted by the participation of the genes in the constraint, as 
determined from Eq. 1. The gene expression profile for the global steady state remains 
unchanged throughout the transition, while the differentially expressed genes (termed 
eigengenes elsewhere [30]) specific to constraints λ1, λ2 and λ3 vary with time. Summing the 
global steady state and the three constraints reproduces the map of the measured 
transcriptome, indicating that, within the noise level of the data, the three major constraints 
are sufficient to accurately recapitulate gene expression levels globally across the transition. 
(Fig 1C and S5 Fig).  
The major biological processes involved in each constraint, at a given time point, can be 
inferred by enrichment on the gene lists ranked by the constraint-specific contributions from 
each gene Gij (Fig 2A, S4 Fig and S2 Table), and by the time-dependent amplitude λj(t) of 
that constraint. The first constraint shows monotonically increased amplitude (λ1) along the 
course of the transition (Fig 1B), with up-regulated mesenchymal signatures, migration, 
invasiveness and metastasis features, as well as NFκB signaling (G1 positive processes). It 
also reflects reduced glucose uptake and metabolism, MITF activity, and oxidative 
phosphorylation (G1 negative processes) (Fig 2A). Constraint 2 contains similar 
transcriptional signatures, but its amplitude (λ2) drops after 3 days of BRAFi exposure and 
slowly increases at later times (Fig 1B). It points to an elevated MITF activity (G2 negative 
process) and reduced cellular proliferation (G2 positive process) at day-3. This is consistent 
with previous observations that a brief BRAFi exposure can induce melanocytic 
differentiation and increased BRAFi sensitivity [31, 32]. The third constraint mainly involves 
oxidative phosphorylation and the TCA cycle, and has a near zero amplitude except for day 
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3 (Fig 1B), implying that initial BRAFi exposure leads to a sharply altered metabolic 
program. The three major constraints associated with M229 displayed similar dynamics and 
are functionally similar to those in M397 (S4 Fig), confirming the robustness of the BRAFi 
induced melanocytic to mesenchymal transition. To get a comprehensive view of the 
enriched transcriptional program, we plotted the enrichment maps of the GSEA results with 
respect to relevant gene function categories and highlighted representative gene sets in these 
categories (Fig 2B and S6 Fig). Overall, these transcriptional signatures are wholly consistent 
with previous reports [5, 9-11, 33], testifying the validity of our cell line model for 
recapitulating the known biology of the transition and confirming the power of surprisal 
analysis for dissecting the underlying biology of the transition.  
Fokker-Planck modeling of phenotypic evolution with single-cell flow cytometry 
phenotyping failed in recapitulating the evolution dynamics 
The same biological system was further characterized at the single-cell level using flow 
cytometry analysis of the established cell-state markers: NGFR and MART-1. The temporal 
transcriptomic signatures resolved by surprisal analysis result from the dynamics of the 
BRAFi-induced phenotypic evolution that can be characterized by MART-1 and NGFR 
marker proteins [5, 9, 25]. As shown in our previous report, these two marker proteins can 
yield the identical phenotypic classification to that of the whole transcriptome data [5]. 
Therefore, they can be used as robust phenotype markers during the course of the drug-
induced transition (Fig 1A and S1 Fig).  
To model the single cell data, we conceptualize cell population distributions as single 
cells moving on a configuration space delineated by the marker proteins. In this space, cell 
states correspond to stable or metastable attractors of a hypothetical potential landscape [34]. 
The dynamics of the protein markers for a single cell can be described by the Langevin type 
equation /d dt  z μ(z) , where z is the concentration vector of the protein markers 
(z1,...,zN), µ(z) is a drift vector in concentration space that describes all of the deterministic 
(non-random) dynamics and can be determined by the gradient of the potential landscape. 
The term ζ is the white noise term from random fluctuations in protein expression:
' '( ) ( ) 2 ( )t t t t   D  where D is the diffusivity tensor measuring the amplitude of those 
fluctuations [18].  
The potential landscape of a cellular system is context-specific. We hypothesized that 
drug treatment altered the original drug naïve landscape into a new landscape, which in turn 
yielded relaxation dynamics as each cell adjusts to this new drift field, potentially with 
motions towards new attractor states.  
Analyzing the dynamics arising from a multi-dimensional drift field is, in general, an 
intractable problem. However, the flow cytometry trajectory (Fig 1A and S1 Fig) upon 
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BRAF inhibition suggested the simplification that cell populations may be considered to 
evolve along a linear chain of a limited number of cell states. Therefore, for computational 
convenience, we projected the protein concentration vectors of the two dimensional (2D) 
flow cytometry data into a one-dimensional (1D) representation where the cell populations 
were constrained to move along in this characteristic 1D trajectory (Fig 3A). The distance 
along the trajectory x=x(z) serves as an effective reaction coordinate of the phenotypic 
evolution (see Methods). 
The flow cytometry data do not track an individual cell stochastic trajectory, but rather 
give statistical snapshots of marker protein expression levels across single cells. Thus, it is 
natural to transform the single-cell Langevin equation into the Fokker-Planck equation for 
resolving the time-dependent probability distribution p(x,t) along the reaction coordinate [35]: 
   
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       (2) 
Here, drift term µ(x) implies that motion along x is influenced by a potential landscape. 
D is a diffusivity that is assumed, for simplicity, to be a constant independent of x or drug 
treatment. Even in cases where the diffusivity depends on the reaction coordinate x, a Fokker-
Planck (FP) equation with constant diffusivity can be obtained by a simple coordinate 
transformation as shown in Ref. [17].  
Because the dynamics under consideration are 1D, the drift µ(x) can always be presented 
as the derivative of a scalar potential
0
( ) ( )
x
U x y dy  . This, in turn, is exactly related to the 
steady state solution of Eq. 2 through a Gibbs relation as 
 lim ( , ) ( ) exp 2 ( ) /
t
p x t p x C U x D

   where C is a normalization constant. Therefore, 
one can determine (up to proportionality to D) the potential U from measurement of the 
steady state distribution p∞(x) as ( ) ln ( )
2
D
U x p x
 
  
 
. This FP approach has been 
successfully applied to understanding the population heterogeneity of model biological 
systems [17, 18]. Here, we used a variation of this method to measure the diffusivity 
20.35 / dayD q (q the unit length of the reaction coordinate) from sorting-relaxation 
experiments in the drug-naïve condition (S7 Fig, See Materials and methods for details). 
Given this D and flow cytometry measurements of the final steady state distribution ( )p x
upon prolonged drug exposure, we inferred the potential U(x), and equivalently the drift µ(x) 
consistent with this model. 
To test the validity of the FP model, we performed direct numerical simulation of the 
FP equation with the inferred µ(x), the diffusivity D, and the measured initial distribution 
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p(x,0) to calculate the cell population distribution p(x,t) for subsequent days, which, as 
shown in Fig 3B (FP model), are in poor agreement with the experiments (green lines in Fig 
3B and S8 Fig). The disagreement indicated the existence of extra factors influencing 
phenotypic transitions which were not considered in Eq. 2. 
Modified Fokker-Planck-type kinetic model that incorporates cell-state-dependent 
proliferation recapitulates the phenotypic evolution and predicts cell-state proliferation 
rates. 
We hypothesized that the disagreement with experiments arose because the drug would 
influence not only the cell phenotypic evolution but also the cell autonomous proliferation 
and survival. In other words, the cells have drug susceptibilities – as reflected by the net 
effect of cell proliferation and cell killing – that vary along the reaction coordinate. These 
factors can also influence the phenotypic compositions, but are neglected in Eq.2. Thus, we 
modified Eq.2 to include a self-sourcing term: 
   
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 (3) 
Here the net growth rate α(x) (the net effect of cell proliferation and cell killing under 
drug treatment) was introduced to account for cell state-dependent drug susceptibility. As an 
additional ansatz, we considered α(x) as a double step function taking different values for the 
intermediate neural crest-like phenotype and late-stage mesenchymal phenotype relative to 
the early stage melanocytic phenotype. It is worthwhile to note that, with Eq. 3, we were no 
longer working with a probability distribution p(x,t), but instead a non-normalized population 
P(x,t). Both the differential drift and self-sourcing term act together to induce the cell number 
changes that are proportional to the population size of a specific cell state. For direct 
comparison between the model P(x,t) and experimentally accessible p(x,t) from flow 
cytometry data, we simply factored out the norm (
( , ) ( , ) ( ) ( , ) / ( , )p x t P x t N t P x t dxP x t


   ). 
In this model, due to the addition of the self-sourcing term, the Gibbs relation between 
the drug-induced steady state p∞(x) and the potential U(x) used in our analysis of the original 
FP equation no longer holds. To determine the parameters for this modified model, we 
therefore resorted to an unbiased numerical search for U(x) and α(x) that best fit the 
experimental data. The model prediction was obtained by numerically simulating Eq. 3 with 
the same experimentally measured diffusivity D and the initial distribution p(x,0) as before, 
together with all possible U(x) and α(x) values in the unbiased search. We determine 
goodness of fit using an un-weighted sum-of-square difference between all the predicted and 
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measured cell population distributions p(x,t). In both cell lines, we were able to find one 
set of U(x) and α(x) for the modified FP-type kinetic model that produced the best prediction 
of population distributions over time. When compared to original FP model, the modified 
model predictions are in much better agreement to experiments (red lines in Fig 3B and S8 
Fig). The agreement appears to confirm the validity of the self-sourcing term in Eq. 3, but 
the value of that term can be put to an independent experimental test. 
We treated the state-dependent net growth rate α(x) as a concrete prediction of the 
model, and found it to be in good agreement with experimentally measured cell growth rates: 
cell populations containing a higher fraction of the mesenchymal phenotype (day21-78) grow 
faster than those with a lower fraction (day0-21) (Fig 4, See Materials and Methods). The 
agreements between model-predicted growth rates and experiments (Fig 4) further confirmed 
the validity of Eq. 3 and show that differences in state-dependent growth rates are important 
in determining the drug-induced phenotypic evolution of the melanoma cells. 
In addition to predicting proliferation rates, Eq. 3 also yielded relative values of the 
epigenetic potential along the reaction coordinate U(x) (Fig 5A and S9(B) and S10(A) Figs), 
which yields an inference of the stability of different states along the coordinate. The scalar 
potential landscape was obtained by integration of μ(x) from Eq. 3 over the reaction 
coordinate x. The shape of the landscape indicates that the intermediate neural crest-like 
states (NGFRpos/MART-1neg) are more stable than both the MART-1pos melanocytic state 
and the mesenchymal-like state (NGFRneg/MART-1neg), and thus the intermediate states can 
be considered as an attractor. However, the net growth rate of those intermediate states is 
relatively low (Figs. 4 and 5A), and so the cells do not naturally populate just that state over 
the course of long-term drug treatment.  
Further confirmation of the concordance of the epigenetic potential landscapes 
calculated from macroscopic and microscopic inputs 
As demonstrated in previous work, surprisal analysis of the bulk RNA-seq data can also 
define a free energy-like potential corresponding to the drug-induced phenotypic evolution 
[16, 28]. This potential, for the entire transcriptome of a cell state at time t, is relative to the 
global steady state, and is given by ( ) ( )j j
j
F t t G , where j i ij
i
G X G (See 
Materials and Methods for details). It has a direct relationship to the entropy of the transcripts 
and thus evaluates, at a transcriptional level, the relative stability of a cell state (see Ref. [23] 
for theoretic details). Here we adopted the same definition to calculate the potential landscape 
over drug-induced phenotypic evolution in melanoma cells. For M397, this potential 
landscape calculated from surprisal analysis, similar to the landscape calculated by the 
modified Fokker-Planck-type (Eq. 3) model, indicates that the cells at D11 and D21, with 
mostly neural-crest like phenotypes are more stable than cells at earlier times (melanocytic 
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phenotypes) or D73 (predominantly mesenchymal phenotype) (Fig 5B). For M229, cells 
at D21 with mostly the neural-crest like phenotype are also more stable than the cells at D90 
(predominantly mesenchymal phenotype) (S10 Fig). Thus, the epigenetic potentials 
calculated from either surprisal analysis of bulk data or the Fokker-Planck kinetic model 
from single-cell data yield a consistent picture. 
Both analyses indicate that neural-crest like cells are more stable than the mesenchymal 
phenotype. This prediction was experimentally validated by sorting the mesenchymal 
(NGFRneg/MART1neg) subpopulation from the M397 D73 distribution (S11 Fig). We carried 
out surprisal analysis of transcriptome data from both the segregated mesenchymal 
subpopulation and the unsorted day-73 population (a mixture of mesenchymal phenotype 
and neural-crest phenotype). Free energy-like potentials were calculated and found to be 
consistent with the scalar potentials of both sorted and unsorted populations determined by 
the modified FP-type kinetic model. The pure mesenchymal phenotype displayed higher 
potentials than the unsorted cells (Fig. 5C). Hence, cell sorting and RNA-seq experiments 
confirmed the consistence between the two theoretic models, and indicated that the drug-
resistant mesenchymal cells are epigenetically unstable relative to the neural crest phenotype. 
Discussion 
Heterogeneous cancer cell populations can often exhibit a phenotypic equilibrium and 
evolution behaviors, meaning that a specific composition comprised of relative abundances 
of distinct cancer cell phenotypes can be a characteristic of the system, and in the meantime, 
this characteristic composition will evolve or recover following the application or release of 
molecular or physical perturbations designed to alter it [2, 5, 12-14]. This can, of course, 
confound the interpretation of responses to drug treatment, but it also provides a compelling 
biophysical puzzle. Here we investigated two statistical physics models to help build a 
predictive picture of such phenotypic equilibria. The models respectively utilize macroscopic 
and microscopic inputs, and we applied them towards understanding the population 
dynamics of phenotypically plastic patient-derived BRAF-mutant melanoma cancer cells 
following BRAFi treatment. During a few months period of drug treatment, the cells evolve 
from drug naïve, drug-sensitive melanocytic-dominated composition to a fully drug-resistant 
mesenchymal-dominated cell population. In an interesting parallel with state transitions in 
physical systems, the associated cell state transitions are fully reversible: upon drug removal, 
the mesenchymal cells revert back to a melanocytic state that is, for all intents and purposes, 
identical to the initial drug naïve state [5]. 
The first theoretical model, surprisal analysis, utilizes a bulk transcriptome kinetic series 
across the drug treatment course to provide a description of the global steady state (the state 
of maximum entropy) and to identify specific, time-dependent constraints that keep the 
system from reaching that steady state. The weights of the constrained processes can be 
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utilized to generate a free energy-like potential of the cell-state space sampled during 
drug treatment [16, 28]. It is worth noting that cells are open systems far from equilibrium. 
While a significant body of work has demonstrated the apparent parallel between equilibrium 
and nonequilibrium thermodynamics [36-38], the potential landscape across the cell state 
evolution in our study is still a metaphor of the real free energy landscape in an equilibrium 
system. However, the maximum entropy methods can infer the most probable distribution of 
a probabilistic system regardless of whether or not it is in equilibrium [39]. Surprisal analysis 
further extends the principles of maximum entropy to understand particularly small systems 
that are not in thermodynamic equilibrium [23, 26, 40]. Therefore, in analogy to entropy in 
equilibrium thermodynamics, the entropy (and free energy-like potential) of the cellular 
transcriptome calculated from surprisal analysis can be used to evaluate the overall stability 
of a cell state [28, 41]. 
The second theoretic approach consists of a modified Fokker-Planck-type kinetic model, 
which takes a kinetic series of single cell flow cytometry data as input. This model considers 
the Langevin dynamics of self-sourcing single cells moving within a configuration space. 
That motion is influenced by both (random) diffusion and drift along a potential gradient, 
thus permitting a potential surface of the traversed cell-state space to also be extracted.  
There are two primary considerations that allow results from these two theories to be 
directly compared. First, the flow cytometry data and the bulk transcriptome data sets capture 
the same essential biology. This is obviously not always true. However, for this particular 
case, the cell phenotype markers NGFR and MART-1 used in the single cell assays are 
known surrogates for drug-induced changes across the whole transcriptome [5]. It also 
implies that a more selective subset of the transcriptome might equally well recapitulate the 
underlying biology, which may be assessed by the contribution scores (Gij values) within 
each respective constraint. Second, the phenotypic evolution the melanoma cells proceeds 
stepwise from melanocytes  neural crest  mesenchymal phenotypes. This permits the 
cell response to BRAF inhibition to be considered as time-dependent motion along a linear 
reaction coordinate, and provides an equivalence between the Fokker-Planck reaction 
coordinate and the surprisal analysis time coordinate (Fig 5A and 5B).  
We do not directly compare the y-axes of the two landscapes (Fig 5A and 5B), but only 
the slopes of the curves. The FP scalar potential and the surprisal analysis free-energy like 
potential have very different origins. The free energy-like potential is derived by comparing 
transcriptional profiles at each time point with that of the time-independent global steady 
state. The FP potential is derived from the drift term of Eq. 3, and is, in fact, the only term in 
that equation that needs to be fitted, since both cell proliferation rate and diffusion along the 
FP reaction coordinate can be experimentally determined. However, both theories predict 
that the most stable cellular population is a largely neural crest phenotype. Surprisingly, that 
is not the cell population that is ultimately induced by the long-term drug exposure. That 
population is dominated by a mesenchymal phenotype with a minor neural crest component, 
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and is arrived at through competing interactions. On the one hand, the neural crest 
phenotype serves as an attractor, but those cells only slowly proliferate. The higher potential 
mesenchymal cells are more proliferative and that is the dominating factor. This highlights a 
major difference between open biological systems and equilibrium thermodynamic systems 
[42]. 
The analyses presented here for the BRAF-mutant melanoma cells might suggest that 
identifying drug susceptibilities in each of the cancer cell phenotypes might lead to a more 
effective therapy. However, such highly plastic cancer cells might eventually switch into cell 
states that are resistant to even broad combination therapies. A more fruitful approach might 
be to target those biological mechanisms that underlie the plastic nature of the cells [5, 43].  
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Materials and Methods 
Patient-derived melanoma tumor models and drug treatment conditions. 
Cells were cultured at 37 °C with 5% CO2 in RPMI 1640 with L-glutamine (Mediatech, 
Inc, Manassas, VA), 10% fetal bovine serum (Omega Scientific Tarzana, CA), and 1% 
penicillin, streptomycin and fungizone (Omega Scientific Tarzana, CA). Cells were 
maintained and tested for mycoplasma as previously described [44, 45]. Cell lines were 
periodically authenticated to their early passages using GenePrint 10 System (Promega, 
Madison, WI). Presence of mutations in the genes of interest was checked by OncoMap 3 
or Iontrone, and was confirmed by PCR and Sanger sequencing as previously described 
[44, 45].  
Vemurafenib (NC0621949, Selleck Chemicals LLC) was dissolved in DMSO at 
designated concentrations before applying to cell culture media. All cell lines were plated 
in 10cm dish at 60% confluency and treated with vemurafenib for the specified numbers 
of days at twice the 50% inhibition concentration (IC50) of each cell line as reported before 
[5]. At different time points after drug treatment, cells were harvest for RNA-seq and flow 
cytometry. Cell number was also counted for determining the growth rate. Cell growth rate 
was fitted as the parameter 𝛼 in the exponential growth curve equation 𝑁 (𝑡) = 𝑁0 ∙ 2
(𝛼∙𝑡),
where 𝑁0 is the cell number at the starting time point, and 𝑁 (𝑡) is the cell number at time 
t. Cell numbers counted at day 0, 7, and 21 were used to fit for the proliferation rate at day
0-21 time period, and cell numbers at day 30, 43, 66, and 78 were used to fit for the one at 
day 21-78 time period. 
Flow cytometry analysis of cell phenotype. 
At different time points, cells were trypsinized from the dish, spun down and washed 
with PBS. Cell suspensions were stained for flow cytometry with PE-conjugated NGFR 
antibody from Biolegend (San Diego, CA). All cells were fixed with Fix-Perm buffer from 
BD Bioscience (San Jose, CA). Cells were then stained for intracellular Melan-A using 
FITC conjugated antibody from Santa Cruz (Dallas, TX). Isotypes for mouse IgG1k and 
mouse IgG1 respectively were used to enable correct gating and to confirm antibody 
specificity. Blue live-dead staining from Life technologies (Waltham, MA) was used to 
gate live cell events. 10000 alive events were collected for each sample. Flow cytometry 
analysis was conducted using LSR-II from BD Biosciences (San Jose, CA), and the data 
were analyzed using FlowJo software (Tree Star, Inc., San Carlos, California, USA).  
Immunofluorescence imaging 
The standard immunofluorescent protocol was implemented using cells grown on the 
gelatin-coated glass surface. Briefly, 10,000 cells/well were seeded in 96-well glass bottom 
plates (Greiner Sensoplate Plus, Cat# 655892) coated with 0.1% gelatin solution, and 
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grown in culture media to ~70% confluency. Cells were washed twice in PBS and fixed 
in 4% paraformaldehyde (PFA) solution for 10 min. After washing twice in wash buffer 
(0.1% BSA in PBS), cells were blocked and permeabilized in blocking buffer (10% normal 
donkey serum, 0.3% Triton X-100) for 45 minutes. After removing the blocking buffer, 
cells were incubated in primary antibody for 4 hours at room temperature. Mouse 
monoclonal anti-NGFR antibody (BioLegend Cat# 345106 RRID:AB_2152647) or sheep 
polyclonal anti-N-Cadherin (R&D Systems Cat# AF6426 RRID:AB_10718850) was 
diluted to 0.25 or 10 μg/mL, respectively, in antibody diluent (1% BSA, 1% normal donkey 
serum, 0.3 % Triton X-100). After washing twice in wash buffer (0.1% BSA in PBS), cells 
were incubated in secondary antibody for 1 hour at room temperature. Donkey anti-Mouse 
IgG, Alexa Fluor 647 (Thermo Fisher Scientific Cat# A-31571 RRID:AB_162542) or 
donkey anti-Sheep IgG Alexa Fluor 594 (Thermo Fisher Scientific Cat# A-11016 
RRID:AB_2534083) was diluted to 4 μg/mL in antibody diluent. After washing twice in 
wash buffer, cells were counter stained for 5 min with 4',6-Diamidino-2-Phenylindole 
(DAPI) diluted to 1 μg/mL in PBS. After washing twice in PBS, the wells were filled with 
78% glycerol. 
Fluorescent images were acquired with a Nikon C2plus confocal microscope (Ti) 
using Plan Apo λ 20× objective (Nikon Inc., Melville, NY). The microscope was controlled 
by NIS elements AR software (4.51.00) with the following settings: 30 μm pin hole, 12-bit 
acquisition, 0.62 μm pixel size, 60 gain, and laser power of 5% (405 nm), 0.3% (561 nm), 
or 0.6% (640 nm). Images were background and contrast adjusted using their respective 
control wells with no primary antibody staining. 
RNA-seq and transcriptomic data analysis 
Cells treated under specified conditions and time periods were trypsinized to harvest 
for cell pellets. RNA extraction was performed at cell pellets using AllPrep DNA/RNA 
Mini kit from Qiagen. Bioanalyzer confirmed correct integrity, the library was constructed 
and Illumina 50 bps single-end RNA-seq data was collected for the samples described. 
RNA sequencing was performed using 50 bps single end sequencing on the Illumina HiSeq 
2500 platform. Libraries were prepared using the IlluminaTruSeq RNA sample preparation 
kit per the manufacturer’s instructions. Reads were mapped and aligned to the Homo 
sapiens NCBI build 37.2 reference genome using TopHat2 v2.0.9 [46]. Expression 
values in fragments per kilobase of exon per million fragments mapped (FPKM) 
were generated using Cufflinks v2.2.1 program and Cuffnorm to quantify and normalize 
aligned reads using the geometric library size normalization method [47].  
Heatmap and clustering analysis of transcriptomic datasets was performed via 
MATLAB. Genes are pre-filtered by RPKM value with criteria of average value greater 
than 0.5 and coefficient of variance greater than 0.15. Filtered gene expression values were 
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standardized across each row (normalized for each individual gene) and represented by 
a redblue colormap. Hierarchical clustering was performed with average linkage and 
Euclidean distance metric. Whole transcriptomic dataset and fractions of contributions 
from each constraints are visualized using self-organized mosaic maps with respect to its 
control via Gene Expression Dynamics Inspector (GEDI) [29]. Gene Set Enrichment 
Analysis (GSEA) [48] was performed using GSEA v2.2.3 software with 1000 permutations 
and weighted enrichment statistics. GSEA enriched gene sets were visualized as interaction 
networks with Cytoscape [49] and Enrichment Map [50]. 
Surprisal analysis and free energy-like potential 
Surprisal analysis was applied as described previously [23, 28]. The measured 
expression level of mRNA i at time t, 𝑙𝑛 𝑋𝑖(𝑡), was expressed as a sum of a steady state 
term 𝑙𝑛 𝑋𝑖
0(𝑡)  and several constraints 𝜆𝑗(𝑡)𝐺𝑖𝑗  representing deviations from the steady
state. Each deviation term was a product of a time-dependent weight of the constraint 𝜆𝑗(𝑡), 
and the time-independent contribution of the transcript to that constraint 𝐺𝑖𝑗 . 
To implement surprisal analysis, we computed the singular value decomposition 
(SVD) of the matrix 𝑙𝑛 𝑋𝑖(𝑡). As well described previously [23], the SVD factored this 
matrix in a way that determined the two sets of parameters that are needed in surprisal 
analysis: the Lagrange multipliers (𝜆𝑗) for all constraints at a given time point, and for all 
times and the 𝐺𝑖𝑗  (time-independent) transcription patterns for all transcripts i at each 
constraint j. 
The free energy-like potential calculation based on the surprisal analysis result was 
implemented as in Ref. 33. Briefly, The steady-state expression level of transcript i at time 
t can be linked to its actual expression level by as
0 ( ) ( )exp( ( ) )i i j ij
j
X t X t t G  . Therefore,
as shown in Ref. 33, surprisal analysis defines the free energy-like potential of a transcript 
i relative to the global steady state at time t as ( ) ( )i j ij
j
f t t G . Taking all the transcripts
into account, the free energy-like potential of the entire transcriptome of a cell state at time 
t relative to the global steady state is given by ( ) ( ) ( )i i j j
i
F t X f t t G   , where 
j i ij
i
G X G [16].
Natural log transformed transcriptomic dataset and fractions of contributions from 
each constraints (𝜆𝑗(𝑡)𝐺𝑖𝑗) calculated from surprisal analysis are visualized using self-
organized maps (SOM). Self-organized map visualization of high-dimensional dataset in a 
form appropriate for human pattern recognition without discarding the global, higher-order 
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information. Here, they present individual samples as a single 2-dimensional heatmap 
and, at the same time, display high-resolution patterns. Thousands of input genes are 
assigned to 625 rectangular “tiles” (SOM nodes), each of which represents a mini-cluster 
of genes, arranged so as to form a pattern within a 2-dimensional mosaic map on the SOM 
grid. Tiles represent most similar clusters will be placed adjacent to each other in the 
mosaic. Gene Expression Dynamics Inspector (GEDI) package is utilized to implement the 
SOM visualization [29]. 
Modified Fokker-Planck-type kinetic model  
The dynamics of the protein markers for a single cell can be described by the Langevin 
type equation /d dt  z μ(z) , where z is the concentration vector of the protein markers 
(z1,...,zN), µ(z) is a drift vector in concentration space that describes all of the deterministic 
(non-random) dynamics and can be determined by the gradient of the potential landscape. 
The term ζ is the white noise term from random fluctuations in protein expression:
' '( ) ( ) 2 ( )t t t t   D , where D is the diffusivity tensor measuring the amplitude of 
those fluctuations [18].  
In the case of melanocytic to mesenchymal transition, for computational convenience, 
we projected the protein concentration vectors of the flow cytometry data into a one-
dimensional (1D) representation where the cell populations were constrained to move 
along in this characteristic trajectory. This converted each snap-shot of cell population 
distribution from the 2D flow cytometry plot onto a one-dimensional distribution along the 
linear trajectory. More specifically, we reduced the dimensionality of the flow cytometry 
data by calculating the principle curve of the full set of measurements using the R package 
princurve. The data points were projected onto the curve, and the distances of these 
projected points along the curve were used as the one-dimensional data for the two Fokker-
Planck models. These data points were converted into probability density functions (PDF) 
using kernel density estimation. 
Consider the fact that flow cytometry data do not track an individual cell stochastic 
trajectory but rather give statistical snapshots of marker expression levels across many 
single cells. Thus, it is natural to transform the single-cell Langevin equation into the 
Fokker-Planck equation for resolving the probability distribution of the protein markers. 
The 1D coordinate (Fig 3A) is defined as a reaction coordinate x(z) such that the Fokker-
Planck (FP) equation for the probability distribution p(x,t) has the following form: 
   
2
2
( , )
( ) ( , ) ( , )
p x t
x p x t Dp x t
t x x

  
  
  
       (M1) 
Here, x is the 1D flow cytometry (FC) coordinate, D is a diffusion constant of the cells 
along x, and drift term µ(x) implies that motion along x is influenced by a potential 
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landscape. In this model, the equilibrium distribution p∞(x)= lim
𝑡→ ∞
𝑝(𝑥, 𝑡)  and the 
potential 𝑈(𝑥) = − ∫ 𝜇(𝑥) ⅆ𝑥 are connected through the Gibbs relation 
( ) ln ( )
2
D
U x p x
 
  
 
 (M2) 
For the unmodified Fokker-Planck equation, this Gibbs relation was applied to the 
long-term drug treated cell population distribution data (day78 for M397 and day60 for 
M229) to infer a potential, whose gradient acted as the drift term driving the dynamic 
changes of the population distribution. This inferred potential and respective drift term, 
when coupled with diffusion constant D and the initial (day0) population distribution, 
generated the prediction results in Fig 3B. 
With regards to calculating diffusion constant D from cell sorting and relaxation 
experiments, the diffusion coefficient D was assumed to be a constant value independent 
of trajectory position x and drug treatment condition for simplicity. Based on this 
assumption, when calculating the diffusion constant, we used time-series flow cytometry 
data of cell sorting and relaxation experiments. In these experiments, we sorted out the 
untreated cells into NGFRpos and NGFRneg subpopulations. Both sorted subpopulations 
were cultured without drug treatment. At different days after sorting and culturing, the cells 
were harvested to quantify its abundance of NGFR and MART-1 using flow cytometry as 
shown S6 Fig.  
Consider the fact that variations of proliferation rates are small in the untreated cells, 
the Fokker-Planck model (Eq. M1) was considered valid and this data was used as input to 
fit the diffusion constant D. Varying D as a free parameter, the (drug-naïve) potential and 
hence drift were calculated with Eq. M2, using the original, untreated distribution as p∞(x). 
The Fokker-Planck equation with these parameters was simulated, with the initial condition 
p(x,0) set by the sorted population distribution. The simulated data were compared to the 
measured time-series distributions with an unweighted sum-of-squares measure. This 
measure was then minimized as a function of D, and yielded the best-fit diffusion constant 
D to be 0.35 q2/day where q represents the unit length on the flow cytometry coordinate. 
For the modified Fokker-Planck-type kinetic model described in equation (3) where 
the same reaction coordinate (x) as the unmodified equation is applied, the state-dependent 
proliferation rate α(x) was modeled as piecewise-constant with different values for the 
melanocytic, neural crest, and mesenchymal cell types. The cutoff locations in terms of the 
reaction coordinate x were chosen as the two local minima in an observed PDF with the 
coexistence of all three subpopulations. One can show that the time evolution of the PDF 
does not depend on an overall constant shift α(x)+c, so we set the proliferation rate of the 
starting melanocytic state to 0 for convenience, as the melanocytic cells were observed to 
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be cytostatic without significant proliferation or cell death upon drug treatment. This 
then left the proliferation rates of the neural crest (α1) and mesenchymal cells (α2) as two 
free parameters. 
Because the Gibbs relationship between the long-time density p∞(x) and the potential 
U(x) no longer held with this nontrivial proliferation rate, we resorted to fitting a cubic 
spline interpolation for the drift ( ) ( )x U x x    . Twenty spline points were used, with 
x values uniformly spaced along the curve and 𝜇 values as free parameters.  
Starting with an estimate of α1(x)= α2(x)=0 and μ ~ x, we calculated the prediction of 
this model using FiPy to numerically simulate the forward evolution with initial condition 
p(x,0) set by the experimentally measured distribution on day-0. To compare with the 
experimental data, we used the L2 norm on the difference between the predicted and 
experimental probability densities  
2
( , ) ( , )pred i exp i
i
L p x t p x t dx


  as the goodness-
of-fit metric. Gradient descent was performed on the proliferation and drift parameters to 
determine the best-fit values that minimize L. The calculated potential landscape results 
are robust to small variations in parameters for calculating the principal curve. (S12. Fig) 
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Figures 
 
Fig 1. Information theoretic analysis of time-series transcriptome data of a patient-
derived BRAF-mutant melanoma cells (M397) treated with a BRAFi. The cells 
responded to BRAFi by transitioning from a melanocytic to mesenchymal phenotype over 
the 2.5 month time course. (A) Top: Illustration of the BRAFi-induced phenotype 
transitions in M397. Middle: Flow cytometry profile of marker proteins MART-1 and 
NGFR along the course of the transition. Bottom: DAPI, NGFR and N-Cadherin staining 
of untreated, neural-crest like, and drug-tolerant mesenchymal cells. Scale bar: 100 μm. (B) 
The amplitude of the steady state and the top three constraints as determined by surprisal 
analysis of the kinetic series of transcriptome data. (C) The contributions of the steady state 
and 3 constraints to gene expression are visualized using a self-organizing map to divide 
the measured transcript levels into 625 (25×25) “miniclusters”. Each minicluster of genes 
is mapped onto the same pixel in each map. The predicted cell state profile appears as the 
sum of the steady state and the top three constraints. 
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Fig 2. Gene set enrichment of the three constrained processes for the phenotypic and 
functional changes over the drug-induced phenotypic evolution. (A) List of relevant 
enriched gene sets, and their relative association with each of the top three constraints. All 
these gene sets exhibit a nominal p value < 0.05.  (B) Cytoscape map that annotates the 
enriched gene sets associated with the G1 constraint with respect to their functional 
categories. Enriched gene sets are represented by nodes, which are grouped and annotated 
based on gene similarity within each gene set. The size of each node is proportional to the 
total number of genes within each gene set. The edge thickness is proportional to the number 
of shared genes between gene sets. Red (blue) gene sets are positively (negatively) correlated 
with G1. Gene sets with similar functions are boxed together with the group name overlaid. 
Ten specific gene sets are highlighted with thicker outline, and numbered. For example, gene 
sets 1 and 2 are labeled within the ‘signaling pathways’ box. The corresponding names for 
those numbered gene sets are provided in the key.  
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Fig 3. Single-cell flow cytometry analysis of the phenotypic evolution of the M397 cells 
from melanocyte to mesenchymal under BRAFi treatment, and results of Fokker-
Planck-type kinetic model. (A) A reaction coordinate (x), represented as a solid line that 
evolves from blue (for melanocytic phenotypes) to red (mesenchymal phenotypes), is fitted 
to the flow cytometry data across all time points. (B) The measured and predicted cell 
probability density distribution along the reaction coordinate x at representative time points 
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over the transition. Blue line: Experimentally measured distribution of cells. Green line: 
predicted cell distribution using the original Fokker-Planck model. Red line: predicted 
distribution from the modified kinetic model that includes a state-dependent cell net growth 
rate. 
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Fig 4. Cell-state-dependent relative net growth rates over the course of the phenotypic 
evolution for M397 cells. (A) Experimentally measured and predicted cell growth rates 
(bars). D0-D21 is associated with melanocytic and neural crest-like states, and D21-D78 is 
primarily associated with the mesenchymal state. Mean values and error bars are defined as 
mean and s.d., respectively. (B) Expression level of proliferation-related genes after short-
term (early) or long-term (late) BRAF inhibition. 
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Fig 5. Potential landscapes describing the drug-induced phenotypic evolution from 
melanocyte to mesenchymal phenotype for M397. (A) The landscape of scalar potential 
extracted from the modified FP-type (Eq. 3) kinetic model. The blue, cyan, and orange 
arrows indicate regions dominated by melanocytic (MART1+/NGFR±), neural-crest 
(MART1+/NFGR-) and mesenchymal (MART1-/NGFR-) phenotypes, respectively. (B) The 
free energy-like potential calculated by surprisal analysis shows the relative cell state stability 
with respect to the global steady state across different time points. The blue, cyan, and orange 
circles represent cell populations primarily at melanocytic, neural-crest and mesenchymal 
phenotypes at the respective time points. (C) Comparison between normalized free energy-
like potential (from surprisal analysis, orange bar) and scalar potential (from modified FP-
type kinetic model, blue bar) for D73, calculated from transcriptional profiles of unsorted 
and sorted NGFR-/MART-1- mesenchymal cells. (D) Cartoon illustration of the competition 
between state-dependent net growth and system stabilization towards the attractor state upon 
drug treatment. 
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Supplementary Information 
 
Supplementary figures 
 
S1 Fig. Kinetic flow cytometry data of drug-induced phenotypic evolution. A. Cartoon 
illustration of the BRAFi-induced transition where the melanoma cells take an approximately 
counterclockwise trajectory around the flow cytometry plot. B. Flow cytometry plots of 
NGFR and MART-1 protein markers for M397 at a set of the points over the drug-induced 
phenotypic evolution. Data are represented as a 2-dimensional density plot for each day. As 
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the de-differentiation transition occurs from day 0 to day 78, the cell population moves 
along a counterclockwise trajectory. C. Flow cytometry plots of NGFR and MART-1 protein 
markers for M229 at a set of the points over the drug-induced phenotypic evolution. 
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S2 Fig. Heatmap and hierarchical clustering for transcriptomic data of M397 and 
M229 cells under different drug treatment and/or sorting conditions. A is for M397 and 
B is for M229. Each Row of the heatmap indicates each gene. Each column is a sample 
condition, as indicated. Color represents gene expression level, with up-regulated genes 
colored in red and down-regulated genes colored in blue. Different molecular baselines of 
the two melanoma cell lines dictate distinct clustering patterns that require Surprisal analysis 
to resolve the altered molecular features shared by the two cell lines across the transition.  
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S3 Fig. Heatmap visualization of amplitudes for steady state and different constraints 
across different samples of M397 and M229. M397 data is shown in panel A and that of 
M229 is shown in panel B. Each row indicates a constraint, with λ0 the global stable state. 
Each column is a sample condition, as indicated. Positive valued constraints are red, and 
negative are blue.  
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S4 Fig. Comparison of surprisal analysis result between M397 and M229. A. The 
amplitude of steady state and top three constraints across different time points determined by 
surprisal analysis of M397 cell line. B. The amplitude of steady state and top three constraints 
across different time points determined by surprisal analysis of M229 cell line. C. Gene set 
enrichment of the three constrained processes for the phenotypic and functional changes of 
M397 (left) and M229 (right) over the drug-induced phenotypic evolution. Each bar 
represents one enriched gene sets associated with the top three constraints as indicated by 
their respective colors. Value represents the normalized enrichment score (NES) calculated 
from GSEA.  
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S5 Fig. Scatter plot comparison of the measured versus the predicted gene expression 
levels for M397 from surprisal analysis across different time points, using the global 
stable state and top three constraints. 
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S6 Fig. Enrichment map of the enriched gene sets in the second constraint, as 
identified by GSEA. 
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S7 Fig. Cell sorting and relaxation experiments of M397. A. Illustration of cell sorting 
experiments. Cells cultured without drug treatment are harvested and stained with NGFR 
antibody. A flow cytometer separates the NGFR+ live cell subpopulations and the sorted 
cells are then cultured in the same condition as before sorting. The NGFR and MART-1 
(not changing) expression levels are measured for subsequent days as the population re-
equilibrates towards the unsorted steady state distribution. B. Flow cytometry data of log 
NGFR level from cell sorting experiment. The relaxation dynamics of the sorted 
subpopulation is measured using flow cytometry. Dataset illustrated here was later 
modeled by a Fokker-Planck equation to determine the diffusion constant of the system. 
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S8 Fig. The measured and predicted cell probability density distribution of M229 along 
reaction coordinate x at various time points. Blue line: experimental data distribution. 
Green line: predicted distribution using the original Fokker-Planck model (FP model). Red 
line: predicted distribution from the modified FP-type kinetic model that includes a state-
dependent net growth rate. 
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S9 Fig. Comparison of potential calculated from unmodified and modified Fokker-
Planck-type kinetic models. Potential landscape calculated from unmodified Fokker-
Planck model is shown in panel A and the one from modified FP-type kinetic model is 
shown in panel B. 
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S10 Fig. The potential landscapes describing the drug-induced phenotypic evolution 
from melanocytic to mesenchymal phenotype for M229. A. Potential landscape 
extracted from modified FP-type kinetic model. B. The free energy-like potential 
calculated by surprisal analysis shows the relative change in stability with respect to the 
global stable state across different time points. 
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S11 Fig. Illustration of cell sorting for NGFR negative phenotype of M397 at day 73. 
To validate the free energy calculation from the surprisal analysis, pure NGFR-/MART- 
subpopulation was sorted using flow cytometry for RNA sequencing and compared against 
RNA-seq from unsorted cells. 
185 
S12 Fig. Sensitivity analysis of “Principal Curve”. A. Three principal curves calculated 
with different iteration number. B. Potential U calculated for all three different principal 
curves. 
186 
Supplementary tables 
S1 Table: Kinetic RNA-seq data for M397 and M229 cells.  
(https://doi.org/10.1371/journal.pcbi.1007034.s013) 
S2 Table: The top 100 genes that contribute positively and negatively to the top3 
constraints. (https://doi.org/10.1371/journal.pcbi.1007034.s014) 
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 C h a p t e r  5  
TRAJECTORIES FROM SNAPSHOTS: INTEGRATED 
PROTEOMIC AND METABOLIC SINGLE-CELL ASSAYS REVEAL 
MULTIPLE INDEPENDENT ADAPTIVE RESPONSES TO DRUG 
TOLERANCE IN A BRAF-MUTANT MELANOMA CELL LINE 
The determination of individual cell trajectories through a high-dimensional cell-state 
space is an outstanding challenge, with relevance towards understanding biological 
changes ranging from cellular differentiation to epigenetic (adaptive) responses of diseased 
cells to drugging. We report on a combined experimental and theoretic method for 
determining the trajectories that specific highly plastic BRAFV600E mutant patient-
derived melanoma cancer cells take between drug-naïve and drug-tolerant states. Recent 
studies have implicated non-genetic, fast-acting resistance mechanisms are activated in 
these cells following BRAF inhibition. While single-cell highly multiplex omics tools can 
yield snapshots of the cell state space landscape sampled at any given time point, individual 
cell trajectories must be inferred from a kinetic series of snapshots, and that inference can 
be confounded by stochastic cell state switching. Using a microfludic-based single-cell 
integrated proteomic and metabolic assay, we assayed for a panel of signaling, phenotypic, 
and metabolic regulators at four time points during the first five days of drug treatment. 
Dimensional reduction of the resultant data set, coupled with information theoretic 
analysis, uncovered a complex cell state landscape and identified two distinct paths 
connecting drug-naïve and drug-tolerant states. Cells are shown to exclusively traverse one 
of the two pathways depending on the level of the lineage restricted transcription factor 
MITF in the drug-naïve cells. The two trajectories are associated with distinct signaling 
and metabolic susceptibilities, and are independently druggable. Our results update the 
paradigm of adaptive resistance development in an isogenic cell population and offer 
insight into the design of more effective combination therapies. 
This chapter includes content from our previously published article: 
[1] Su, Yapeng, Guideng Li, Melissa E. Ko, Hanjun Cheng, Ronghui Zhu, Min Xue, Jessica Wang et al. 
"Trajectories from Snapshots: Integrated proteomic and metabolic single-cell assays reveal multiple 
independent adaptive responses to drug tolerance in a BRAF-mutant melanoma cell line." Nature 
Communications (Under revision). doi: 10.1101/767988 
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Introduction 
Cellular processes ranging from the development of drug-tolerant states in cancer cells 
to stem cell differentiation, can be described as cell state changes. Specifically, certain cancer 
cells that are initially responsive to targeted inhibitors that act against these oncogenic 
drivers[1–4] can evolve into a drug-tolerant state via non-genetic mechanisms, perhaps 
preceding the emergence of drug-resistant clones[5–7].  The molecular details of how the 
cancer cells transition between the two states can inform the use of additional drugs designed 
to arrest the transition[8–10] . Dating back to the epigenetic landscapes of Waddington[11], 
a prevalent picture is that cells take a single path that connects the initial to the final state, 
but this does not have to be the case. In fact, if cells can take multiple independent paths 
between the two states, then the challenge of finding drug combination that can arrest the 
unfavorable cell state transition is significantly increased. Here we investigate a highly 
plastic cancer cell line that, when treated with a targeted inhibitor, switches from a rapidly 
dividing, drug responsive state to a drug-tolerant, slow cycling state within a few days.  We 
show that the cells can take multiple classes of trajectories between the two states. Each 
trajectory class is characterized by a unique signaling and metabolic networks with distinct 
druggable susceptibilities.   
From a functional perspective, cell state changes are often accompanied by changes in 
gene expression[10,12–15], protein signaling[12,14,16–22] and cellular metabolism.[23–26] 
Highly multiplex single-cell methods[27–30] can provide powerful tools for mapping out 
cell-state landscapes associated with cell state changes[20,31–35].  However, capturing the 
trajectories that individual cells take as they traverse those landscapes is challenging, even 
for the case of an isogenic cell line. This is because multiplex single-cell omics methods only 
provide snapshots of the occupied cell state space at a given instant. Measured similarities 
between cells captured at successive time points can imply probable paths through the 
landscape[36–40]. However, cells may stochastically switch from one state to another, so an 
individual cell may not take a smooth trajectory between states. Time-lapse imaging methods 
can map individual cell trajectories, but for only a couple of analytes for each cell, and so 
provide a limited view of the cell state space[41–43]. Thus, the ability to extract cellular 
trajectories from a kinetic series of cell state space snapshots would have high value. Here 
we report on combined experimental and theoretical approaches towards addressing this 
fundamental challenge.  
We utilized a patient-derived BRAFV600E mutant melanoma cancer cell line as a model 
for the rapid development of drug tolerance against targeted inhibitors. Under BRAF 
inhibition, these highly plastic cells rapidly (and reversibly) transition from a drug-
responsive state to a drug-tolerant state[12,19]. We characterized this transition using 
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integrated single-cell functional proteomic and metabolic assays designed to broadly 
sample proteins and metabolites associated with selected cancer hallmarks and cell state-
specific processes. Dimensional reduction, information-theoretic analysis, and visualization 
of the time-series single-cell data uncovered a complex cell state space landscape, and hinted 
at the possibility of two distinct paths between drug-naïve and drug tolerant states. Further 
experiments tested whether these paths constituted independent (and thus independently 
druggable) cellular trajectories. In fact, we find that even isogenic tumor cells can undertake 
different, independent trajectories to drug tolerance. The two trajectories are associated with 
distinct signaling and metabolic networks, and are independently druggable. This finding 
challenges the current paradigm of targeted inhibitor resistance development, and also 
provides guidelines for assessing the value of combination therapies. 
Results 
Integrated single-cell proteomic and metabolic analysis characterizes early 
BRAFi adaptation in melanoma cells  
We characterized drug adaptation in individual melanoma cells by assaying for a panel 
of selected proteins, plus glucose uptake, in BRAFV600E mutant M397 cell cultures during the 
first five days of BRAFi treatment using the Single Cell Barcode Chip (SCBC)[12,20,29,44–
47] (Fig 1a). Following 0, 1, 3, and 5 days (D0 control, D1, D3, and D5) of drug treatment, 
individual cells were isolated into nanoliter-volume microchambers within an SCBC. Each 
isolated cell was lysed in situ to release the cellular contents. Each microchamber within an 
SCBC contains a full barcode array in which each barcode element is either an antibody for 
specific protein capture[48] or a molecular probe designed to assay for a specific metabolite 
via a competition assay[46,47] (Fig.1a). The design of this panel was informed by 
transcriptomic analysis of BRAFi-treated M397 cells (Supplementary Fig. 1) and existing 
literature[12,14,16,23,49,50]. The panel broadly samples various functional and metabolic 
hallmarks of cancer, as well as cell state markers.  
Single-cell profiling of BRAFi-naïve (D0) M397 cells revealed heterogeneous levels of 
many assayed markers at baseline. Referring to Fig. 1b,c and Supplementary Fig. 2, certain 
analytes exhibit high variability across the cell population. These include the melanocytic 
lineage transcription factor MITF and its downstream melanocytic cell state marker MART1, 
the metabolic regulators HIF1α  and p-AMPKα, and the proliferation marker Ki67. The 
variance in Ki67 implies that the population contains both rapid-cycling and slow-cycling 
cells.  By contrast, a high glucose uptake and the expression of metabolic enzymes LDH and 
PKM2 were relatively uniform from cell-to-cell. Drug treatment initially (at D1) inhibits 
glucose uptake and represses most metabolic regulators and signaling phosphoproteins, as 
  
195 
well as Ki67. The repression of these cancer hallmarks reflects blockage of the key 
oncogenic signaling pathway upon initial BRAF inhibition. The drug also promotes transient 
cell differentiation followed by dedifferentiation, as evidenced by an increase of MART1 
expression in D3 followed by its downregulation in D5. However, a small subpopulation of 
M397 cells remains Ki67-high in D1, implying a slower drug response in that subset of cells. 
At D3, most analytes exhibit a sharp and transitory increase in variance, which shrinks by 
D5. This change includes all of the metabolic regulators except p-LKB, all resistant state 
markers and regulators except Slug, all of the metabolic enzymes, and all of the signaling 
phosphoproteins. The increased magnitude of the fluctuations of many markers at D3, based 
upon previous reports[45,51], implies one or more cell state changes near this time point. By 
D5, glucose uptake has increased back to near D0 levels, but with increased variance. Ki67 
is further decreased, and with sharply decreased variance relative to D0. Additionally at this 
day, the variance and abundance of the epithelial–mesenchymal transition (EMT)-related 
transcription factor, Slug, has increased, indicating the emergence of some cells that are 
trending towards a mesenchymal phenotype. Further, the levels of the other assayed protein 
markers that are associated with drug resistance (AXL, N-cadherin, NGFR, and TNFR) are 
all higher by D5. The upregulation of glucose uptake and many resistance marker indicates 
that cells have initiated drug resistance programs by D5. Thus, single-cell integrated 
proteomic and metabolic analysis, when viewed at the level of individual analytes, provides 
evidence of initial drug response at D1, a drug-induced cell state change at D3, and emerging 
drug tolerance at D5, prior to an increase in cell proliferation (full drug resistance) which has 
been shown to occur a few weeks later. These observations are all consistent with existing 
literature[12,14,16,52,53].  
Dimensional reduction analysis implies multiple trajectories  towards drug 
adaptation  
Simultaneous visualization of the time-dependent, coordinated changes across multiple 
markers requires algorithms that can reduce the high-dimensionality of the dataset. We  
applied two such algorithms: the FLOW-MAP algorithm[54] and the t-SNE algorithm[32]. 
Both approaches provided an intuitive representation of the dataset (Fig. 2 and 
Supplementary Figs. 3 and 4). FLOW-MAP analysis revealed that melanoma cells 
clustered primarily based upon drug exposure time (Fig. 2, upper left plot) indicating 
chronological cell state trajectories. Most untreated M397 cells (in the lower left of the graph) 
were characterized by uniform levels of all measured analytes excepting N-cadherin, MITF, 
HIF1α, Ki67 and MART1 (see analyte-specific plots of Fig. 2 and Supplementary Fig. 3). 
Most of these non-uniformly expressed proteins exhibit differences that vary gradually from 
left-to-right across the D0 cluster of cells, with a small subpopulation of untreated cells (right 
hand side of D0 cluster) exhibiting lower expression of Ki67, MITF, and MART1. These 
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features point to a small group of dedifferentiated, slow-cycling cells. Upon BRAFi 
treatment, the cells initially split to occupy two regions of the FLOW-MAP. At D1 (green 
points), the majority of the cells cluster to the upper right of the D0 cells, while a small 
subpopulation clusters directly to the right of the D0 group. This trend continues at D3, with 
most cells clustering above the largest D1 mass, while a small number cluster to the right of 
the small D1 group. By D5 (purple), all cells cluster to the right hand side of the graph. The 
bifurcation of cells at Day 1 and 3 implies the possibility of “upper” and “lower” trajectories 
towards the drug-tolerant state. The possibility of two classes of trajectories was also 
indicated by t-SNE analysis[32] (Supplementary Fig.4). Thus, both computational analyses 
of the single-cell data set indicate a bifurcated drug response during the early stages of 
BRAFi adaptation.  
Surprisal analysis uncovers analyte modules of the bifurcated drug -
response trajectories 
To further dissect the dynamics of molecular changes associated with the bifurcated 
drug-response trajectories, we applied surprisal analysis[55–57] to our single-cell dataset. 
Surprisal analysis is a thermodynamics-inspired method that has been broadly applied to 
understanding large-scale bulk and single-cell omics data sets[51,55,57–59]. This approach 
is based on the identification of the steady state of the system (formally speaking the state of 
minimum free energy), and any constraints (analyte modules) that increase the free energy 
from this theoretical minimum[57,60]. Using this approach, we identified two main modules, 
each representing a set of analytes that are coordinately changing together across cells.  The 
predicted expression of all 20 analytes based on these two modules matched well with the 
measured single-cell dataset (Supplementary Figs. 5 and 6), demonstrating that modules 1 
and 2 recapitulate the overall changes of all molecular signatures across all cells over the 
five-day course of drug treatment.  
The influence score (the lambda values defined in ref [57]) of a module in a cell 
represents the extent to which the module-associated analytes are enriched or repressed in 
that cell.  Modules 1 and 2 were visualized by color-coding their influence scores onto each 
node in the FLOW-MAP graph (Fig. 3a). We found that the influence score of module 1 
gradually increased from negative (blue) to positive (red) value along both the upper and 
lower paths, with a clear “biophysical barrier” (lambda1 = 0) in the middle time points (Fig. 
3a, left panel). We have previously shown that such a sign change can imply a cell state 
transition[55]. The time-dependence of module 1 appears to reflect the transition from a 
drug-responsive state to a slow-cycling, drug-tolerant state between days 1 and 3. This 
observation is consistent with the negative correlation of Ki67 expression and positive 
correlation of NGFR/AXL expression with the module 1 score (Supplementary Fig. 7). The 
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module 2 projection on the FLOW-MAP also exhibits a sign change, or biophysical 
barrier (lambda2 = 0), which separates the upper and lower paths (Fig. 3a, right panel). In 
fact, module 2 distinguishes cell subpopulations for each of the analyzed time points. 
Notably, the expression of melanocytic phenotype transcription factor MITF and its 
downstream protein MART1 both showed negative correlations with module 2 score (Fig 
3b and Supplementary Fig. 8), indicating that the separation of the two paths may be related 
to the melanocytic lineage of the cells. In summary, surprisal analysis resolves both time-
dependent and path-specific modules. It also reveals that, as the cells advance from drug-
naïve to drug-tolerant, they occupy a rather complex landscape of cellular states separated 
by multiple biophysical barriers (Supplementary Fig. 9). 
Experimental validation supports bifurcated drug-response trajectories 
Surprisal analysis provides theoretical support for the existence of both the upper and 
lower paths from drug-naïve to drug-tolerant cell states. However, experimental validation 
is required to determine whether individual cells exclusively follow a single trajectory along 
one path or the other, or if cells stochastically switch between paths. The map of module2 on 
the D0 cells data hints at biological differences that separate even the untreated D0 cells into 
two subpopulations (Supplementary Fig. 9). The expression levels of the transcription 
factor MITF and its direct downstream target MART1 are among the top four markers that 
distinguish the two D0 subpopulations (Supplementary Fig. 10). This finding suggests that 
drug-treated MITFlow cells might follow the lower path, while MITFhigh cells might follow 
the upper path (Supplementary Figs. 11 a). We thus generated MITF-GFP reporter cell lines 
and sorted GFPhigh (MITFhigh) and GFPlow (MITFlow) subpopulations (Supplementary Figs. 
11 b and 12). Consistent with our hypothesis, MITFhigh cells displayed higher expression of 
Ki67 and MITF as well as a shorter doubling time relative to sorted MITFlow subpopulations 
(Fig. 3 c-f). This data is consistent with reported observations of melanoma phenotype 
switching from a melanocytic, highly proliferative state to a non-melanocytic, more invasive 
state[61]. It also confirmed that the two subpopulations in D0 cells can be separated using 
this reporter system, and further suggests that the MITFhigh and MITFlow subpopulations at 
D0 may represent cells destined to follow the upper and lower paths, respectively, following 
drug treatment.  
To quantify the frequency of stochastic interconversion between the sorted MITFhigh and 
MITFlow subpopulations during the drug treatment, we monitored the MITF activity within 
large numbers of single-cells, over a 5-day period of BRAFi treatment. As expected, the 
MITFhigh cells always displayed higher activity (quantified by the GFP-reporter) than did the 
MITFlow cells (Fig. 3g), with no significant stochastic switching between the two trajectories 
observed.  
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To further confirm that the sorted cells reach their respective destination states after 
five days of drugging, we quantified the markers that are differentially expressed between 
the upper and lower paths at D5. Mining of the single-cell data sets revealed that several 
markers, including Slug, MITF, MART1 and PFK are differentially expressed between the 
two paths (negative- and positive-valued module 2) at D5 (Fig. 3h, Supplementary Figs. 9 
and 13a). By analyzing the expression of these four genes in sorted MITFhigh and MITFlow 
D0 cells after five days of treatment (Supplementary Fig. 13b), we found that their 
expression levels in sorted MITFlow cells were significantly lower than those in MITFhigh 
cells after five days of treatment (Fig. 3i). These results experimentally support that, upon 
drug treatment, MITFhigh and MITFlow cells take distinct trajectories toward drug tolerance 
along the upper and lower paths respectively (Supplementary Fig. 13a, left panel).  
MITF is the molecular driver for the two drug response trajectories 
MITF is suggested to be an elicitor of intrinsic drug tolerance[62]. To investigate if 
MITF drives the bifurcation in drug response, we generated a M397 cell line with MITF 
stably knocked down. Before treatment, knockdown of MITF induced the cells to become 
slow-cycling with characteristic low Ki67 expression (Supplementary Fig. 14a, b), 
suggesting that downregulation of MITF will force these cells to transition along the lower 
path. Furthermore, upon five days of BRAFi treatment, MITF knockdown cells showed 
significantly lower levels of Slug, MITF, MART1 and PFK relative to control 
(Supplementary Fig. 14 c), suggesting that MITF-silenced cells did, in fact, follow a 
trajectory along the lower path. Thus, MITF is identified as an important molecular driver 
that discriminates between the two drug response trajectories we identified.   
Critical point analysis identifies central regulators along both trajectories  
Surprisal analysis of the single-cell data sets indicates that both the upper and lower 
paths are characterized by a cell state transition in the D1-D3 time window (Fig 3a, left 
panel). A critical point analysis of the single-cell data in different regions of the FLOW-
MAP can provide validation of this picture, and can also help identify the tipping points at 
which those cell state changes take place.[51,63,64] Furthermore, network analysis of those 
tipping points can be used to identify key regulators that drive the transition from drug-naïve 
to drug-tolerant[12,51,58,63,65,66].  
We first clustered the single-cell data from all time points into 14 different sub-clusters 
on the FLOW-MAP. Clusters 1, 6, 7, 8, 10, 11, and 12 align with the upper path, while 
clusters 2, 3, 9, 13, and 14 fall along the lower path (Fig. 4a). Two previously reported critical 
state transition indices, the signaling network activity index (SNAI)[12] and the critical 
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transition index (Ic)[64], were utilized to evaluate the tipping points associated with the 
lower and upper paths. We found cluster 7 in the upper path and cluster 9 in the lower path 
showed the highest values of these indices within their respective path (Fig.4 b, c and 
Supplementary Figs. 15, 16, and 17), suggesting that clusters 7 and 9 are closest to the 
tipping points.  
We next investigated the correlation networks[12,20,44] for clusters 7 and 9. These two 
networks are characterized by different structures (Fig. 4d, e), implying these transitions are 
regulated in different ways. We quantified the participation of each analyte (node) in the 
correlation networks by calculating the node degree and hub score for each node (See 
Methods). For cluster 7 (upper path), we found that several transcription factors and 
enzymes, including MITF, PFK, p-LKB, PKM2, LDH2 and Slug, showed high levels of 
network participation by both scoring metrics (Fig. 4f and Supplementary Fig. 18).  For 
cluster 9 (lower path), TNFR, N-cadherin and p-NFκB-p65 appeared dominant. An 
interesting observation was that the markers that exhibited a high score in cluster 7 often 
displayed a low score in cluster 9, and vice versa, indicating that the two paths are 
dissimilarly regulated. 
To examine if the transitions along the two paths are driven by distinct hub regulators, 
we perturbed the respective hub nodes identified within clusters 7 and 9, and probed for 
differential influence on the two trajectories. We hypothesized that inhibition of the 
glycolysis enzyme PKM2 and the signaling phosphoprotein p-NFκB-p65 would 
differentially influence the transitions along upper and lower paths respectively (Fig. 4f and 
Supplementary Fig. 18). Accordingly, we used a PKM2 inhibitor (PKM2i) or an NFκB 
inhibitor (NFκBi) in combination with the BRAFi to treat sorted MITFhigh and MITFlow cell 
subpopulations. Consistent with our hypothesis, the MITFlow subpopulation was more 
sensitive to the BRAFi + NFκBi combination (Fig. 5a), while the MITFhigh subpopulation 
was more sensitive to the BRAFi + PKM2i combination (Fig. 5b). This hypothesis was 
further validated by testing the same drug combinations on the MITF-knockdown cell line 
relative to unmodified M397 cells (Fig. 5c, d). Thus, cells passing along the different 
trajectories displayed differential sensitivities to PKM2 and NFκB inhibition. 
Considering the differential regulator dependence of the two trajectories, we further 
hypothesized that co-blocking both trajectories by simultaneously inhibiting PKM2 and 
NFκB signaling might show additive effects in preventing the transitions towards BRAFi 
tolerance. To test this hypothesis, we used the triple drug combination (BRAFi + PKM2i + 
NFκBi) to treat the M397 cells in vitro for five days and compared the resulting cell number 
against monotherapies (BRAFi only) and double-drug combinations (BRAFi + PKM2i and 
BRAFi + NFκBi) for five days. Consistent with our prediction, the triple-drug combination 
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significantly outperformed the double-drug combinations which in turn were superior to 
the monotherapy (Fig. 5e). Further, PKM2i or NFκBi monotherapy showed minimal growth 
inhibition on the M397 cells (Supplementary Fig.19), implying that these drugs likely 
function by selectively blocking the BRAFi-induced cell state transitions to the drug-tolerant 
state. These results demonstrate that the upper and lower paths are independent, have 
different regulators, and are independently druggable. 
Discussion 
We explored here whether cell trajectories connecting between the initial and final states 
of a cell-state transition could be determined from a kinetic series of static snapshots of the 
traversed cell-state space landscape. As a model system, we utilized a highly plastic, patient-
derived M397 BRAFV600E mutant melanoma cell line, which has been shown to reversibly 
transition between drug-naïve and drug-resistant states upon treatment with a BRAF 
inhibitor. While single-cell omics tools have proven immensely valuable for resolving the 
cellular heterogeneity of tissues at a single given time point, here we sought to quantitatively 
connect that cellular heterogeneity to dynamic heterogeneity of cell state changes.  
We utilized microfluidic-based SCBC technology to characterize the cellular 
heterogeneity during the first five days of drug-response. Because both metabolic activity 
and signaling pathways display functional changes during the early drug-response, SCBC is 
uniquely suited here since it is capable of simultaneously capturing both metabolites and 
cytoplasmic proteins (and phosphoproteins) from single cells. However, unlike single-cell 
RNA-seq, single cell proteomics is typically limited to assaying only tens of functional 
proteins and metabolites. In order to accurately capture the cell state space accessed by M397 
cells under BRAFi treatment, we first utilized transcriptomic analysis and literature guidance 
to define a panel of 20 analytes that included phenotypic markers, and markers of metabolic 
activity, oncogenic signaling, and cell proliferation, all of which are altered during the initial 
drug-response. Single cell analysis using this carefully selected panel readily resolved the 
complex cell-state space traversed by the cells during the first few days of BRAFi treatment. 
Of course, moving towards larger numbers of analytes would certainly provide for a deeper 
characterization.[67–69] 
We utilized computational and theoretical methods[32,33,36,37,70–73], integrated with 
additional cell biology experiments, to translate the SCBC kinetic series of snapshots in to 
classes of single cell trajectories.  Dimensional reduction of the dataset using the FLOW-
MAP algorithm revealed suggested that the cells might take one of two paths (labeled 
“upper” and “lower”) through cell-state space that connected the drug-naïve cells to the drug-
resistant cells. Surprisal analysis of the same data resolved both a time-dependent module 
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and a path-dependent module. The path-dependent module suggested that cells traveling 
along one path are separated from the other path by a biophysical barrier, which appeared to 
be associated with the transcription factor MITF and its downstream melanocytic marker 
MART1. These analyses further predicted that the trajectory a specific cell takes is 
determined by its MITF level prior to drug treatment. These predictions were verified 
experimentally, which supported the integration of computational visualization methods with 
theoretical biophysical approaches to gain insight into a complex biological system. Such an 
approach should be broadly applicable to other dynamic, complex biological systems, 
including studies of cellular differentiation, tumorigenesis, and more.  
Proliferative and invasive phenotypes are well-known in melanoma[61,74]. MITF, 
MART1, and Ki67 have been reported as robust markers for distinguishing these two 
phenotypes[61,74]. We have found that these two distinct phenotypes can co-exist even in 
the untreated, isogenic M397 cell line used in our study. The MITFhigh and MITFlow 
subpopulations not only displayed different doubling time without BRAFi treatment but also 
followed distinct drug-response trajectories upon treatment. This finding is consistent with 
the observations of melanoma phenotype switching from a melanocytic and highly 
proliferative state to a non-melanocytic and more invasive state61. In that study, proliferative 
or invasive cell lines displayed fixed gene expression profiles in culture, but when 
transplanted in vivo, each class generated heterogeneous tumors containing cells with both 
kinds of expression profile. Consistent with their observation of fixed gene expression 
profiles in vitro, we did not observe significant inter-conversion between cells traveling along 
different paths during the five-day treatment period. These findings suggested that these two 
phenotypes are relatively stable in short term period of BRAFi treatment in vitro. Of course, 
our in vitro study may not fully recapitulate in vivo melanoma biology in which the tumor 
microenvironment can wield a strong influence. Furthermore, we also found that transition 
towards MITF-low invasive-like phenotype can be easily induced by artificial knockdown 
of a single transcription factor: MITF. This indicates that the complex cell-state landscape is 
likely regulated by very few master-regulators. It also emphasizes the importance of MITF 
as a molecular driver in regulating melanoma phenotype determination[75]. These findings, 
which add significantly to our understanding of melanoma phenotype regulation, would not 
have been evident had it not been for single-cell analytics.   
The coexistence of two distinct drug-response trajectories even in an isogenic cell line may 
explain the so-called “mixed-responses”, which is commonly observed during the 
therapeutic treatment of melanoma in clinical settings.  Such alternative “escape paths” may 
also explain why melanomas are so refractory to BRAFi targeted therapy. Intriguingly, for 
each of the two paths, different drug-susceptibilities were identified by critical point analysis 
and network analysis: the upper path was found to be susceptible to inhibition of the 
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glycolysis enzyme PKM2, while the lower path is sensitive to NFκb-p65 inhibition. 
These differential drug sensitivity results are consistent with previous bulk studies on 
invasive phenotypes of melanoma: MITF-low, invasive (or mesenchymal) melanoma cells 
have been reported to be more dependent on NFκB signaling[12,76], and the single-cell 
resolution of our study reveals the exact molecular and cellular dynamics behind that 
observation. Co-inhibition of PKM2 and NFκB pathways demonstrated superior effects in 
inhibiting tumor growth, however, both genes are essential regulators in normal cells and 
their inhibition can cause toxicity to non-malignant tissue[77,78].  Nevertheless, the resolved 
heterogeneous drug response trajectories update the current understanding of resistance 
development, and can provide a powerful methodology for identifying effective therapy 
combinations. 
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Methods 
Cell lines, reagents and cell culture    
Patient-derived melanoma cell line, M397, used in this study was generated under 
UCLA IRB approval # 11–003254. Cells were cultured at 37 °C with 5% CO2 in RPMI 
1640 with L-glutamine (Life Technologies), supplemented with 10% fetal bovine serum 
(Omega), and 0.2% antibiotics (MycoZapTM Plus-CL from Lonza). The cell line was 
periodically authenticated to its early passage using GenePrint® 10 System (Promega). 
Presence of mutations in the genes of interest was checked by OncoMap 3 or Iontrone, and 
was confirmed by PCR and Sanger sequencing as previously described[79,80]. BRAF 
inhibitor (vemurafenib), PKM2 inhibitor (Compound 3K) and NFκB inhibitor (JSH-23), 
all from Selleck Chemicals LLC, were dissolved in DMSO at designated concentrations 
before applying to cell culture media. M397 cells were plated in 10cm tissue culture plate 
at 60% confluency and treated with 3 µM BRAF inhibitor for the specified numbers of 
days.  
Microchip fabrication and integrated single-cell proteomic and metabolic assay 
The fabrication of the SCBC devices and the protocol of the integrated single-cell 
proteomic assays were extensively discussed in our previous publications[44,46]. Briefly, 
the DNA microarrays within each microchamber were converted to antibody or Nano-
probe microarrays by flowing the DNA-antibody or DNA-probe conjugate cocktail 
solution immediately before use. Cells treated with Gluc-Bio[46] were randomly loaded 
into microchambers within the SCBC. Each microchamber has an assay component, and a 
separate reservoir of lysis buffer, and was photographed after cell loading. The SCBC was 
then cooled on ice for cell lysis. Following a 2-hour protein and metabolite capture period 
at room temperature, the microchambers were flushed and the captured protein or 
metabolite on the arrays were converted into fluorescent readout and digitized by a Genepix 
scanner (Molecular Devices).  
Data processing from Genepix scanner   
By a custom MATLAB code, the average fluorescence signals for all bars within a 
given barcode were extracted and matched with the micrograph of that array to prepare a 
table that contains the microchamber address, the numbers of cells, and the measured 
fluorescence levels of each assayed protein or metabolite. The SCBC readouts from the 
microchambers with a single cell were collected to form an m × n matrix table where each 
row (m) represents a specific microchamber address and each column (n) represents the 
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abundance of a specific analyte. This matrix table is used for further analysis. 
FLOW-MAP Visualizations  
All FLOW-MAP visualizations were created with the FLOWMAPR R package 
available on GitHub (https://github.com/zunderlab/FLOWMAP/). Graphs were produced 
with seed.X = 1 and no clustering or downsampling. Final figures were produced in Gephi 
(https://gephi.org/) either using the “bluered” palette described in the FLOWMAPR 
package or using the “jet” rainbow palette. The code used to generate the exact FLOW-
MAP graphs is available upon request. 
Surprisal Analysis  
Surprisal analysis was applied as previously described[57]. Briefly, the measured level 
of analyte i at cell c, ln 𝑋𝑖(𝑐), is expressed as a sum of a steady state term ln 𝑋𝑖
0(𝑐), and
several constraints (modules) 𝜆𝑗(𝑐) × 𝐺𝑖𝑗  representing deviations from the steady state. 
Each deviation term is a product of a cell-dependent weight (influence score) of the 
constraint 𝜆𝑗(𝑐), and the cell-independent contribution of the analyte to that constraint 
(module) 𝐺𝑖𝑗. To implement surprisal analysis, we compute the singular value 
decomposition (SVD) of the matrix ln 𝑋𝑖(𝑐) . This factors this matrix in a way that 
determines the two sets of parameters that are needed in surprisal analysis: the Lagrange 
multipliers (𝜆𝑗) for all constraints (modules) at a given time point, and for all times and the 
𝐺𝑖𝑗  (time-independent) analyte patterns for all analyte i at each constraint j. In figure 3, 
cells with the top 10% most positive module2 score are defined as Module2-High cells 
(M2-High cells), and the most negative 10% ones are defined as Module2-Low cells (M2-
Low cells). 
Time-lapse microscopy  
Movies were acquired on an Olympus IX8 inverted fluorescence microscope with 
hardware autofocus (ZDC2) and an environmental chamber maintaining a 37C, 5% CO2 
culture environment. Automated acquisition software (METAMORPH, Molecular 
Devices) was used to acquire differential interference contrast (DIC) and GFP images 
every 15 min from multiple stage positions. 
Image segmentation and single-cell fluorescence calculation 
Custom MATLAB code (R2017a, MathWorks) was used to pre-process the DIC 
images of each movie. DIC images were first corrected for uneven illuminations of the 
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field, then adjusted contrast to sharpen the cell edges. The processed DIC images were 
then segmented using image segmentation software ilastik[81] (version 1.3.2) to acquire 
segmented cell bodies. 6 frames (out of 474 frames) were used as the training set for image 
segmentation of each movie. Pixel Classification feature of ilastik 1.3.2 was used to 
segment pixels of all 474 frames into ‘Background’, ‘Cell edge’, and ‘Cell body’ based on 
the labeled 6-image training set of each movie. GFP fluorescence data was extracted from 
cell body segments using a custom Python code. In each movie frame, each separated ‘Cell 
Body’ pixel block from DIC segmentation was first labeled as separated individual single 
cell. Then GFP fluorescence of each single cell block was calculated by integrating 
fluorescence from the corresponding pixels from GFP images. Background GFP 
fluorescence was calculated by the median GFP values of ‘Background’ pixels, and was 
subtracted from GFP values of ‘Cell Body’ pixels. Mean and standard error of the mean 
(SEM) were calculated for each time point from ensemble single-cell GFP fluorescence. 
Single-Cell Clustering  
Prior to clustering, all single-cell data were separated by time point (i.e. day 0, day 1, day 
3, and day 5). Rclusterpp clusters then applied which cluster the cells into 14 
subpopulations. Rclusterpp clusters were produced using the Rclusterpp R package using 
all default settings (https://github.com/nolanlab/Rclusterpp). All clustering algorithms 
were performed with cells clustered on the following markers: Ki67, Mart1, HIF1a, LDH, 
AMPKA, p-ERK1, PFK, p-ACAC, Slug, and p-LKB. The code used for clustering is 
available upon request. 
Signaling Activity Indices  
The signaling network activity index (SNAI) value is defined as “the reciprocal of the 
determinant of the protein-protein correlations” in previous publications[12]. The Ic value 
or critical transition index is defined as “the ratio of the average of all pairs of protein-to-
protein correlation coefficients to the average of all pairs of cell-to-cell correlation 
coefficients” and was calculated as described previously[64]. The code used to calculate 
the SNAI/Ic indices for individual cell clusters is available upon request. 
Network Analysis   
Pair-wise correlation matrices were calculated on within each of the 14 clusters using the 
Hmisc R package (https://cran.r-project.org/web/packages/Hmisc/index.html). Spearman 
correlations were calculated. Correlation output from the Hmisc package produces the pair-
wise correlation values matrix. Bonferroni corrected p-value was used to filter the 
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correlation network through statistical significance, and the correlation networks were 
drawn using a custom MATLAB code. Hub score and node degree for each marker in each 
correlation network were calculated using the igraph R package. Both scores were rescaled 
from 0 to 1 for each marker for side-by-side comparison and plotted to visualize marker-
to-marker variation in hub behavior between methods of calculating correlation. The code 
used to perform the correlation network analysis is available upon request. 
mRNA extraction and qPCR    
RNA was extracted from cells using the RNeasy Mini Kit or RNeasy plus Micro Kit 
(Qiagen) according to the manufacturer's protocol. First-strand cDNA was synthesized 
from extracted total RNAs using the iScript cDNA Synthesis Kit (Bio-Rad). The 
expression of human Slug, MITF, MART1and PFK transcripts were analyzed by SYBR 
Green–based real-time quantitative RT-PCR (qRT-PCR) using specific primers purchased 
from Santa Cruz. Data were normalized to the expression of RPL19 and are expressed as 
fold changes. 
MITF knockdown cell line    
Short hairpin RNA (shRNA) targeting the coding sequence of MITF and control shRNA 
were purchased from Santa Cruz.  Lentiviruses encoding control shRNA and MITF shRNA 
were produced in HEK-293T cells by transient transfection of lentiviral based vectors and 
their packaging vectors psPAX2 and pMD2.G as previously described[82]. The virus was 
collected, filtered through a 0.45µm syringe filter after 48 hours and the M397 cells were 
spin-infected with viral supernatant supplemented with 10 µg/mL polybrene at 2,500 rpm 
and 30°C for 90 min.  The transduced cells were selected using puromycin, starting at 3 
days post-transduction.  
MITF Reporter Cell Line    
The human Tyrosinase Promoter (TP) was subcloned from pLightSwitch Prom S700747 
(SwitchGear Genomics, Carlsbad, CA) into the BamH1 and EcoRI sites of the lentiviral 
vector backbone, driving the expression of the Zsgreen gene. Lentivirus particles were 
generated as described above to stably transduced M397 cells. A clonal cell line was further 
generated via single cell sorting and expansion. Cells were then sorted as GFPhigh and 
GFPlow population by BD FACSAria Fusion Cell Sorter for further treatment and analysis.  
Fluorescence microscopy   
Images were acquired at 10X (Olympus, 10X FL PH, 0.3 NA) on an EVOS FL Auto 
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Imaging System (Fisher Scientific) in YFP and differential interference contrast (DIC) 
channel. Light or laser intensity, exposure and gain were set to be the same 
between MITFhigh well and MITFlow well. 
Clonogenic assay   
M397 cells were plated onto six-well plates with fresh media at an optimal confluence. The 
media (with drug or DMSO) were replenished every two days. Upon the time of staining, 
4% paraformaldehyde was applied onto colonies to fix the cells and 0.05% crystal violet 
solution was used for staining the colonies. 
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Figures 
 
Fig. 1. Single-cell proteomic and metabolic analysis of early drug response in M397 
cells. a. The single-cell integrated proteomic and metabolic analysis experiments design. 
Cells from different time points during BRAFi treatment are harvested and individually 
analyzed using the microfluidic based single-cell barcode (SCBC) technology. Each cell was 
characterized for the levels of 6 different categories of markers. b. Heatmap representation 
of integrated proteomic and metabolic analysis dataset. Each row represents an individual 
cell and each column (except the last column) represents an individual analyte, with the color 
in the heatmap representing measured level of the analyte. The last column represents the 
number of days after starting BRAFi treatment. On the X-axis, markers are colored 
corresponding to which of the six functional categories they belong to. c. Violin plot 
representation of distribution of certain representative markers across 4 time points. Y-axis 
represents natural log of measured marker level. Each plot is bordered by the color of the 
functional category of the measured marker. 
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Figure.2 Visualization of single-cell data by FLOW-MAP.   Each dot represents an 
individual cell. The distance between each pair of cells represents the overall multi-omic 
dissimilarity between them. Cell pairs that are close enough are linked with an edge in 
between. The colors of the dots in the main panel (upper-left) represent BRAFi exposure 
time (0, 1, 3, or 5 days) of the corresponding cells. Dot colors in the other panels represent 
the abundance of each marker in each cell. The dashed-line box in the panels for MITF, 
MART1, and Ki67 levels shows a small subpopulation of day-0 cells that are slow cycling 
with less melanocytic phenotype. 
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Fig. 3. Surprisal analysis identifies time-dependent and path-specific analyte modules 
that explain the bifurcated trajectories and identify MITF as a transcription factor 
regulating the bifurcation.  a. Visualization of the influence score of the two regulatory 
modules identified from surprisal analysis. Module1 is time-dependent, while module2 
exhibits a path-specific pattern. The dashed black lines indicate the region for which the 
respective module scores of each cell approach zero. b. Pearson correlation between 
individual marker levels and the module2 score. c, d. Ki67 and MITF expression level in 
module2 score-high and -low subpopulations at day 0. e. Ki67 relative expression, measured 
by q-PCR in sorted MITF-high and MITF-low cells at day 0. f. Doubling time measured in 
treatment-naïve condition, collected from sorted MITF-high and MITF-low cells at day 0. g. 
Single-cell time-lapsed microscopy analysis of MITF-activity during 5 days of BRAFi. Top 
panel: Time-lapse images of sorted GFP-High and GFP-low cells before and after 5 days of 
BRAFi. Bottom panel: Average trace representing MITF activity dynamics across single 
MITF-Low (blue trace) and MITF-High (orange trace) cells over 5 days of BRAFi. Shading 
indicates SEM of the mean. h. Slug, MITF, MART1, and PFK relative expression levels in 
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module2 score-high and -low subpopulations, collected from cells at day 5 and analyzed 
from single-cell dataset. i. Slug, MITF, Mart1, and PFK expression, measured by q-PCR in 
sorted MITF-high and MITF-low day-0 cells that have been treated with BRAFi for 5 days. 
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Figure 4. Critical point analysis (SNAI) and network analysis of two trajectories.  a. 
Clustering of all cells into 4 time point-defined subpopulations. Left panel is FLOW-MAP 
with cells color coded by drug exposure time. Right panel is FLOW-MAP with cell color-
coded as one of the 14 subpopulations defined from clustering analysis. b. Critical point 
transition analysis for upper path. Critical point index SNAI is calculated within each 
subpopulation associated with the upper path and color-coded onto the FLOW-MAP. Red 
indicates higher SNAI value, while blue represents lower SNAI value. Cluster7, shown 
where labeled, shows the highest SNAI value in the upper path. c. Critical point transition 
analysis for lower path. Critical point index SNAI is calculated within each subpopulation 
associated with the lower path and color-coded onto the FLOW-MAP. Red indicates higher 
SNAI value, while blue represents lower SNAI value. Cluster9, shown where labeled, shows 
the highest SNAI value in the lower path. d. Marker-marker correlation networks, extracted 
from SCBC data within cluster7 cells. The correlation strengths are reflected in the color of 
each edge (orange indicates positive correlation and blue indicates negative correlation).  e. 
Marker-marker correlation networks, extracted from SCBC data within cluster9 cells. The 
correlation strengths are reflected in the color of each edge (orange indicates positive 
correlation and blue indicates negative correlation). f. Importance score of each node within 
each network, as defined by node-degree. Colors indicate the node-degree value of each node 
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within cluster7 or cluster9 networks. Nodes labeled with stars were further-tested with 
drug perturbation. 
 
Figure 5. Differential drug sensitivity of cells associated with two trajectories. a. MITF-
GFP reporter cell line were sorted for MITF-high and MITF-low subpopulation before 
drugging. The sorted cells were then treated with BRAFi+NFΚBi combination for 5days and 
then harvest for cell number counting. Relative cell survival of sorted MITF-high and MITF-
low cells after undergoing BRAFi+NFΚBi combination therapy for 5 days were plotted. 
Survival data were normalized to MITF-high sample. b. MITF-GFP reporter cell line were 
sorted for MITF-high and MITF-low subpopulation before drugging. The sorted cells were 
then treated with BRAFi+PKM2i combination for 5days and then harvest for cell number 
counting. Relative cell survival of sorted MITF-high and MITF-low cells after undergoing 
BRAFi+PKM2i combination therapy for 5 days were plotted. Survival data were normalized 
to MITF-low sample. c. MITF knockdown cells and control cells were treated with 
BRAFi+NFΚBi combination for 5days and then harvest for cell number counting. Relative 
cell survival of sorted control and MITF-sh cells after undergoing BRAFi+NFΚBi 
combination therapy for 5 days were plotted. Survival data were normalized to control 
sample. d. MITF knockdown cells and control cells were treated with BRAFi+PKM2i 
combination for 5days and then harvest for cell number counting. Relative cell survival of 
sorted control and MITF-sh cells after undergoing BRAFi+PKM2i combination therapy for 
5 days were plotted. Survival data were normalized to MITF-KO sample. e. M397 cell treated 
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with BRAFi, BRAFi+NFΚBi, BRAFi+PKM2i, and BRAFi+NFΚBi+PKM2i for 5 days 
were harvest for cell number counting. Relative cell survival of cells after undergoing 
BRAFi, BRAFi+NFΚBi, BRAFi+PKM2i, or BRAFi+PKM2i+NFΚBi therapy for 5 days 
were plotted. Survival data were normalized to cells undergoing BRAFi monotherapy 
treatment. 
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Supplementary Information 
 
Supplementary Figures 
 
Supplementary Figure 1. Transcriptomic analysis guided panel marker selection 
a. Pathways that are differentially altered from day 0 to day 3 after BRAFi treatment. Each 
row represents a certain signaling pathway and each bar indicates normalized enrichment 
score (NES) calculated from geneset enrichment analysis (GSEA) of cells harvested at day 
3 versus day 0. Each pathway is color-coded by its functional category as described in Fig. 
S1b. 
b. Panel of markers per pathway selected to quantify with single-cell barcode chip (SCBC) 
analysis. 20 markers were selected for SCBC analysis. Markers with similar biological 
function are organized together and color-coded by functional category.  
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Supplementary Figure 2. Distribution of all 20 markers across 4 time points. 
Each of the 20 plots represents the distributions of a certain marker level across 4 time 
points. Y-axis represents natural log of measured marker level. Markers within the same 
functional category are boxed together. Border color of each plot corresponds to the 
functional category of each marker, as described in Fig. 1a.  
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Supplementary Figure 3. Visualization of integrated single-cell proteomic and 
metabolic analysis data by FLOW-MAP. 
Each dot represents an individual cell. The distance between each pair of cells represents the 
overall multi-omic dissimilarity between them. Cell pairs that are close enough are linked 
with an edge in between. The colors of the dots in the central panel represent BRAFi exposure 
time (0, 1, 3, or 5 days) of the corresponding cells. Dot colors in the other panels represent 
the abundance of each marker in each cell. Markers belonging to the same functional 
category, as described in the bottom of the figure, were assigned to a certain shape and color. 
The dashed-line box in the panels for MITF, MART1, and Ki67 levels shows a small 
subpopulation of day-0 cells that are slow cycling with less melanocytic phenotype. 
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Supplementary Figure 4. Dimension reduction with t-SNE and marker abundance 
visualization.  Each dot per plot represents an individual cell. The distance between each 
pair of dots represents the overall multi-omic dissimilarity between that pair of cells. The dot 
colors in the central panel represent the drug exposure time of each cell. Dot colors in the 
other panels represent the abundance of the specified marker in each cell. Markers that belong 
to the same functional category were assigned to a certain shape and color, as described in 
the bottom of the figure. T-SNE visualizations show both the heterogeneity that exists at 
baseline as well as the progression across time through two separate paths. 
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Supplementary Figure 5. Two modules from surprisal analysis recapitulated the 
original experimental measured marker levels.  Each plot represents an individual 
marker. Each dot within a single plot represents a single cell. The x-axis value of each dot 
represents the experimentally measured marker expression within a cell. The y-axis value 
of each dot represents the predicted marker level of the same cell as calculated by surprisal 
analysis of only module1 and module2. The strong positive correlation between the x- and 
y-axis values indicate that surprisal analysis of the two modules recapitulates 
experimentally measured marker levels per cell. 
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Supplementary Figure 6. Two modules from surprisal analysis recapitulated the 
overall experimental measured marker levels.  a. Schematic illustration of workflow to 
project raw data and surprisal analysis-predicted data onto the same 2-dimensional space. 
Each cell has measured levels of all 20 markers. Similarly, each cell also has predicted levels 
of all 20 markers as calculated from surprisal analysis. The raw and surprisal-predicted data 
matrices were combined to make a bigger matrix with double the original number of rows, 
each row representing a cell from raw data or predicted data. Each column represents a single 
marker, with each matrix value representing a single cell’s abundance of a marker. The 
combined, 20-dimensional dataset was projected onto a single t-SNE map where cells with 
similar levels of all 20 markers will be in nearby coordinates.   b. Each dot represents an 
individual cell. In the left panel, the x-axis represents the t-SNE x-value of the cell projected 
from raw data, while the y-axis represents the t-SNE x-value of the cell projected from 
surprisal analysis-predicted data. The right panel is similar to left panel, but instead compared 
t-SNE y-values. The linear, x = y plots indicate that single cells, as projected from raw data 
and from surprisal analysis-predicted data, are in the same location in a reduced dimension; 
therefore, the experimentally measured and surprisal analysis-predicted expression profiles 
of all 20 markers are similar. 
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Supplementary Figure 7. Lambda1 associated markers displayed time dependent 
changes. 
a. Pearson correlation of marker level vs. module1 score (lambda1) across cells from all 
timepoints of BRAFi exposure. Correlations that are not statistically significant (i.e. p > 0.05) 
are not shown. 
b. Representative markers that showed strongest positive (AXL, NGFR) or negative (Ki67) 
correlation with module1 score are shown in individual cells on FLOW-MAP. 
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Supplementary Figure 8. Lambda2 associated markers displayed path-specific 
expression patterns. 
a. Pearson correlation of marker level with module2 score (lambda2) across cells from all 
time points after BRAFi exposure. Correlations that are not statistically significant (i.e. p > 
0.05) were not shown. 
b. Representative markers that showed strongest negative correlation with module1 score are 
shown in individual cells on FLOW-MAP. 
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Supplementary Figure 9. Four different cell states inferred from Module1 and 
Module2 associated biophysical barriers. 
Module1 and module2-associated barriers, as defined by the points at which a module score 
changes sign, separate the cells into roughly 4 different states, labeled from 1 to 4. States 
1 and 2 are separated from states 3 and 4 by the module1-associated barrier. States 1 and 3 
are separated from states 2 and 4 by the module2-associated barrier. 
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Supplementary Figure 10. Day-0 cell analysis of marker correlation with module2, 
suggesting MITF as the driver for bifurcation in cell state transition trajectories. a. 
Pearson correlation of marker level and module2 score in day 0 cells from single-cell dataset. 
The four most highly-correlated markers are labeled with gray arrows. b. Scatter plots 
showing expression levels of the four most highly-correlated markers versus module2 score 
in day-0 cells from single-cell dataset. 
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Supplementary Figure 11. Illustration of MITF-reporter line sorting experiment on 
untreated cells.  a. Untreated cells in state 1 and state 2 showed significantly different levels 
of MITF and Ki67. b. For MITF-GFP reporter line, cells with higher GFP level and lower 
GFP level were sorted out using FACS. The sorted cells were then harvested for qPCR 
quantitation of MITF and Ki67 expression. 
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Supplementary Figure 12. Sorted state 1 and state 2 cells shows different MITF-GFP 
level and morphology. 
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Supplementary Figure 13. Illustration of MITF-reporter line sorting and drug 
treatment experiments.  a. Day-5 cells in state 3 and state 4 showed different levels of 
MITF, MART1, PFK and Slug. b. For MITF-GFP reporter line, cells with higher GFP level 
and lower GFP level were sorted out using FACS. The sorted cells were then treated with 
BRAFi for another five days, then harvested for qPCR quantitation of MITF, MART1, PFK 
and Slug expression. 
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Supplementary Figure 14. MITF knock-down cells showed similar phenotype as sorted 
state 2 day-0 cells which will follow the bottom trajectory to become state 4-like cells 
upon 5days of BRAFi.  a. Expression level of Ki67 from qPCR of MITF knockdown cells 
versus control cells. b. Measured doubling time of MITF-knockdown cells versus control 
cells. c. Expression level of MITF, MART1, PFK, and Slug after 5 days of BRAFi treatment 
in control cells and MITF-knockdown cells. 
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Supplementary Figure 15. Ic value of single cells for critical point transition analysis 
of each trajectory.  a. Critical point transition analysis for upper path. Critical point 
index Ic is calculated within each subpopulation associated with the upper path and color-
coded onto the FLOW-MAP. Red indicates higher Ic value. Blue represents lower Ic 
value. Cluster 7, circled and labeled, shows the highest Ic value in the upper path.  b. 
Critical point transition analysis for lower path. Critical point index Ic is calculated 
within each subpopulation associated with the lower path and color-coded onto the 
FLOW-MAP. Red indicates higher Ic value. Blue represents lower Ic value. Cluster 9, 
circled and labeled, shows the highest Ic value in the lower path.  
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Supplementary Figure 16. Network structure and respective SNAI and Ic values for 
subpopulations associated with the upper path.  a. Network of subpopulations associated 
with the upper path. Each network structure plot is bordered by the color label of the 
corresponding cluster.  b. SNAI and Ic values of networks associated with subpopulations 
in the upper path. 
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Supplementary Figure 17. Network structure and respective SNAI and Ic values for 
subpopulations associated with the lower path.  a. Network of subpopulations associated 
with the lower path. Each network structure plot is bordered by the color label of the 
corresponding cluster.  b. SNAI and Ic values of networks associated with subpopulations 
in the lower path. 
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Supplementary Figure 18. Hub-score of each node at networks for cluster7 (C7) and 
cluster9 (C9).  Colors in C7 and C9 columns indicate the hub-score value of each node 
found within the cluster 7 or cluster 9 networks, respectively. Nodes labeled with stars 
were further tested using drug perturbation. 
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Supplementary Figure 19. Short-term clongenic assay for 397 cells.  M397 was 
treated with either DMSO control or PKM2i or NFKBi or PKM2i+NFKBi or BRAFi. No 
significant toxicity to the cells was observed for using PKM2i or NFKBi or combination 
of both. 
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